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Abstract	  	  	   Epigenetics,	  or	  the	  reversible	  and	  heritable	  marks	  of	  gene	  regulation	  not	  including	  DNA	  sequence,	  encompasses	  modifications	  on	  both	  the	  DNA	  and	  histones	  and	  is	  as	  important	  as	  the	  DNA	  sequence	  itself.	  	  Gene	  transcription,	  DNA	  repair,	  DNA	  replication,	  and	  the	  cell	  cycle	  are	  each	  impacted	  by	  the	  chromatin	  structure.	  	  A	  variety	  of	  enzymes	  modulate	  these	  modifications,	  and	  a	  suite	  of	  factors	  interacts	  with	  them	  to	  aid	  in	  promoting	  or	  inhibiting	  cellular	  functions.	  	  Many	  of	  these	  chromatin-­‐modifying	  factors	  are	  deregulated	  in	  cancer,	  making	  them	  novel	  therapeutic	  targets.	  	  This	  dissertation	  describes	  the	  identification	  of	  an	  H3K9	  histone	  methyltransferase,	  SUV39H1,	  as	  a	  suppressor	  of	  rhabdomyosarcoma	  formation	  in	  zebrafish.	  	  This	  suppressor	  is	  dependent	  on	  the	  methyltransferase	  domain	  of	  the	  enzyme,	  ruling	  out	  any	  scaffold	  effects	  since	  this	  enzyme	  is	  a	  part	  of	  a	  multiprotein	  complex.	  	  SUV39H1-­‐overexpressing	  and	  control	  tumors	  share	  many	  of	  the	  same	  characteristics,	  including	  proliferation	  rate,	  muscle	  differentiation	  state,	  and	  tumor	  growth	  rate.	  	  The	  tumor	  suppressive	  phenotype	  cannot	  be	  rescued	  by	  alterations	  in	  the	  downstream	  muscle	  program	  alone.	  	  However,	  SUV39H1-­‐overexpressing	  fish	  initiate	  fewer	  tumors,	  which	  results	  in	  the	  observed	  suppressive	  
iv	  	  	  	  
phenotype.	  	  This	  initiation	  defect	  occurs	  between	  5	  and	  7	  days	  of	  life	  in	  the	  zebrafish,	  likely	  by	  impacting	  cyclin	  B1	  expression.	  	  This	  dissertation	  also	  describes	  the	  development	  of	  a	  novel	  F1	  transgenic	  screening	  strategy	  in	  the	  zebrafish.	  	  This	  approach	  was	  utilized	  to	  screen	  a	  variety	  of	  chromatin-­‐modifying	  factors	  for	  their	  effects	  on	  hematopoietic	  development.	  	  The	  developed	  strategy	  will	  have	  future	  applications	  as	  a	  zebrafish	  screening	  tool.	  	  Our	  data	  suggest	  that	  chromatin-­‐modifying	  factors	  play	  an	  important	  role	  in	  rhabdomyosarcoma	  and	  illustrate	  the	  use	  of	  the	  zebrafish	  in	  discovering	  genes	  involved	  in	  tumorigenesis	  and	  hematopoiesis.	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Chromatin	  	   Every	  living	  creature	  carries	  DNA	  in	  its	  cells	  as	  its	  blueprint	  for	  life.	  	  From	  bacteriophages	  that	  contain	  their	  eleven	  genes	  in	  5000	  base	  pairs	  (bp)	  to	  humans	  that	  have	  their	  twenty	  thousand	  genes	  encoded	  across	  3.3	  billion	  bp,	  each	  cell	  of	  the	  organism	  contains	  the	  entire	  genome.	  	  This	  DNA	  must	  be	  packaged	  efficiently	  yet	  remain	  accessible	  for	  potential	  gene	  transcription.	  	  The	  chromatin	  structure	  of	  a	  nucleus,	  in	  which	  the	  DNA	  and	  proteins	  are	  packaged	  together,	  ensures	  this	  balance.	  	  In	  eukaryotic	  organisms,	  DNA	  is	  packaged	  into	  nucleosomes,	  where	  147	  bp	  are	  wrapped	  twice	  around	  an	  octamer	  of	  histone	  proteins;	  the	  octamer	  contains	  two	  copies	  each	  of	  histones	  H2A,	  H2B,	  H3,	  and	  H4	  [1-­‐5].	  	  The	  linker	  histone	  H1	  sits	  at	  the	  DNA	  entry	  and	  exit	  points	  of	  the	  nucleosome	  beads,	  and	  the	  neighboring	  beads	  are	  connected	  by	  up	  to	  80	  bp	  of	  DNA	  [5-­‐8].	  	  This	  somewhat	  open	  structure	  is	  known	  as	  euchromatin.	  	  The	  nucleosome	  structure,	  resembling	  beads	  on	  a	  string,	  can	  be	  compacted	  further	  along	  the	  H1	  proteins	  to	  create	  a	  30	  nm	  fiber	  (heterochromatin),	  and	  the	  addition	  of	  other	  scaffolding	  proteins	  can	  compact	  the	  structure	  even	  further,	  eventually	  resulting	  in	  the	  most	  densely	  packed	  metaphase	  chromosome	  [9-­‐12].	  	   To	  control	  the	  thousands	  of	  eukaryotic	  genes	  buried	  among	  billions	  of	  compacted	  base	  pairs	  requires	  another	  level	  of	  regulation	  known	  as	  epigenetics.	  	  Epigenetics	  is	  the	  reversible	  and	  heritable	  marks	  of	  gene	  regulation,	  which	  have	  proven	  to	  be	  just	  as	  important	  in	  the	  field	  of	  genetics	  as	  the	  DNA	  sequence	  itself.	  	  Epigenetic	  marks	  seem	  to	  be	  among	  the	  first	  developmental	  instructions	  that	  an	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embryonic	  cell	  receives	  and	  continue	  through	  the	  life	  of	  an	  organism	  to	  mark	  changing	  states	  of	  a	  cell	  without	  ever	  affecting	  the	  nucleotide	  sequence	  [13,	  14].	  	   One	  method	  of	  epigenetic	  regulation	  is	  to	  mark	  the	  DNA	  itself.	  	  This	  is	  done	  through	  methylation	  of	  cytosine	  bases	  with	  the	  family	  of	  DNA	  methyltransferase	  (DNMT)	  enzymes.	  	  This	  mark	  silences	  the	  genes	  and	  non-­‐coding	  regions	  in	  the	  methylated	  sequence	  and	  tends	  to	  occur	  in	  repetitive	  regions	  [15,	  16].	  	  The	  covalent	  methyl	  mark	  can	  be	  maintained	  through	  cell	  divisions	  when	  it	  occurs	  at	  the	  dinucleotide	  pair	  of	  a	  cytosine	  next	  to	  a	  guanine	  (CpG)	  [17,	  18].	  	  Of	  the	  three	  main	  DNMTs,	  DNMT1	  is	  responsible	  for	  maintaining	  the	  methylations	  after	  cell	  division	  whereas	  DNMT3A	  and	  DNMT3B	  are	  de	  novo	  enzymes	  that	  initiate	  new	  methylations	  [19-­‐22].	  	  By	  methylating	  CpG	  islands	  in	  promoter	  regions,	  DNMTs	  can	  directly	  shut	  off	  gene	  expression	  by	  making	  the	  promoter	  inaccessible	  to	  transcription	  factors.	  	  Additionally,	  methyl-­‐CpG-­‐binding	  domain	  (MBD)	  proteins	  can	  bind	  the	  DNA	  methylations;	  MBD	  proteins	  can	  recruit	  other	  chromatin	  factors	  to	  silence	  the	  gene	  or	  promote	  further	  methylation	  of	  the	  DNA	  [23,	  24].	  	   A	  second	  level	  of	  epigenetic	  regulation	  occurs	  on	  the	  tails	  of	  the	  histone	  proteins.	  	  Each	  of	  the	  histones	  in	  the	  nucleosome	  has	  a	  flexible	  charged	  N	  terminal	  tail	  coming	  out	  of	  the	  nucleosome	  bead	  containing	  twenty	  to	  thirty	  amino	  acids	  that	  can	  be	  modified	  by	  methylation,	  acetylation,	  ubiquitination,	  phosphorylation,	  and	  sumoylation	  [25-­‐27].	  	  There	  are	  over	  sixty	  residues	  associated	  with	  these	  modifications,	  and	  new	  marks	  and	  residues	  are	  constantly	  being	  discovered	  [27,	  28].	  	  These	  marks	  are	  generally	  associated	  with	  activation	  or	  repression	  of	  transcription.	  	  This	  can	  depend	  on	  the	  marks	  physically	  altering	  the	  chromatin	  structure	  into	  an	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open	  or	  closed	  conformation.	  	  Additionally,	  other	  proteins	  can	  recognize	  and	  bind	  the	  different	  marks,	  such	  as	  chromodomain	  proteins	  binding	  acetyl	  marks	  and	  bromodomain	  proteins	  binding	  methyl	  marks,	  which	  then	  recruit	  other	  factors	  important	  for	  cellular	  and	  transcriptional	  function	  [29,	  30].	  	  A	  combination	  of	  marks	  at	  different	  sites	  is	  known	  as	  the	  histone	  code,	  with	  the	  precise	  combinations	  resulting	  in	  particular	  biological	  functions.	  	  The	  collections	  of	  enzymes	  that	  add	  and	  remove	  these	  modifications	  as	  well	  as	  the	  proteins	  that	  interact	  with	  them	  are	  known	  as	  chromatin-­‐modifying	  factors.	  Histone	  methylation	  is	  associated	  with	  both	  transcriptional	  activation	  and	  repression,	  depending	  on	  the	  specific	  mark.	  	  Lysine	  residues	  on	  the	  histone	  tails	  are	  subject	  to	  mono-­‐,	  di-­‐,	  and	  tri-­‐methylation	  [27].	  	  Two	  classes	  of	  HMTs	  (histone	  methyltransferases)	  catalyze	  the	  reaction	  on	  the	  lysines,	  those	  with	  a	  SET	  domain	  and	  those	  without	  [31,	  32].	  	  Arginine	  residues	  can	  accept	  mono-­‐	  or	  di-­‐methyl	  groups	  [27].	  	  PRMTs	  (protein	  arginine	  methyltransferases)	  catalyze	  the	  reaction	  on	  the	  arginines	  [33].	  	  Methylation	  was	  thought	  to	  be	  a	  permanent	  histone	  mark	  until	  the	  more	  recent	  discovery	  of	  histone	  demethylases,	  completing	  the	  understanding	  of	  how	  the	  mark	  is	  reversible	  [34].	  	  Methylation	  on	  histone	  H3	  lysine	  4	  (H3K4)	  is	  a	  mark	  of	  transcriptional	  activation	  and	  is	  associated	  with	  the	  enzymes	  MLL	  and	  Set7	  [35,	  36].	  	  Also	  linked	  to	  transcriptional	  activation	  are	  H3K36,	  which	  is	  methylated	  by	  Set2,	  and	  H3K79,	  which	  is	  methylated	  by	  DOT1	  [32,	  37].	  	  In	  contrast,	  H3K9	  is	  associated	  with	  repression	  and	  heterochromatin	  formation;	  this	  is	  mediated	  by	  enzymes	  such	  as	  SUV39H1,	  G9a,	  and	  SETDB1	  [31,	  38,	  39].	  	  Additionally,	  methylation	  at	  H3K27	  is	  a	  mark	  of	  transcriptional	  repression	  as	  well,	  mediated	  by	  G9a	  and	  EZH2	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[38,	  40].	  	  The	  arginine	  methylations	  also	  have	  mixed	  outcomes	  since	  PRMT5	  methylates	  H3R8	  to	  repress	  transcription,	  whereas	  CARM1	  methylates	  H3R17	  to	  activate	  transcription	  [41,	  42].	  
Acetylation is most often seen as an epigenetic transcriptional activator, with 
hyperacetylated histones a hallmark of active chromatin.  Both histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) have been found in vertebrates, using acetyl-
CoA to place and remove the acetyl mark, respectively [43].  A commonly acetylated 
mark associated with transcriptional activation is H3K14, which can be added by 
enzymes including Gcn5, PCAF, Esal, Tip60, SRC-1, TAF1, and p300 [44-50].  Gcn5 
and p300/CBP are also known to acetylate H3K23 [42, 44, 51].  These same enzymes, 
along with ATF2 and Elp3, acetylate H4K5, H4K8, H4K12, and H4K16 to activate gene 
transcription as well [44-49, 52, 53]. 
Cellular functions relying on the epigenetic state 
 The epigenetic state of a cell is important for many cellular processes, including 
transcription, DNA repair, DNA replication, and the cell cycle.  Being able to transcribe a 
gene requires the DNA to be accessible to the transcription machinery; conversely, 
closing the chromatin, thus denying access to the DNA, can facilitate repression of gene 
transcription.  Since histone modifications dictate the open versus closed state of the 
chromatin, they play a key role in regulating transcription.  Acetylation is associated with 
transcriptional activation for two main reasons.  First, the acetyl group decreases the 
charge of the histone tail, weakening the histone’s interaction with DNA and creating a 
more physically open state [54].  Second, acetylated histones are bound by chromatin-
modifying factors that are proteins associated with RNA polymerase or that directly 
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recruit the polymerase for transcription [55].  The impact of methylation on transcription 
depends on the specific mark.  H3K4 and H3K36, both correlated with activation, recruit 
activators to the nucleosomes, some of which have been co-purified with RNA 
polymerase II [37, 56-59].  H3K9, H3K20, and H3K27 induce a closed chromatin state 
while also recruiting transcriptional repressors, such as Polycomb Group proteins [60].  
Ubiquitin modifications also vary in their transcriptional response, as the mark on H2A 
K119 represses while ubiquitin on H2B K120 activates transcription [61, 62].  
Phosphorylation is associated with active transcription, particularly at H3S10 [63].  In 
addition, crosstalk of phosphorylated H3S10 can augment acetylation of H3K14, 
eliminate acetylated H3K9, and block methylated H3K9 [31, 64-66].  Transcription is 
unmistakably influenced by the epigenetic histone marks. 
 DNA repair is another process that requires an open chromatin state.  The repair 
machinery must be able to access the broken DNA region, and nucleosomes and 
individual histones may need to be shifted to facilitate the repair process.  One of the first 
steps in DNA repair is the phosphorylation of the H2A variant H2AX by PI3K at the 
damage site, which acts to recruit and maintain the necessary repair proteins [67-70].  
This H2AX phosphorylation can also bring in HATs to acetylate other residues and relax 
the chromatin structure [69].  Acetylation is known to be essential for DNA repair, as 
cells are more sensitive to DNA damaging agents when they cannot acetylate H3K56 
[71].  Methylation of yeast H4K20 is required in the recruitment of Crb2 to sites of DNA 
breakage, which is a critical protein to activate the cell cycle checkpoint; a similar 
mechanism is in place in humans with the Crb2-equivalent 53BP1 [72, 73].  
Ubiquitination of histones H3 and H4 plays a valuable role during UV-induced DNA 
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damage in recruiting the XPC repair protein [61].  Lastly, phosphorylation of H4S1 
occurs after the repair is complete, coinciding with the decrease in acetylation levels; this 
mechanism likely reinstates the normal chromatin state [74]. 
 DNA replication is a process that must be highly accurate, for both the DNA 
sequence and the maintenance of the cell’s epigenetic state, to provide the correct genetic 
information to both daughter cells.  During replication, the DNA polymerase and proteins 
associated with the replication fork need to access the DNA, resulting in disruption of the 
nucleosomes.  Following replication, the nucleosomes must be reassembled with their 
proper histone modifications.  As with the other processes, acetylation is critical to 
opening the chromatin structure to make the DNA available.  In yeast, higher levels of 
histone acetylation are correlated with an earlier firing of the replication origin [75].  
Similarly in humans, the replication timing is linked to acetylation level [76].  
Furthermore, the HAT complex HBO1 is associated with MCM2, a replication factor, as 
well as the origin recognition complex 1 [77, 78].  Without this complex or its HAT 
member, ING5, S phase progression is inhibited [79]. 
SUV39H1, an HMT with important cellular roles 	   One	  of	  the	  quintessential	  sets	  of	  experiments	  to	  identify	  genes	  encoding	  chromatin	  proteins	  occurred	  in	  Drosophila.	  	  This	  relied	  on	  the	  concept	  of	  position	  effect	  variegation	  (PEV),	  where	  chromosomal	  rearrangements	  place	  regions	  of	  euchromatin	  next	  to	  heterochromatin.	  	  PEV	  was	  first	  discovered	  in	  the	  1930s	  in	  fruit	  flies,	  when	  radiation-­‐induced	  mutants	  showed	  variable	  expression	  of	  the	  white	  gene,	  leading	  to	  mosaic	  eye	  color	  in	  the	  flies	  [80].	  	  The	  phenomenon	  was	  later	  found	  to	  be	  caused	  by	  chromosomal	  breakage	  in	  heterochromatic	  regions,	  resulting	  in	  the	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spreading	  of	  heterochromatin	  marks	  and	  silencing	  of	  the	  normally	  transcriptionally	  active	  euchromatin	  region	  [81,	  82].	  	  Two	  laboratories	  embarked	  on	  a	  large	  genetic	  screen,	  looking	  for	  enhancers	  and	  suppressors	  of	  PEV,	  with	  the	  idea	  that	  these	  mutations	  would	  identify	  genes	  involved	  in	  regulation	  of	  chromatin	  structure	  [83,	  84].	  	  They	  found	  over	  one	  hundred	  genes	  that	  could	  suppress	  or	  enhance	  PEV;	  most	  had	  dominant,	  dose-­‐dependent	  effects	  where	  loss	  of	  one	  allele	  led	  to	  the	  suppressor	  or	  enhancer	  effect.	  	  However,	  a	  few	  suppressors	  also	  had	  dose-­‐dependent	  effects	  in	  the	  presence	  of	  a	  duplication,	  where	  losing	  one	  copy	  reversed	  the	  enhancer	  effect	  and	  losing	  two	  copies	  led	  to	  the	  suppressive	  phenotype,	  and	  one	  of	  them	  was	  Su(var)3-­‐9,	  or	  suppressor	  of	  variegation	  3-­‐9	  [85].	  	   Su(var)3-­‐9	  was	  of	  particular	  interest	  because	  it	  contained	  both	  a	  chromo	  domain	  and	  a	  SET	  domain,	  two	  highly	  evolutionarily	  conserved	  chromatin	  domains.	  	  The	  suppressor	  mutations	  isolated	  in	  Su(var)3-­‐9	  were	  dominant	  over	  nearly	  all	  of	  the	  enhancer	  mutations	  tested,	  suggesting	  this	  gene	  had	  an	  important	  role	  in	  gene	  inactivation	  [86].	  	  Correspondingly,	  a	  gain-­‐of-­‐function	  mutation	  in	  Su(var)3-­‐9	  led	  to	  ectopic	  heterochromatin	  formation	  [87].	  	  Additionally,	  an	  orthologous	  gene	  was	  found	  in	  the	  fission	  yeast	  Schizosaccharomyces	  pombe	  as	  clr4,	  involved	  in	  centromere	  silencing	  and	  mating	  type	  switching	  through	  the	  action	  of	  each	  of	  the	  critical	  domains	  [88-­‐90].	  	  Mammalian	  homologues	  were	  later	  isolated,	  which	  also	  play	  a	  role	  in	  heterochromatin	  and	  mitotic	  centromeres	  [91].	  	  It	  was	  with	  the	  mammalian	  SUV39H1	  that	  the	  Su(var)3-­‐9	  family	  of	  proteins	  were	  demonstrated	  to	  be	  H3K9me3	  HMTs	  with	  the	  catalytic	  SET	  domain	  [31].	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   SUV39H1	  and	  its	  corresponding	  H3K9	  methylation	  have	  a	  variety	  of	  impacts	  on	  chromatin	  structure	  and	  cellular	  function	  as	  a	  major	  transmitter	  of	  heterochromatin.	  	  First,	  the	  silencing	  methylation	  itself	  depends	  on	  the	  H3K9	  residue	  being	  deacetylated;	  this	  is	  why	  SUV39H1	  is	  physically	  associated	  with	  HDAC1	  across	  many	  species	  [92-­‐94].	  	  SUV39H1	  has	  also	  been	  shown	  to	  interact	  with	  other	  HMTs,	  including	  SETDB1,	  G9a,	  and	  GLP,	  allowing	  for	  specificity	  among	  the	  enzymes	  as	  mono-­‐,	  di-­‐,	  and	  trimethyltransferases	  [95].	  	  One	  of	  SUV39H1’s	  important	  roles,	  along	  with	  the	  closely	  related	  SUV39H2,	  is	  to	  control	  the	  heterochromatic	  state	  of	  telomeres;	  cells	  lacking	  SUV39H1	  and	  H2	  have	  abnormal	  telomere	  elongation	  [96].	  	  SUV39H1	  is	  important	  during	  mammalian	  development	  and,	  in	  particular,	  the	  balance	  between	  proliferation	  and	  differentiation	  in	  cell	  fate	  decisions	  [97].	  	  It	  interacts	  with	  heterochromatin	  protein	  1	  (HP1),	  and	  together	  these	  proteins	  are	  recruited	  by	  the	  retinoblastoma	  (Rb)	  protein	  as	  the	  mechanism	  in	  which	  Rb	  silences	  S	  phase	  genes	  [98-­‐101].	  	  In	  mice,	  Suv39h1-­‐mediated	  H3K9	  methylation	  acts	  to	  suppress	  a	  set	  of	  genes	  upon	  lineage	  specification	  in	  the	  murine	  blastocyst,	  implicating	  Suv39h1	  and	  its	  regulation	  of	  chromatin	  structure	  in	  early	  development	  [102].	  
 
Chromatin in Zebrafish 
Zebrafish as a model organism 	   Danio	  rerio,	  commonly	  known	  as	  the	  zebrafish,	  is	  a	  member	  of	  the	  teleost	  family,	  consisting	  of	  bony	  fish	  with	  rayed	  fins.	  	  Technically	  easy	  to	  work	  with,	  the	  zebrafish	  has	  traditionally	  been	  an	  excellent	  vertebrate	  model	  organism	  for	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studying	  development.	  	  Zebrafish	  eggs	  are	  fertilized	  externally,	  development	  occurs	  entirely	  ex	  vivo,	  and	  embryos	  are	  optically	  clear,	  making	  their	  eggs	  accessible	  and	  amenable	  to	  genetic	  manipulation.	  	  They	  are	  competent	  for	  large-­‐scale	  genetic	  screens	  since	  their	  small	  size	  requires	  less	  space	  than	  mammalian	  systems.	  	  In	  addition,	  females	  can	  produce	  one	  to	  two	  hundred	  eggs	  every	  week,	  and	  their	  generation	  time	  is	  short.	  	  The	  zebrafish	  genome	  is	  fully	  sequenced,	  facilitating	  the	  use	  of	  genetic	  tools.	  	   Zebrafish	  development	  occurs	  rapidly	  over	  the	  course	  of	  a	  few	  days,	  all	  able	  to	  be	  visualized	  through	  the	  clear	  chorion.	  	  Immediately	  after	  fertilization,	  the	  zygote	  remains	  in	  the	  one-­‐cell	  stage	  for	  forty-­‐five	  minutes,	  permitting	  genetic	  manipulations	  as	  nucleic	  acid	  injections	  can	  be	  performed	  at	  this	  stage.	  	  Gastrulation	  to	  form	  the	  three	  primary	  germ	  layers	  commences	  around	  5	  hours	  post	  fertilization	  (hpf).	  	  Somites	  and	  organs	  begin	  to	  form	  beginning	  at	  10	  hpf.	  	  Shortly	  after	  24	  hpf,	  circulation	  and	  pigmentation	  commence;	  by	  48	  hpf	  the	  zebrafish	  begin	  hatching	  from	  their	  chorions	  and	  by	  72	  hpf	  are	  swimming	  freely	  [103].	  
Chromatin studies in zebrafish development 
 Numerous studies utilizing zebrafish as a model organism have demonstrated the 
important and varied roles that chromatin plays in vertebrate development.  The first 
study noted that injected plasmids were methylated de novo early in embryonic 
development to repress transcription; expression of the injected transgene could be 
induced by treatment with 5-azacytidine to block this DNA methylation or sodium 
butyrate to block histone deacetylation [104].  Since then, the zebrafish has proven useful 
in other large-scale studies.  By profiling H3K4 mono- and tri-methylation marks in 
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embryonic zebrafish, cis regulatory features were identified, leading to a more defined 
transcriptional network [105].  Epigenetic modifications have been shown to specifically 
mark genes needed during development, whether with marks solely associated with 
active transcription or also with repressive marks to ensure the genes are off but ready, 
which often occurs as early instructive signals before the onset of zygotic genome 
activation [106, 107].  Large scale profiling has also been used for cancer gene 
expression, noting that there is global genomic repression due to silencing histone 
methylation modifications in zebrafish melanoma, similar to what is observed in human 
melanomas [108]. 
 Several HDACs have been shown to control critical steps in zebrafish embryonic 
development.  In one study, HDAC1 was shown to be necessary for proper formation of 
craniofacial cartilage, the pectoral fins, and the retina, as both mutant fish and 
morpholino-injected fish exhibited deformities [109].  HDAC1 has also been shown to be 
required for blood stem cell development [110].  In another study, loss of HDAC1 caused 
defects in specification and differentiation of both the liver and exocrine pancreas while 
producing ectopic endocrine pancreatic clusters [111].  It was demonstrated that HDAC3 
also plays a role in liver and exocrine pancreas development, as blocking it with valproic 
acid or with a anti-sense blocking morpholino impaired their organogenesis; these effects 
could be rescued by HDAC3 overexpression [112]. 
 Other chromatin-modifying factors have been demonstrated to act as regulators of 
zebrafish myogenesis.  Chd7, a chromodomain protein, controls left-right symmetry in 
the developing somites, as loss of the gene results in asymmetric segmentation of the 
mesoderm [113].  Knockdown of Brg1 leads to a stunted tail and disorganization of actin 
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in the muscle, phenocopying loss of Dicer; this observation led to the discovery that Brg1 
regulates microRNAs important for the myogenic program [114].  DPF3, a novel 
epigenetic factor that can bind both acetylation and methylation marks, acts specifically 
in muscle and heart development, recruiting the BAF chromatin remodeling complex to 
complete cardiac looping and proper muscle fiber assembly [115].  The timing of 
myogenesis is controlled by Smarcd3, a SWI/SNF remodeler family member, as its 
expression triggers myod and myf5 expression [116]. 
 Several other chromatin-modifying factors play key parts in zebrafish embryonic 
development.  Brg1 is important for accurate retinal differentiation, craniofacial 
formation, brain patterning, sensory neuron formation, and neural crest induction [117].  
The BAF complex, which includes members Brg1 and Brm to promote chromatin 
remodeling, exists in a delicate balance with cardiac transcription factors to moderate 
heart development; this repression caused by the BAF complex may be the mechanism 
underlying cardiac transcription factor haploinsufficiency [118].  A double morpholino 
injection for Hmgb1 and Hmgb2 revealed that these two factors play redundant roles in 
maintaining Wnt signals throughout the embryo and Shh expression in the developing 
pectoral fin; this parallels research in mice that the loss of these two genes reduces Shh 
levels, resulting in loss of the fifth digit [119]. 
 The zebrafish embryo has acted as a platform for chromatin enzymatic discovery 
and characterization.  Zebrafish were utilized for demonstration of the first reproducible 
DNA demethylase, involving the combination of a deaminase and glycosylase, with this 
interaction enhanced by Gadd45 [120].  After showing it could demethylate H3K9 and 
H3K27 in vitro, researchers moved novel demethylase KDM7 into the fish to display its 
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in vivo function as a remover of repressive marks; knockdown of KDM7 resulted in 
developmental defects in the brain, including reduced size and number of neurons [121].  
Similarly, when the SMCX family was discovered as a family of H3K4me3 demethylases, 
the in vivo studies were performed in fish, showing a cell autonomous role for SMCX in 
neuronal survival and brain patterning [122].  Two sets of chromatin-modifying enzymes 
have been shown to act together as a cell fate network during development.  Dnmt1 and 
SUV39H1 appear to work together to control differentiation of the intestine, exocrine 
pancreas, and retina, as individual knockdown of one gene phenocopies the other and 
overexpression of one can rescue knockdown of the other [123].  Likewise, Dnmt3 and 
G9a displayed a similar epistatic interaction for neurogenesis in the brain and retina, 
suggesting the pair of factors plays a key tissue-specific silencing role in cell fate 
determination [124]. 
 Several chromatin factors have been revealed as regulators of Hox genes in the 
zebrafish embryo.  Hoxb1-regulated promoters are highly acetylated, and binding of Meis 
to Pbx at these promoters inhibits HDACs from silencing the loci in fish [125].  
Bromodomain-containing Brpf1 was shown to regulate anterior Hox gene expression 
important for segmental identity by promoting histone acetylation through MYST3 and 
remaining at the chromosomes throughout mitosis [126].  These studies, and the ones 
mentioned above, reveal how important the zebrafish has been as a model system to 
elucidate mechanisms surrounding chromatin structure and the factors that regulate it. 
 
Cancer 
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 Cancer is the second leading cause of death in the United States, causing one 
quarter of all deaths each year.  Over 577,000 cancer-related deaths are predicted to occur 
in America in 2012 [127].  The lifetime probability in the US for developing an invasive 
cancer is 45% for men and 38% for women.  As such a large public health issue, much 
scientific research is focused on cancer and its underlying pathways to illuminate the 
molecular mechanisms causing malignancy.  This is leading to the development of 
improved diagnostic and therapeutic practices, as is evidenced by the modest yet growing 
decline in mortality over the past decade [127].  Much of this research occurs in animal 
models to obtain the most physiologically relevant results possible. 
 Previously, cancer was thought of as a genetic disease, consisting of an 
accumulation of various genetic lesions.  This was first discovered when a single 
oncogene was not sufficient to transform fibroblasts but a combination of two was [128, 
129].  The first model using this idea of multiple hits was proposed for colon 
carcinogenesis [130].  This was supported by the concept of clonal evolution, where the 
more mutations accumulate, the more unstable the cell becomes, thus making further 
mutations likely [131].  At its core, cancer is a disease of unrestrained cell division, 
where proper checkpoints fail and cell proliferation can run rampant.  Genetic mutations 
certainly impact these processes, but more recent research has revealed that epigenetics 
has just as big of an impact.  This will be reviewed further below. 
 Tumor suppressors are genes that keep the cell cycle tightly regulated and are 
often silenced en route to malignancy.  To develop cancer, both copies need to be lost, 
whether both by somatic mutations or by one germline followed by one somatic lesion 
[132].  The most studied tumor suppressor gene is p53, as more than 50% of cancers 
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contain mutations in this gene [133].  The protein can be activated by DNA damage, 
hypoxia, and low ribonucleoside levels, arresting the cell in G1 so that aberrant DNA 
synthesis does not occur.  Activated p53 can also induce apoptosis if the cell cannot fix 
the above issues [134].  When mutated or inactivated, these functions cannot occur, 
leaving the cell susceptible to uncontrolled growth under conditions of DNA damage, 
leading to further mutations.  Patients with Li-Fraumeni syndrome are heterozygotes for 
p53 through germline transmission, leaving only one good copy of this critical gene; this 
puts them at a higher susceptibility for developing cancer [135]. 
 Oncogenes are genes that promote cell growth and are generally overexpressed or 
activated during tumorigenesis.  The first oncogene discovered was src, part of the 
chicken retrovirus Rous sarcoma virus required to maintain a transformed state [136].  
Since then, numerous oncogenes have been discovered.  One of the earliest ones found 
and most common ones is RAS, a small GTPase that is activated by growth factor 
signaling.  The RAS gene was first found to be the main transforming unit in two rat 
sarcoma viruses; it was later connected to human cancer as an oncogene [137-140].  RAS 
proteins activate several fundamental cell signaling pathways, including the MAP kinases, 
PI3Ks, and RALGDS proteins [141].  All three family members, HRAS, KRAS, and 
NRAS, are mutated in cancer, most commonly gain of function mutations at codons 12, 
13, and 61; the cancer types range from pancreatic, colon, and lung adenocarcinoma to 
thyroid tumors to myeloid leukemias [142]. 
 
Cancer Modeling in the Zebrafish 
Genetic tools for cancer research in the zebrafish 
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 Zebrafish, traditionally known for their role in developmental biology, have 
emerged as a thriving vertebrate model organism for cancer research.  This is made 
possible by the myriad of genetic tools available for use in the zebrafish.  For embryonic 
manipulations, specific genes can be overexpressed by microinjecting mRNA into a one 
to two cell stage embryo.  Conversely, genes can be knocked down by microinjection of 
morpholinos, antisense oligonucleotides that can either block translation initiation or 
promote frameshift mutations through aberrant splicing [143].  Mutations in specific 
genes can be identified via TILLING (Targeted Induced Local Lesions in Genomes), 
leading to functional studies by reverse genetics [144, 145].  More recently, zinc finger 
nucleases have been used to target mutations to desired genes for reverse genetics 
purposes [146, 147].  The zebrafish is also amenable to transgenic technology, both in 
mosaic and stable forms, by microinjecting DNA vectors into one-cell stage embryos. 
 Other tools of particular interest to cancer researchers have also been developed.  
An array comparative genomic hybridization (CGH) platform was designed specifically 
for zebrafish to impartially detect genomic imbalances [148].  Transplantation has also 
emerged, enabling the assessment of migration and self-renewal capacities of a particular 
tumor [149].  Transplants have been used in leukemias and myeloproliferative disorders 
to assess serial transplantability, melanomas to determine metastatic potential, and 
rhabdomyosarcomas to isolate the cancer stem cell [150-155].  Two strains of fish have 
been developed to facilitate the transplantation assay.  First, the double pigment mutant 
casper are nearly transparent fish that allow ease of visualization of transplanted tumor 
cells [154].  The casper mutants have been combined with confocal imaging and an in 
vivo flow cytometer to create a platform for simultaneous cell visualization and tracking 
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in the zebrafish [156].  Second, clonal, isogenic zebrafish lines were generated, 
permitting tumor cell transplantation into unirradiated recipients, thus minimizing the 
irradiation-related immune response on the recipient fish [157]. 
Screens for study of cancer in the zebrafish 
 The potential of the zebrafish as a cancer-modeling organism was first realized 
upon exposure of embryos and larvae to MNNG (N-methyl-N'-nitro-N-nitrosoguanidine), 
a carcinogen.  Upon exposure to the drug, zebrafish developed a wide spectrum of tumors, 
including hepatocellular adenoma and carcinoma, chondroma, biliary adenoma and 
carcinoma, seminoma, pancreatic adenoma, and various mesenchymal neoplasias [158].  
A similar group of diseases arose in fish treated with DMBA (7,12-
dimethylbenz[a]anthracene) [159].  These studies proved that zebrafish could develop 
cancer histologically similar to that of humans. 
 A large-scale, insertional mutagenesis screen was completed in the zebrafish, 
looking at genes essential for early development, using a mouse retroviral as the mutating 
agent [160-162].  Of the over three hundred genes identified, twenty-eight were 
ribosomal proteins.  However, when heterozygous fish for each of these ribosomal 
mutations were grown to adulthood, seventeen out of the twenty-eight developed 
malignant peripheral nervous sheath tumors (MPNSTs) [163, 164].  This displayed how 
forward screens could be used to identify cancer causing mutations. 
 Another large-scale screen for cell proliferation mutants revealed multiple cancer 
related genes.  After treating zebrafish with mutagenizing ENU (ethylnitrosourea), 
progeny were stained for phospho-H3, a marker of mitotic cells.  The first mutation 
characterized was in the bmyb gene, which was shown to play a role in mitotic 
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progression; the mutants were marked by misregulation of cyclin B, genomic instability, 
and susceptibility to cancer when treated with MNNG [165].  Another mutant from the 
screen, in the separase gene, displayed increased apoptosis, aneuploidy, and a similar 
higher susceptibility to cancer upon MNNG treatment [166].  Another mutation found by 
increased phospho-H3 staining was that of the sil (SCL-interrupting locus) gene; the 
mutants had disorganized mitotic spindles, leading to genomic instability [167].  A 
similar screen revealed other mutations that resulted in genomic instability and tumor 
predisposition [168]. 
Zebrafish mutant cancer models 
 Several zebrafish mutants have developed cancer similar to their human 
counterparts, proving again the efficacy of zebrafish as a cancer model organism.  
Zebrafish harboring a hypomorphic allele for p53 were resistant to apoptosis following 
irradiation and were prone to developing MPNSTs [169].  An additional p53 mutation 
leads to the formation of sarcomas in homozygous mutants and heterozygotes undergoing 
loss of heterozygosity [170].  Heterozygous zebrafish containing a mutation in the APC 
(adenomatous polyposis coli) gene, a tumor suppressor that regulates the Wnt/beta-
catenin pathway, develop intestinal, hepatic, and pancreatic neoplasias upon carcinogen 
treatment [171].  Mutants for the vhl (von Hippel-Lindau) gene form retinal neoplasms, 
closely mimicking the human diseases associated with this mutation [172]. 
Zebrafish transgenic cancer models 
 The first transgenic cancer model developed in zebrafish was a model of T cell 
leukemia, where murine c-Myc was overexpressed in the T cell compartment by the rag2 
promoter [173].  This leukemia was clonal and serially transplantable, and this study 
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opened up a whole field of cancer modeling using the fish.  A conditional variant of the 
rag2-mMyc was later developed as well as a novel model overexpressing NOTCH to 
induce malignancy [151, 174].  B cell leukemia was generated by driving the TEL-AML1 
fusion protein with the ubiquitous beta-actin promoter [150].  The first model of acute 
myeloid leukemia (AML) drove the MYST3-NCOA2 fusion protein behind the spi1 
promoter to produce AML in a low percentage of adult fish [175]. 
Transgenic melanoma was created by combining the mitf promoter driving 
hBRAFV600E specifically in melanocytes with a p53 null background; adding the p53 
mutation provided a needed second hit, as the transgenic alone formed benign moles but 
no malignant tumors [176].  A second transgenic melanoma model was made using 
hNRASQ61K behind the mitf promoter, also in a p53 null background [177].  Another 
melanoma model utilized the kita promoter to drive oncogenic hHRASG12V; these 
zebrafish displayed expanded melanocytes as larvae and developed tumors at an earlier 
onset than the previous melanoma models, making this model particularly amenable to 
screening [178].  A model of rhabdomyosarcoma was developed utilizing mosaic 
transgenic animals, caused by expression of rag2-hKRASG12D in the muscle satellite cells 
[155].  A model of pancreatic neuroendocrine carcinoma, using myod to drive MYC, was 
made that histologically resembled human tumors [179].  Using the ptf1a promoter to 
drive hKRASG12D, a model of invasive exocrine pancreatic carcinoma was created [180]. 
 Having transgenic models such as these has proved useful for learning about 
novel modifier pathways that affect cancer development.  The Tg(BRAFV600E); p53-/- 
melanoma model has been the target of two major screens.  The first also put an mitf 
mutation into the background, so the fish would have no melanocytes.  The researchers 
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injected back the mitf open reading frame driven by the mitf promoter, along with a 
candidate gene of interest also driven by mitf; the candidates came from a region on 
human chromosome one that is amplified in human melanoma.  This strategy ensured 
that fish with melanocytes got the injected vector, and those melanocytes would contain 
the candidate gene.  Using this elegant approach, the researchers were able to find that 
SETDB1, an H3K9 HMT, accelerated melanoma development [181].  This study showed 
that the zebrafish could successfully be utilized as a platform for oncogene discovery and 
that histone methyltransferase activity may be important in cancer development. 
 The second screen using this melanoma model instead utilized the embryos rather 
than the adult fish.  Microarray analyses comparing the embryos to the tumors revealed a 
set of genes important for both melanocyte development and tumor development.  Noting 
that one of these genes, crestin, a marker of neural crest progenitors, had a different 
pattern in the transgenic embryos compared to wild-type embryos, the researchers used 
this expression pattern as the assay for a chemical screen.  They found that leflunomide, a 
DHODH (dihydroorotate dehydrogenase) inhibitor, suppressed the expression of crestin, 
and through its effects on transcriptional elongation, also suppressed tumor growth in cell 
lines and xenografts [182].  This study showed how the embryos of a zebrafish tumor 
model could be utilized to discover a novel in vivo effect of a drug and potentially unveil 
a novel melanoma therapeutic. 
 
Chromatin and Cancer 	   It	  is	  evident	  that	  epigenetics	  may	  serve	  as	  a	  mechanism	  on	  the	  road	  to	  oncogenesis	  in	  addition	  to	  genetic	  mutations.	  	  An	  aberrant	  epigenetic	  state	  could	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realistically	  affect	  many	  stages	  of	  cancer	  development,	  including	  initiation,	  promotion,	  invasion,	  metastasis,	  and	  drug	  resistance.	  	  This	  is	  apparent	  since	  the	  epigenetic	  state	  impacts	  transcription,	  DNA	  repair,	  DNA	  replication,	  and	  the	  cell	  cycle,	  all	  factors	  that	  alterations	  of	  could	  lead	  to	  cellular	  transformation.	  	  Since	  histone	  modifications	  keep	  these	  processes	  under	  tight	  control,	  altering	  the	  modifications	  could	  misregulate	  them,	  leading	  to	  transformation.	  	  There	  are	  countless	  examples	  of	  how	  epigenetic	  alterations	  could	  aid	  in	  tumorigenesis	  along	  with	  traditional	  genetic	  aberrations.	  	  Epigenetics	  may	  be	  easier	  to	  treat	  in	  patients	  because	  the	  modifications	  are	  reversible,	  unlike	  genetic	  alterations.	  	   Specific	  histone	  modifications	  are	  linked	  to	  cancer	  development	  when	  their	  global	  levels	  are	  altered.	  	  These	  changes	  are	  predictive	  of	  clinical	  prognosis.	  	  For	  example,	  the	  precise	  levels	  of	  acetylated	  H3K9,	  acetylated	  H3K18,	  acetylated	  H4K12,	  dimethylated	  H4R3,	  and	  dimethylated	  H3K4	  in	  combination	  can	  predict	  in	  low-­‐grade	  prostate	  cancer	  whether	  the	  tumor	  will	  recur	  over	  the	  next	  ten	  years	  [183].	  	  Additionally,	  a	  global	  loss	  of	  acetylated	  H4K16	  and	  trimethylated	  H4K20	  is	  an	  early	  event	  in	  carcinogenesis,	  indicative	  of	  tumor	  development	  in	  a	  wide	  variety	  of	  cancers	  [184].	  	   A	  variety	  of	  HMTs	  are	  involved	  in	  cancer,	  with	  both	  tumor	  suppressive	  and	  oncogenic	  functions.	  	  SUV39H1	  is	  known	  to	  act	  as	  a	  tumor	  suppressor.	  	  In	  a	  double	  knockout	  mice	  with	  SUV39H2,	  loss	  of	  SUV39H1	  results	  in	  increased	  genomic	  instability	  and	  therefore	  increased	  tumor	  risk	  [185].	  	  SUV39H1-­‐mediated	  senescence	  protects	  mice	  from	  developing	  Ras-­‐induced	  T	  cell	  lymphomas	  [186].	  	  Conversely,	  SUV39H1	  was	  found	  silencing	  the	  tumor	  suppressor	  genes	  p15	  and	  E-­‐
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cadherin	  in	  AML	  cell	  lines,	  suggesting	  that	  when	  SUV39H1	  is	  dysregulated,	  it	  can	  participate	  in	  tumor	  formation	  [187].	  	  SETD2	  has	  also	  been	  shown	  to	  play	  a	  tumor	  suppressive	  role	  in	  breast	  cancer	  and	  clear	  cell	  renal	  cell	  carcinoma	  [188-­‐190].	  	  G9a	  is	  listed	  in	  the	  Oncomine	  database	  as	  being	  overexpressed	  in	  a	  number	  of	  tumor	  types;	  its	  overexpression	  is	  also	  known	  to	  increase	  metastatic	  and	  invasive	  potential	  of	  lung	  cancer	  [191,	  192].	  	  SMYD2	  is	  overexpressed	  in	  esophageal	  squamous	  cell	  carcinoma	  and	  maintains	  MLL-­‐AF9-­‐induced	  AML	  cells	  in	  an	  undifferentiated	  state	  [193,	  194].	  	  HMT	  EZH2	  is	  highly	  expressed	  in	  metastatic	  human	  prostate	  cells	  as	  opposed	  to	  the	  primary	  tumor;	  silencing	  it	  along	  with	  fellow	  Polycomb	  Group	  protein	  BMI-­‐1	  reverts	  the	  metastatic	  potential	  of	  the	  cells	  and	  diminishes	  their	  apoptotic-­‐resistant	  properties	  [195].	  	  In	  fact,	  EZH2	  is	  a	  marker	  of	  poor	  prognosis	  for	  prostate,	  breast,	  and	  endometrial	  cancers	  [196,	  197].	  	  In	  follicular	  and	  diffuse	  large	  B-­‐cell	  lymphoma,	  a	  heterozygous	  EZH2	  mutation	  acts	  dominantly	  to	  increase	  methylation	  levels	  and	  thereby	  induce	  tumorigenesis,	  yet	  requires	  the	  wild-­‐type	  allele	  for	  its	  mechanism	  of	  action	  [198].	  	   HDMs	  are	  also	  emerging	  as	  playing	  a	  role	  in	  cancer	  formation.	  	  LSD1,	  the	  first	  HDM	  discovered,	  is	  overexpressed	  in	  high-­‐grade	  prostate	  cancers	  and	  may	  be	  useful	  for	  prognostic	  purposes	  [199].	  	  It	  is	  also	  highly	  expressed	  in	  high-­‐grade	  neuroblastomas	  and	  estrogen	  receptor	  negative	  breast	  cancers	  [43,	  200].	  	  Conversely,	  LSD1	  has	  been	  shown	  to	  suppress	  breast	  cancer	  metastases	  through	  the	  TGFbeta1	  pathway;	  the	  mechanism	  to	  explain	  these	  differences	  remains	  unknown,	  but	  it	  is	  evident	  that	  LSD1	  can	  be	  involved	  in	  cancer	  [201].	  	  JMJD2C,	  a	  trimethylation-­‐specific	  HDM,	  was	  found	  to	  be	  overexpressed	  in	  esophageal	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squamous	  cell	  carcinoma	  [202].	  	  PLU-­‐1,	  an	  H3K4	  demethylase,	  is	  overexpressed	  in	  breast	  cancer	  cells;	  knockdown	  of	  the	  gene	  by	  RNAi	  decreases	  the	  proliferation	  of	  these	  cells	  [203,	  204].	  	  Inactivating	  mutations	  have	  been	  found	  in	  JARID1C,	  an	  H3K4	  HDM,	  and	  UTX,	  an	  H3K27	  HDM,	  in	  clear	  cell	  renal	  cell	  carcinoma	  [189,	  205].	  	  As	  more	  is	  known	  about	  HMTs	  and	  HDMs,	  they	  may	  become	  a	  popular	  drug	  target	  for	  cancer	  therapies,	  similar	  to	  HDACs	  and	  DNMTs	  currently.	  	   Histone	  acetylations	  and	  the	  HATs	  that	  add	  acetyl	  groups	  to	  histones	  are	  widely	  known	  to	  play	  a	  role	  in	  cancer	  development.	  	  Mutations	  in	  TIP60	  that	  compromise	  its	  acetyltransferase	  activity	  impair	  DNA	  repair,	  leading	  to	  genetic	  mutations	  and	  general	  genomic	  instability	  [48].	  	  TIP60	  also	  associates	  with	  the	  androgen	  receptor	  and	  is	  linked	  to	  the	  development	  of	  prostate	  cancer	  [206,	  207].	  	  HATs	  p300	  and	  CBP	  are	  known	  to	  modify	  critical	  cellular	  regulators	  such	  as	  p53,	  Rb,	  myb,	  and	  HIFalpha	  [208].	  	  They	  are	  frequently	  part	  of	  chromosomal	  rearrangements	  in	  leukemias,	  and	  mice	  with	  inactivated	  alleles	  for	  these	  genes	  develop	  blood	  tumors	  [209,	  210].	  	  ING3,	  ING4,	  and	  ING5,	  all	  HATs	  involved	  in	  different	  cellular	  complexes,	  act	  as	  tumor	  suppressors	  controlling	  cell	  proliferation	  that	  can	  impact	  cancer	  development,	  including	  glioblastomas	  [79,	  211].	  	  MOZ	  is	  a	  common	  translocation	  partner	  in	  AML,	  often	  with	  p300	  or	  CBP;	  these	  translocations	  involving	  2	  HATs	  can	  lead	  to	  activation	  of	  Hox	  genes	  and	  their	  cofactor	  Meis1,	  which	  can	  initiate	  AML	  [212,	  213].	  	  Similarly,	  MORF	  is	  often	  found	  translocated	  in	  AML	  to	  CBP	  and	  p300;	  it	  is	  also	  found	  translocated	  in	  uterine	  leiomyomata	  [214,	  215].	  	   Histone	  deacetylases	  (HDACs)	  are	  commonly	  deregulated	  in	  human	  cancers.	  	  For	  example,	  since	  HDAC1	  is	  known	  to	  interact	  with	  Rb	  and	  E2F,	  misregulation	  of	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HDAC1	  could	  have	  profound	  effects	  on	  the	  cell	  cycle	  [216-­‐218].	  	  HDAC1	  was	  first	  found	  to	  play	  a	  role	  in	  leukemia,	  as	  part	  of	  the	  mechanism	  triggered	  by	  the	  PLZF-­‐RARalpha	  fusion	  product	  that	  represses	  transcription	  of	  differentiation	  genes	  [219,	  220].	  	  HDAC1	  overexpression	  has	  been	  seen	  in	  gastric,	  renal,	  bladder,	  colorectal,	  and	  breast	  cancers	  and	  underexpression	  in	  ovarian	  cancer	  and	  glioblastomas	  [221-­‐223].	  	  Frameshift	  mutations	  in	  HDAC2	  in	  sporadic	  cancers	  can	  cause	  loss	  of	  deacetylase	  activity	  along	  with	  resistance	  to	  HDAC	  inhibitors;	  HDAC2	  overexpression	  in	  APC-­‐deficient	  colorectal	  tumors	  prevents	  cancer	  cell	  apoptosis	  [224,	  225].	  	  High	  HDAC6	  levels	  in	  breast	  cancer	  can	  be	  correlated	  with	  smaller	  tumors,	  good	  prognosis,	  and	  possibly	  responsiveness	  to	  endocrine	  therapy	  [226].	  	   DNA	  methylation	  is	  often	  found	  awry	  in	  cancer	  cells.	  	  Overall,	  cancer	  cells	  are	  hypomethylated,	  especially	  at	  the	  repetitive	  regions	  containing	  many	  CpG	  islands.	  	  This	  hypomethylation	  results	  in	  genomic	  instability	  as	  well	  as	  oncogene	  activation,	  both	  important	  factors	  in	  cancer	  risk.	  	  The	  oncogene	  myc	  is	  noted	  as	  a	  frequently	  hypomethylated	  gene	  in	  tumors	  [227].	  	  However,	  CpG	  islands	  at	  specific	  promoters	  tend	  to	  be	  hypermethylated	  in	  cancers.	  	  These	  generally	  come	  at	  the	  promoters	  of	  genes	  that	  would	  keep	  the	  cell	  in	  check,	  such	  as	  those	  involved	  with	  DNA	  repair,	  cell	  cycle,	  apoptosis,	  detoxification,	  and	  p53,	  inactivating	  these	  anti-­‐tumor	  genes.	  	  In	  addition,	  mutations	  have	  been	  found	  in	  the	  DNMT3A	  genes	  in	  patients	  with	  T-­‐cell	  lymphoma	  and	  AML,	  implying	  that	  aberrant	  DNA	  methylation	  has	  a	  role	  in	  cancer	  [228-­‐230].	  	   There	  is	  often	  interplay	  between	  the	  DNA	  methylation	  and	  the	  histone	  modifications	  in	  cancer	  development.	  	  A	  high	  percentage	  of	  genes	  often	  methylated	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in	  oncogenesis	  are	  premarked	  during	  development	  with	  H3K27-­‐trimethylation	  [231].	  	  This	  trimethylation	  is	  completed	  by	  Polycomb	  Repressive	  Complex	  2	  (PRC2)	  member	  EZH2,	  which	  may	  recruit	  the	  DNMTs	  to	  methylate	  the	  DNA;	  the	  authors	  found	  a	  correlation	  between	  de	  novo	  methylation	  on	  genes	  implicated	  in	  cancer	  and	  PRC2-­‐association	  on	  these	  same	  genes	  early	  in	  development.	  	  Often,	  PRC2	  acting	  in	  a	  stem	  cell	  would	  repress	  transcription	  factors	  needed	  for	  differentiation;	  these	  same	  genes	  appear	  to	  have	  promoter	  DNA	  methylation,	  locking	  in	  stem	  cell-­‐like	  properties	  and	  predisposing	  the	  cell	  to	  cancer	  [232,	  233].	  	  This	  crosstalk	  between	  the	  PRC2	  and	  DNMTs	  may	  occur	  aberrantly	  early	  in	  oncogenesis,	  when	  the	  distribution	  of	  PRC2	  across	  the	  genome	  is	  similar	  to	  that	  of	  a	  stem	  cell.	  	  
Conclusion	  	   The	  epigenetic	  state	  of	  the	  cell	  is	  vital	  for	  the	  regulation	  of	  cellular	  processes	  such	  as	  transcription,	  DNA	  repair,	  and	  DNA	  replication.	  	  When	  the	  chromatin	  state	  is	  not	  properly	  maintained,	  these	  functions	  can	  go	  awry,	  potentially	  leading	  to	  cancer	  development.	  	  The	  zebrafish	  has	  proven	  itself	  as	  an	  ideal	  vertebrate	  model	  organism	  for	  the	  study	  of	  the	  chromatin	  state,	  chromatin-­‐modifying	  factors,	  embryonic	  development,	  and	  tumorigenesis.	  	  In	  fact,	  a	  cancer	  screen	  in	  the	  zebrafish	  has	  already	  revealed	  a	  chromatin-­‐modifying	  factor,	  SETDB1,	  to	  be	  a	  driver	  of	  tumorigenesis	  [181].	  	  The	  studies	  in	  this	  dissertation	  utilize	  the	  zebrafish	  as	  a	  screening	  tool	  for	  a	  set	  of	  chromatin-­‐modifying	  factors	  in	  both	  cancer	  and	  hematopoiesis.	  	  Using	  a	  rhabdomyosarcoma	  model,	  the	  H3K9	  HMT	  SUV39H1	  was	  found	  to	  be	  a	  regulator	  of	  tumor	  initiation.	  	  We	  demonstrate	  that	  the	  suppressive	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Introduction	  
Rhabdomyosarcoma	  Rhabdomyosarcoma	  (RMS)	  is	  a	  pediatric	  cancer	  representing	  more	  than	  half	  of	  all	  soft	  tissue	  sarcomas	  in	  children.	  	  There	  are	  about	  350	  new	  cases	  each	  year	  in	  the	  United	  States,	  with	  two-­‐thirds	  of	  those	  occurring	  in	  children	  under	  the	  age	  of	  ten	  [234-­‐236].	  	  It	  is	  generally	  a	  sporadic	  tumor	  and	  tends	  to	  occur	  more	  frequently	  in	  boys	  than	  girls	  [234].	  	  In	  about	  20%	  of	  cases,	  the	  disease	  is	  metastatic	  at	  presentation,	  and	  even	  with	  aggressive	  treatments,	  five-­‐year	  survival	  rates	  hover	  around	  20%	  [234].	  	  However,	  the	  overall	  survival	  rate	  when	  including	  nonmetastatic	  cases	  is	  currently	  nearly	  80%,	  as	  compared	  to	  only	  25%	  in	  the	  1970s	  [237].	  	  This	  is	  likely	  due	  to	  advancements	  in	  molecular	  biology	  techniques	  that	  allow	  for	  improved	  diagnosis	  and	  imaging,	  leading	  to	  tailored	  therapies.	  	  Patients	  generally	  undergo	  an	  intensive	  treatment	  regimen	  to	  ensure	  any	  micrometastases	  are	  removed,	  involving	  a	  multimodal	  approach	  of	  surgery,	  chemotherapy,	  and	  radiation	  therapy	  [236-­‐238].	  	  Future	  research	  in	  understanding	  the	  biology	  underlying	  the	  disease	  could	  aid	  in	  improving	  the	  overall	  survival	  rate	  even	  more	  as	  well	  as	  the	  metastatic	  survival	  rate,	  particularly	  in	  the	  biological	  differences	  between	  metastatic	  and	  nonmetastatic	  tumors.	  There	  are	  two	  main	  distinct	  histological	  subtypes	  of	  RMS.	  	  The	  embryonal	  RMS	  (ERMS)	  subtype	  consists	  of	  80%	  of	  RMS	  cases,	  is	  mainly	  in	  the	  pediatric	  population,	  and	  typically	  has	  a	  better	  prognosis.	  	  ERMS	  tumors	  tend	  to	  arise	  on	  the	  head	  and	  neck,	  extremities,	  and	  in	  the	  genitourinary	  tract	  [234].	  	  Histologically,	  these	  tumors	  look	  like	  developing	  skeletal	  muscle,	  with	  characteristic	  alternating	  zones	  of	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dense	  hypercellular	  myogenesis	  and	  hypocellularity	  [239].	  	  Molecularly,	  ERMS	  is	  characterized	  by	  mutations	  or	  dysregulation	  of	  the	  RAS	  pathway	  and	  loss	  of	  heterozygosity	  at	  BWR1A	  [155,	  240-­‐244].	  	  The	  alveolar	  subtype	  (ARMS)	  is	  more	  likely	  to	  occur	  in	  adolescents,	  be	  metastatic,	  and	  have	  a	  poorer	  prognosis.	  	  This	  subtype	  is	  named	  because	  tumor	  histology	  resembles	  clusters	  of	  primitive	  cells	  floating	  in	  alveolar	  spaces;	  ARMS	  tend	  to	  occur	  in	  limbs	  and	  axial	  musculature	  [239].	  	  Molecularly,	  it	  is	  caused	  by	  a	  chromosomal	  translocation	  between	  either	  Pax3	  or	  Pax7	  and	  forkhead	  transcription	  factors	  [234,	  242,	  245].	  
Rhabdomyosarcoma	  in	  Zebrafish	  	   Two	  transgenic	  models	  of	  ERMS	  have	  previously	  been	  developed	  in	  the	  zebrafish,	  both	  involving	  injections	  of	  linearized	  transgenes	  [153,	  155].	  	  The	  first	  was	  accomplished	  by	  driving	  expression	  of	  oncogenic	  human	  KRASG12D	  with	  the	  rag2	  promoter,	  which	  was	  unexpectedly	  shown	  to	  express	  in	  mononuclear	  muscle	  satellite	  cells.	  	  The	  fish	  begin	  developing	  tumors	  as	  larvae,	  equivalent	  to	  the	  pediatric	  patients	  seen	  in	  the	  clinic	  [155].	  	  The	  second	  was	  an	  inducible	  model,	  with	  hKRASG12D	  driven	  by	  the	  beta-­actin	  promoter	  [153].	  	  Both	  sets	  of	  tumors	  express	  the	  traditional	  clinical	  markers	  of	  ERMS,	  including	  myogenin,	  myod,	  and	  desmin.	  	   The	  rag2-­‐hKRASG12D	  transgenic	  model	  was	  shown	  to	  be	  amenable	  to	  a	  co-­‐injection	  strategy.	  	  A	  second	  linearized	  transgene,	  also	  utilizing	  the	  rag2	  promoter,	  will	  always	  segregate	  together	  with	  the	  oncogenic	  transgene	  when	  both	  are	  microinjected	  into	  a	  one-­‐cell	  stage	  embryo	  [155,	  246].	  	  This	  approach	  was	  used	  to	  demonstrate	  that	  overexpression	  of	  noxa,	  a	  p53	  target,	  could	  suppress	  RMS	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formation	  [246].	  	  This	  study	  suggests	  that	  other	  genes	  potentially	  involved	  in	  RMS	  formation	  could	  be	  evaluated	  for	  their	  function	  in	  a	  similar	  co-­‐injection	  system.	  
The	  role	  of	  Chromatin	  in	  Rhabdomyosarcoma	  	   Though	  little	  is	  known	  about	  the	  role	  of	  chromatin-­‐modifying	  factors	  in	  RMS,	  a	  few	  studies	  are	  beginning	  to	  implicate	  specific	  factors.	  	  BAF47,	  the	  human	  SNF5	  homolog	  and	  a	  key	  component	  of	  the	  SWI/SNF	  chromatin	  remodeling	  complex,	  was	  noted	  to	  be	  mutated	  or	  deleted	  in	  25%	  of	  primary	  tumors	  and	  10%	  of	  RMS	  cell	  lines	  analyzed	  [247,	  248].	  	  Polycomb	  Group	  member	  YY1	  was	  found	  to	  be	  upregulated	  in	  RMS	  cell	  lines	  and	  primary	  tumors,	  leading	  to	  recruitment	  of	  EZH2	  and	  HDAC1	  to	  miR-­‐29,	  silencing	  this	  microRNA,	  and	  thereby	  preventing	  muscle	  differentiation	  and	  facilitating	  tumor	  development	  [249].	  	  Upon	  treatment	  with	  12-­‐O-­‐Tetradecanoylphorbol-­‐13-­‐acetate	  (TPA),	  the	  ERMS	  cell	  line	  RD	  differentiates	  through	  a	  mechanism	  involving	  PCAF	  and	  the	  BRG1	  subunit	  SWI/SNF	  complex	  being	  sequentially	  recruited	  to	  the	  myogenin	  promoter;	  this	  may	  represent	  a	  novel	  therapeutic	  strategy	  to	  get	  tumors	  to	  differentiate	  in	  vivo	  [250].	  	  SUV39H1	  expression	  increases	  in	  an	  ARMS	  cell	  line	  under	  differentiation	  conditions,	  blocking	  MyoD	  and	  tumor	  differentiation,	  similar	  to	  its	  role	  inhibiting	  normal	  muscle	  development	  [251,	  252].	  	  The	  histone	  demethylase	  LSD1	  was	  shown	  to	  have	  high	  expression	  levels	  in	  malignant	  sarcomas,	  including	  ARMS	  (2/2)	  and	  ERMS	  (6/7)	  tumors;	  it	  may	  prove	  useful	  as	  a	  diagnostic	  marker	  or	  a	  novel	  drug	  target	  [253,	  254].	  	  Since	  the	  regulation	  of	  chromatin	  structure	  can	  play	  a	  determinative	  role	  in	  the	  formation	  and	  behavior	  of	  cancers	  of	  the	  muscle,	  it	  is	  likely	  that	  many	  more	  chromatin	  factors	  participate	  in	  RMS,	  but	  they	  remain	  to	  be	  discovered.	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   Here,	  using	  an	  injection-­‐based	  screening	  approach,	  we	  screened	  nineteen	  chromatin-­‐modifying	  factors	  for	  their	  role	  in	  RMS	  formation.	  	  One,	  SUV39H1,	  was	  determined	  to	  be	  a	  strong	  suppressor,	  and	  this	  effect	  was	  dependent	  on	  an	  active	  SET	  domain.	  	  SUV39H1	  did	  not	  impact	  overall	  tumor	  characteristics	  when	  compared	  to	  control	  tumors,	  including	  histological	  and	  gene	  expression	  analyses.	  	  Studies	  of	  tumor	  initiation	  using	  a	  fluorescent	  monitoring	  system	  demonstrated	  that	  SUV39H1	  acts	  between	  5	  and	  7	  dpf	  at	  the	  beginning	  of	  tumor	  formation.	  	  Gene	  expression	  studies	  demonstrate	  reduced	  cyclin	  B1	  mRNA	  expression	  in	  SUV39H1	  injected	  embryos,	  and	  the	  cyclin	  B1	  gene	  was	  bound	  by	  SUV39H1	  in	  muscle	  progenitor	  cells.	  	  This	  data	  suggests	  a	  model	  in	  which	  altered	  cyclin	  B1	  and	  cell	  cycle	  defects	  caused	  by	  SUV39H1	  overexpression	  is	  responsible	  for	  the	  defect	  in	  tumor	  initiation.	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Methods	  
Zebrafish	  Zebrafish	  were	  maintained	  and	  developmentally	  staged	  as	  previously	  described	  according	  to	  IACUC	  guidelines	  [255].	  	  The	  Animal	  Care	  and	  Use	  Committee,	  Children’s	  Hospital	  Boston	  approved	  all	  animal	  protocols.	  
Vectors	  and	  cloning	  The	  rag2-­‐hKRASG12D	  and	  rag2-­‐GFP	  vectors	  were	  obtained	  from	  D.	  Langenau	  [155].	  	  The	  mylz2-­‐GFP/mCherry,	  mcad-­‐GFP/dsRedexpress,	  myog-­‐GFP,	  rag2	  destination,	  
rag2-­‐hSUV39H1H324K,	  and	  rag2-­‐hSUV39H1C326A	  vectors	  were	  obtained	  from	  N.	  Storer	  [256,	  257].	  	  rag2-­‐chromatin	  factor	  expression	  vectors	  were	  generated	  by	  Gateway	  recombination	  using	  human,	  full-­‐length	  open	  reading	  frames	  from	  the	  Ultimate	  ORF	  Clone	  collection	  (Invitrogen).	  	  A	  pENTR-­‐mPAX7	  vector	  was	  obtained	  from	  Open	  Biosystems	  and	  was	  put	  behind	  the	  rag2	  promoter	  through	  Gateway	  recombination.	  	  To	  generate	  the	  mylz2-­‐hSUV39H1	  and	  mcad-­‐hSUV39H1	  vectors,	  SUV39H1	  was	  amplified	  from	  rag2-­‐hSUV39H1	  DNA using 5’- 
AATTCCGGATCCCACCATGGCGGAAAATTTAAAAGGCT-3’ and 5’- 
TCAGGACGGCGTTTATGGAGAAGATCTTCGAATTAAGG-3’.  The forward primer 
contains a BamHI site and the reverse a HindIII site.	  	  The	  amplified	  SUV39H1,	  mylz2-­‐GFP,	  and	  mcad-­‐GFP	  vectors	  were	  digested	  with	  BamHI	  and	  HindIII,	  treated	  with	  Antarctic	  Phosphatase,	  and	  ligated.	  
Microinjection	  and	  tumor	  scoring	  The	  rag2-­hKRASG12D,	  rag2-­chromatin	  factor,	  and	  all	  fluorescent	  protein/SUV39H1-­‐containing	  vectors	  were	  linearized	  with	  XhoI,	  purified,	  and	  diluted	  in	  0.5xTE	  +	  0.1M	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KCl.	  	  For	  co-­‐injection	  of	  three	  transgenes,	  each	  was	  diluted	  to	  40	  ng/uL,	  and	  for	  co-­‐injection	  of	  four	  transgenes,	  each	  was	  diluted	  to	  30	  ng/uL.	  	  For	  co-­‐injection	  of	  five	  transgenes,	  each	  was	  diluted	  to	  25	  ng/uL.	  	  One	  nL	  of	  the	  vector	  dilutions	  was	  microinjected	  into	  one-­‐cell	  stage	  AB	  strain	  zebrafish	  embryos.	  	  For	  the	  screen,	  fish	  were	  scored	  for	  visible	  tumor	  formation	  every	  2-­‐4	  days	  commencing	  at	  12	  dpf.	  	  For	  younger	  larvae,	  fish	  were	  scored	  for	  tumor	  formation	  by	  presence	  of	  fluorescence	  every	  2-­‐3	  days	  commencing	  at	  6	  dpf.	  	  For	  the	  tumor	  growth	  analysis,	  fluorescent	  photos	  of	  each	  fish	  were	  taken	  at	  the	  same	  zoom	  and	  magnification,	  and	  photos	  were	  analyzed	  for	  number	  of	  fluorescent	  particles	  on	  ImageJ.	  
Identification	  of	  known	  and	  putative	  chromatin	  modifying	  factors	  Human	  chromatin	  modifying	  factors	  were	  identified	  using	  CREMOFAC,	  SMART	  domain,	  CDD,	  and	  Pfam	  databases.	  
GSEA	  GSEA	  on	  published	  human	  microarray	  data	  sets	  was	  performed	  as	  described	  previously	  [155,	  258].	  
Statistical	  analysis	  Tumor-­‐free	  survival	  over	  time	  is	  graphically	  represented	  as	  a	  Kaplan-­‐Meier	  estimate	  of	  survival.	  	  The	  log-­‐rank	  test	  was	  used	  to	  compare	  survival	  of	  experimental	  and	  control	  groups.	  
Quantitative	  RT-­PCR	  analysis	  RNA	  was	  isolated	  from	  whole	  tumors	  using	  RNeasy	  Mini	  Kit	  (Qiagen)	  using	  the	  animal	  tissue	  protocol	  and	  subsequently	  treated	  with	  DNase	  I.	  	  cDNA	  synthesis	  was	  performed	  using	  SuperScript	  III	  First-­‐Strand	  Synthesis	  SuperMix	  for	  qRT-­‐PCR,	  and	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quantitative	  RT-­‐PCR	  was	  performed	  using	  SYBR	  GreenER	  qPCR	  SuperMix	  for	  iCycler	  (Invitrogen).	  The	  following	  primers	  were	  used	  to	  detect	  gene	  expression:	  EF1-­alpha	  5’-­‐CATCGAGAAGTTCGAGAAGGAAGC-­‐3’,	  5’-­‐GTCAATGGTGATACCACGCTCAC-­‐3’;	  hKRAS	  5’-­‐TTGATGGAGAAACCTGTCTCTTGG-­‐3’,	  5’-­‐CAAATACACAAAGAAAGCCCTCCC-­‐3’;	  
hSUV39H1	  5’-­‐TGTGTGCGTATCCTCAAGCAAGTTC-­‐3’,	  5’-­‐CCTCATTCTCTACAGTGATGCGTCC-­‐3’;	  pax7	  5’-­‐CAGTATTGACGGCATTCTGGGAG-­3’,	  5’-­TCTCTGCTTTCTCTTGAGCGGC-­‐3’;	  myf5	  5’-­‐CCAGACAGTCCAAACAACAGACC-­‐3’,	  5’-­‐TGAGCAAGCAGTGTGAGTAAGCG-­‐3’;	  cdh15	  5-­‐‘CTAAGGAAAGATGCACCCCATTAC-­‐3’,	  5’-­‐TCAGAGCTGTGTCGTATGGTGG-­‐3’;	  myog	  5’-­‐GTGGACAGCATAACGGGAACAG-­‐3’,	  5’-­‐TCTGAAGGTAACGGTGAGTCGG-­‐3’;	  desmin	  5’-­‐CGAGATTGACTCTCTCAAGGGCAC-­‐3’,	  5’-­‐GGGCGATAGTGTCCTGATAACCAC-­‐3’;	  mylz2	  5’-­‐TTGACCACTCAGTGCGACAGGTTC-­‐3’,	  5’-­‐AACATTGCCAGCCACATCTGGG-­‐3’.	  	  Gene	  expression	  was	  normalized	  to	  EF1-­alpha.	  
Microarray	  analysis	  RNA	  was	  isolated	  from	  six	  tumors	  each	  of	  the	  rag2-­‐mCherry	  and	  rag2-­‐hSUV39H1	  types	  with	  the	  RNeasy	  Mini	  Kit	  (Qiagen)	  using	  the	  animal	  tissue	  protocol	  and	  subsequently	  treated	  with	  DNase	  I.	  	  cDNA	  was	  prepared	  and	  hybridized	  to	  zebrafish	  Affymetrix	  arrays.	  	  Genes	  differentially	  regulated	  between	  the	  tumor	  types	  were	  identified	  (>2-­‐fold	  change,	  p<0.05).	  	  For	  the	  larval	  samples,	  RNA	  was	  isolated	  in	  the	  same	  manner	  from	  approximately	  twenty	  sibling	  embryos	  per	  sample	  and	  time	  point,	  with	  three	  biological	  replicates	  for	  each.	  	  Microarrays	  were	  performed	  on	  Affymetrix	  chips.	  
EdU	  incorporation	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Tumor-­‐bearing	  fish	  at	  28	  to	  30	  dpf	  were	  injected	  intraperitoneally	  with	  10ul	  of	  2.5mg/ml	  EdU	  per	  0.25g	  body	  weight.	  	  After	  24	  hours,	  fish	  were	  euthanized	  and	  frozen	  in	  Optimal	  Cutting	  Temperature	  (OCT)	  medium	  at	  -­‐80°C	  overnight.	  	  12um	  cryostat	  sections	  were	  prepared	  for	  each	  tumor,	  and	  EdU	  labeling	  was	  performed	  using	  the	  Click-­‐iT	  EdU	  Alexa	  Fluor	  594	  Imaging	  Kit	  (Invitrogen).	  	  Labeled	  sections	  were	  imaged	  at	  400x	  magnification	  using	  a	  compound	  fluorescent	  microscope,	  and	  the	  number	  of	  EdU-­‐positive	  and	  DAPI-­‐positive	  nuclei	  were	  counted	  in	  three	  separate	  1.37	  x	  104	  um2	  fields	  per	  tumor.	  	  The	  ratios	  of	  EdU-­‐positive	  to	  DAPI-­‐positive	  nuclei	  in	  the	  three	  fields	  were	  averaged	  to	  calculate	  an	  EdU/DAPI	  ratio	  for	  each	  tumor.	  
Histopathology	  Fish	  were	  euthanized	  and	  fixed	  in	  4%	  paraformaldehyde	  overnight	  at	  4°C	  and	  then	  decalcified	  in	  0.5M	  EDTA,	  pH8.	  	  Paraffin	  embedding,	  sectioning,	  H&E	  staining,	  and	  RNA	  in	  situ	  hybridization	  were	  performed	  according	  to	  standard	  techniques	  by	  the	  Brigham	  &	  Women’s	  Pathology	  Core.	  
In	  Situ	  Hybridization	  Whole	  mount	  in	  situ	  hybridizations	  (ISHs)	  were	  performed	  as	  previously	  described	  [259,	  260].	  	  Antisense	  mRNA	  probes	  were	  synthesized	  from	  digested	  plasmids	  [260].	  	  After	  linearization	  and	  phenol:chloroform	  extraction,	  the	  DIG-­‐labeled	  probes	  were	  synthesized	  using	  T7	  polymerase	  and	  purified	  using	  the	  RNeasy	  kit	  (Qiagen).	  
FACS	  Analysis	  Quadruple	  injected	  SUV39H1	  and	  mCherry	  control	  5	  and	  7	  dpf	  larvae,	  along	  with	  uninjected	  wild-­‐type	  controls,	  were	  homogenized,	  resuspended	  in	  0.9X	  PBS,	  and	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filtered	  (40um).	  	  The	  samples	  were	  run	  on	  a	  FACS	  LSRII	  (Becton	  Dickinson)	  and	  analyzed	  with	  FloJo.	  
TUNEL	  Whole-­‐mount	  staining	  for	  TUNEL was completed on 5 and 7 dpf triple injected 
SUV39H1 and mCherry larvae.  Larvae were fixed in 4% paraformaldehyde (PFA) 
overnight, bleached to remove melanocytes in a 3% H2O2/0.5% KOH solution for 45 
minutes, then fixed again overnight in 4% PFA.  Larvae were then stained as previously 
described using the ApopTag® Plus Peroxidase In Situ Apoptosis Kit (Millipore) [165]. 
Confocal	  Imaging	  Analysis	  Imaging	  was	  performed	  on	  a	  Zeiss	  710	  NLO	  laser	  scanning	  confocal	  microscope	  (Zeiss).	  	  GFP	  and	  mCherry	  were	  excited	  by	  488	  and	  594 nm	  laser	  lines,	  respectively.	  	  Larval	  fish	  were	  first	  scored	  for	  fluorescence,	  then	  anesthetized	  in	  2%	  Tricaine	  and	  embedded	  in	  agarose.	  	  Images	  were	  analyzed	  with	  ZEN	  2011	  and	  ImageJ.	  
Cell	  cycle	  analysis	  Well-­‐injected	  embryos	  were	  homogenized	  in	  0.9x	  PBS	  +	  10%	  FBS	  using	  QIAshredder	  columns;	  the	  cells	  were	  filtered,	  spun	  down,	  washed,	  and	  fixed	  in	  2%	  PFA	  in	  0.95x	  PBS	  for	  30	  minutes.	  	  Then	  the	  cells	  were	  spun	  down,	  washed	  in	  0.9x	  PBS,	  and	  incubated	  in	  70%	  ethanol	  for	  30	  minutes.	  	  Following	  another	  spin,	  the	  cells	  were	  then	  incubated	  in	  a	  PI	  solution	  for	  30	  minutes,	  filtered,	  then	  run	  on	  a	  FACSCantoII	  machine	  (Becton	  Dickinson)	  and	  analyzed	  with	  FloJo.	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Results	  
An	  in	  vivo	  overexpression	  screen	  in	  zebrafish	  to	  identify	  modifiers	  of	  
embryonal	  rhabdomyosarcoma	  Because	  of	  the	  importance	  of	  epigenetic	  regulation	  in	  muscle	  development	  and	  cancer,	  we	  sought	  to	  determine	  whether	  chromatin-­‐modifying	  factors	  play	  a	  role	  in	  RMS	  formation.	  	  Using	  protein	  domain	  family	  databases,	  333	  human	  genes	  were	  identified	  that	  were	  predicted	  to	  encode	  proteins	  harboring	  domains	  associated	  with	  chromatin	  regulation	  (Figure	  2.S1.A).	  	  While	  some	  of	  these	  genes	  have	  known	  roles	  in	  chromatin	  regulation,	  we	  hypothesized	  that	  other	  genes	  on	  the	  list	  would	  have	  roles	  in	  chromatin	  regulation	  that	  have	  not	  yet	  been	  characterized.	  	  Using	  gene	  set	  enrichment	  analysis	  (GSEA)	  on	  human	  RMS	  microarray	  data	  sets,	  we	  found	  that	  this	  list	  of	  putative	  or	  known	  chromatin	  modifiers	  was	  significantly	  upregulated	  in	  human	  ERMS	  and	  ARMS	  (p<0.05,	  Figure	  2.S1.B,C).	  	  	  These	  data	  suggest	  that	  deregulation	  of	  chromatin	  modifying	  factors	  may	  play	  an	  important	  role	  in	  RMS	  pathogenesis.	  To	  identify	  chromatin-­‐modifying	  factors	  that	  act	  as	  modifiers	  of	  RMS,	  we	  utilized	  a	  previously	  characterized	  model	  of	  ERMS	  in	  the	  zebrafish	  [155].	  	  This	  model	  was	  based	  on	  a	  microinjection	  strategy	  amenable	  to	  co-­‐injection	  of	  different	  factors	  with	  their	  expression	  driven	  by	  the	  rag2	  promoter.	  	  Injection	  of	  a	  rag2-­‐hKRASG12D	  construct	  drives	  tumor	  formation;	  additional	  genes	  expressed	  on	  separate,	  linearized	  plasmids,	  all	  also	  driven	  by	  rag2,	  would	  be	  co-­‐integrated	  with	  and	  co-­‐expressed	  in	  the	  rag2-­‐hKRASG12D	  tumors.	  	  Therefore,	  we	  developed	  a	  strategy	  to	  identify	  suppressors	  or	  enhancers	  of	  RMS	  formation	  when	  the	  candidate	  gene,	  driven	  by	  rag2,	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was	  co-­‐injected	  with	  rag2-­‐hKRASG12D.	  	  To	  eliminate	  variability,	  a	  third	  construct,	  
mylz2	  (myosin	  light	  polypeptide	  2)-­‐GFP,	  was	  co-­‐injected.	  	  This	  allowed	  the	  microinjected	  embryos	  to	  be	  separated	  into	  categories	  of	  GFP-­‐low,	  middle,	  and	  high	  mosaicism	  at	  2	  dpf.	  	  The	  level	  of	  GFP	  mosaicism	  directly	  correlated	  with	  successful	  microinjection	  of	  the	  hKRASG12D	  and	  therefore	  tumor	  levels	  (data	  not	  shown).	  	  Those	  with	  high	  GFP	  mosaicism	  were	  selected	  and	  analyzed	  for	  visual	  tumor	  formation	  every	  3	  days	  from	  12	  to	  50	  dpf	  (Figure	  2.1.A).	  	  A	  list	  of	  nineteen	  factors	  were	  chosen	  for	  analysis,	  which	  represent	  proteins	  containing	  SET	  or	  chromo	  domains,	  as	  well	  as	  nine	  of	  the	  most	  highly	  upregulated	  genes	  in	  human	  ERMS	  versus	  normal	  muscle	  (Figure	  2.1.B).	  	  Of	  these	  factors,	  SUV39H1	  emerged	  as	  the	  strongest	  modifier,	  significantly	  suppressing	  tumor	  formation	  by	  the	  logrank	  test	  (p=0.0001,	  Figure	  2.1.C).	  
Suppression	  by	  SUV39H1	  occurs	  early	  and	  is	  dependent	  on	  enzymatic	  activity	  SUV39H1-­‐overexpressing	  tumors	  had	  a	  delay	  in	  tumor	  onset,	  so	  the	  Kaplan-­‐Meier	  curve	  appears	  suppressed	  from	  the	  beginning	  of	  the	  assay	  at	  12	  dpf.	  	  To	  examine	  tumor	  formation	  with	  a	  more	  sensitive	  and	  quantitative	  assay,	  we	  used	  a	  quantitative	  fluorescent	  assay	  with	  a	  quadruple	  injection	  approach.	  	  As	  before,	  zebrafish	  were	  injected	  with	  rag2-­‐hKRASG12D	  and	  either	  rag2-­‐hSUV39H1	  or,	  as	  a	  control,	  rag2-­mCherry.	  	  The	  third	  construct	  was	  rag2-­‐GFP	  to	  track	  the	  tumors	  by	  fluorescence	  as	  they	  arose,	  as	  it	  has	  been	  shown	  that	  100%	  of	  rag2-­‐GFP-­‐positive	  foci	  go	  on	  to	  eventually	  form	  a	  tumor	  (X.	  Le,	  personal	  communication).	  	  The	  fourth	  construct	  was	  mylz2-­‐mCherry	  to	  continue	  analyzing	  only	  successfully	  microinjected	  embryos.	  	  By	  analyzing	  GFP	  fluorescence	  in	  the	  musculature	  of	  highly	  mCherry	  






Figure	  2.1.	  	  An	  overexpression	  screen	  reveals	  SUV39H1	  as	  a	  suppressor	  of	  
rhabdomyosarcoma	  formation	  in	  zebrafish.	  	  (A)	  Three	  linearized	  DNA	  constructs	  were	  injected	  into	  one-­‐cell	  stage	  embryos,	  rag2-­‐hKRASG21D,	  rag2-­‐chromatin	  factor,	  and	  mylz2-­‐GFP.	  	  At	  2	  dpf,	  embryos	  were	  scored	  for	  GFP	  mosaicism;	  only	  those	  that	  were	  GFP-­‐high	  were	  kept	  for	  tumor	  evaluation.	  	  Tumor-­‐free	  survival	  curves	  were	  then	  constructed	  for	  days	  12-­‐50	  of	  life,	  looking	  for	  enhancers	  or	  suppressors	  of	  the	  curve	  produced	  by	  injected	  of	  rag2-­‐hKRASG12D	  without	  a	  modifier	  gene.	  	  (B)	  Nineteen	  chromatin-­‐modifying	  factors	  were	  analyzed	  for	  their	  effects	  on	  RMS	  formation.	  	  Most	  did	  not	  result	  in	  significant	  differences	  from	  the	  three	  historical	  control	  curves,	  seen	  as	  dotted	  black	  lines.	  	  (C)	  SUV39H1	  significantly	  suppressed	  RMS	  formation,	  compared	  to	  a	  control	  curve	  where	  the	  modifier	  gene	  was	  dsRed	  (SUV39H1	  n=73,	  dsRed	  n=80,	  p=0.0001).	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mosaic	  larvae,	  SUV39H1	  still	  significantly	  suppressed	  RMS	  formation	  (p=0.0003,	  Figure	  2.2.A).	  To	  determine	  if	  the	  HMT	  activity	  of	  SUV39H1	  played	  a	  role	  in	  tumor	  suppression,	  we	  co-­‐injected	  SUV39H1	  with	  point	  mutations	  in	  the	  enzymatic	  SET	  domain	  along	  with	  rag2-­‐hKRASG12D	  and	  analyzed	  early	  tumor	  formation	  by	  fluorescence.	  	  Both	  point	  mutations,	  H324K	  and	  C326A,	  resulted	  in	  tumor	  curves	  similar	  to	  the	  control	  mCherry-­‐overexpression	  curve	  rather	  than	  the	  suppressed	  SUV39H1-­‐overexpression	  curve	  (C326A	  p=0.0525,	  H324K	  p=0.7642,	  Figure	  2.2.B,C).	  	  This	  result	  indicates	  that	  the	  tumor	  suppression	  depends	  on	  the	  HMT	  activity	  of	  the	  SET	  domain	  in	  SUV39H1,	  ruling	  out	  any	  scaffold	  effects	  since	  this	  enzyme	  is	  a	  part	  of	  a	  multiprotein	  complex.	  
Characterization	  of	  SUV39H1-­overexpressing	  tumors	  Since	  SUV39H1	  is	  known	  to	  play	  a	  role	  in	  regulation	  of	  cell	  cycle	  and	  S	  phase	  genes	  [100,	  101,	  261,	  262],	  we	  determined	  if	  there	  was	  any	  difference	  in	  cell	  cycle	  rate	  between	  SUV39H1-­‐overexpressing	  tumors	  and	  control	  tumors	  overexpressing	  mCherry.	  	  5-­‐ethynyl-­‐2'-­‐deoxyuridine	  (EdU),	  a	  bromodeoxyuridine	  analog,	  was	  injected	  intraperitoneally	  into	  five	  fish	  of	  each	  tumor	  type.	  	  Twenty-­‐four	  hours	  post	  injection,	  the	  fish	  were	  embedded	  in	  OCT	  and	  cryosectioned	  (Figure	  2.3A).	  	  Staining	  for	  EdU	  in	  GFP-­‐positive	  tumor	  sections	  revealed	  no	  difference	  in	  the	  percentage	  of	  cells	  dividing	  during	  labeling	  when	  normalized	  to	  cell	  number	  by	  DAPI	  staining,	  indicating	  no	  difference	  in	  cell	  cycle	  rate	  in	  the	  SUV39H1-­‐overexpressing	  and	  control	  tumors	  (Student’s	  t-­‐test,	  p=0.78,	  Figure	  2.3B).	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Figure	  2.2.	  Suppression	  by	  SUV39H1	  depends	  on	  enzymatic	  SET	  domain.	  	  (A)	  Injections	  into	  one-­‐cell	  stage	  embryos	  of	  rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry,	  then	  selected	  for	  mCherry-­‐high	  embryos,	  and	  monitored	  for	  tumor	  formation	  by	  GFP	  presence,	  results	  in	  a	  tumor	  curve	  that	  is	  significantly	  suppressed	  from	  rag2-­‐mCherry	  control	  curves.	  	  (SUV39H1	  n=56,	  mCherry	  n=58,	  p=0.0003).	  	  (B)	  Injection	  of	  the	  point	  mutant	  SUV39H1C326A	  results	  in	  a	  tumor	  curve	  not	  significantly	  different	  from	  the	  mCherry	  control	  curve.	  	  However,	  this	  curve	  is	  significantly	  different	  from	  rag2-­‐hSUV39H1	  tumors	  (C326A	  n=57,	  mCherry	  n=48,	  p=0.0525).	  	  (C)	  Similar	  injections	  of	  the	  rag2-­‐hSUV39H1H324K	  point	  mutant	  also	  results	  in	  a	  tumor	  curve	  like	  the	  rag2-­‐mCherry	  curve	  and	  significantly	  different	  from	  the	  rag2-­‐hSUV39H1	  curve	  (H324K	  n=17,	  mCherry	  n=19,	  p=0.7642).	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Figure	  2.3.	  SUV39H1	  overexpression	  does	  not	  impact	  cell	  cycle	  or	  muscle	  
differentiation	  status	  of	  mature	  tumors.	  	  (A)	  Experimental	  design	  for	  in	  vivo	  cell	  cycle	  analysis.	  	  One-­‐cell	  stage	  embryos	  were	  injected	  with	  three	  constructs	  rag2-­‐hKRASG12D,	  either	  rag2-­‐mCherry	  or	  rag2-­‐hSUV39H1,	  and	  mylz2-­‐GFP.	  	  High-­‐GFP	  expressing	  fish	  were	  grown	  up,	  and	  those	  with	  tumors	  were	  injected	  IP	  with	  EdU.	  	  After	  24	  hours,	  the	  injected	  fish	  were	  sacked	  and	  cryopreserved.	  	  (B)	  Number	  of	  EdU-­‐positive	  cells,	  stained	  on	  GFP-­‐positive	  tumor	  sections,	  was	  normalized	  to	  number	  of	  total	  cells,	  determined	  by	  presence	  of	  DAPI.	  	  No	  difference	  was	  observed	  between	  the	  control	  and	  SUV39H1	  tumors	  (n=5	  for	  each	  group;	  p=0.78).	  	  (C)	  H&E	  staining	  of	  RMS	  tumors	  overexpression	  either	  mCherry	  or	  SUV39H1.	  	  Both	  sets	  of	  tumors	  are	  very	  poorly	  differentiated;	  they	  also	  look	  similar	  to	  each	  other,	  indicating	  no	  difference	  in	  differentiation	  state	  of	  the	  tumors	  (bars	  represent	  50um,	  n=6	  for	  each	  group).	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   We	  hypothesized	  that	  muscle	  differentiation	  may	  be	  affected	  in	  the	  modified	  tumors,	  since	  SUV39H1	  is	  known	  to	  regulate	  the	  master	  regulator	  MyoD	  [252].	  	  H&E	  staining	  on	  SUV39H1	  and	  control	  tumors	  revealed	  no	  change	  in	  muscle	  differentiation	  status.	  	  Both	  sets	  of	  tumors	  were	  in	  an	  undifferentiated	  state,	  with	  higher	  cellularity	  and	  mostly	  mononucleated	  cells	  	  (Figure	  2.3.C).	  	  Global	  gene	  expression	  analysis	  of	  control	  and	  SUV39H1	  tumors	  did	  not	  result	  in	  any	  major	  differences	  (data	  not	  shown).	  	  These	  studies	  demonstrate	  that	  overexpression	  of	  SUV39H1	  did	  not	  significantly	  affect	  cell	  cycle	  rate	  or	  the	  differentiation	  state	  of	  
rag2-­‐hKRASG12D	  RMS	  tumors,	  at	  least	  at	  the	  gross	  histological	  level.	  
SUV39H1	  suppress	  initiation	  of	  RMS	  tumors	  The	  suppressive	  phenotype	  of	  SUV39H1	  tumors	  in	  the	  Kaplan-­‐Meier	  survival	  curves	  has	  already	  occurred	  at	  the	  first	  time	  point	  of	  12	  dpf	  (Figure	  2.1.C).	  	  To	  examine	  earlier	  time	  points,	  we	  utilized	  the	  quadruple	  co-­‐injection	  approach	  described	  above	  and	  shown	  in	  Figure	  2.2.	  	  At	  7	  dpf,	  highly	  mCherry	  mosaic	  larval	  fish	  were	  examined	  for	  the	  presence	  of	  GFP	  in	  the	  musculature.	  	  Those	  that	  had	  GFP	  positive	  cells	  at	  7	  dpf	  were	  examined	  again	  at	  10	  and	  13	  dpf	  for	  the	  growth	  of	  these	  fluorescent	  patches	  into	  tumors	  (Figure	  2.4.A).	  	  In	  100%	  of	  cases,	  the	  GFP-­‐positive	  patches	  went	  on	  to	  produce	  a	  tumor,	  some	  as	  early	  as	  13	  dpf	  (Figure	  2.4.B).	  	  The	  size	  of	  the	  developing	  tumors	  can	  be	  quantified	  by	  measuring	  the	  number	  of	  fluorescent	  pixels	  in	  the	  image	  using	  the	  image	  analysis	  software	  ImageJ.	  	  Relative	  growth	  rates	  for	  SUV39H1	  and	  control	  cohorts	  revealed	  that	  both	  sets	  of	  tumors	  grew	  at	  the	  same	  rate	  (Student’s	  t-­‐test,	  p=0.46,	  Figure	  2.4.C).	  	  Within	  clutches	  containing	  equivalent	  levels	  of	  mCherry	  mosaicism,	  the	  number	  of	  larvae	  in	  a	  given	  clutch	  with	  GFP-­‐	  





Figure	  2.4.	  SUV39H1	  impacts	  the	  initiation,	  not	  the	  growth	  rate,	  of	  the	  tumors	  	  
(A)	  Experimental	  design	  to	  view	  the	  tumors	  in	  larval	  stages	  by	  fluorescence.	  	  Four	  constructs	  are	  injected	  into	  one	  cell	  stage	  embryos,	  rag2-­‐hKRASG12D,	  rag2-­hSUV39H1	  or	  control	  rag2-­‐mCherry,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry.	  	  Fish	  highly	  mosaicism	  for	  
mylz2-­‐mCherry	  expression	  are	  analyzed	  on	  day	  7	  for	  presence	  of	  GFP,	  indicative	  of	  developing	  tumors.	  	  Analysis	  is	  also	  performed	  on	  day	  10	  to	  note	  tumor	  growth.	  	  (B)	  Representative	  images	  of	  7	  and	  10	  dpf	  larvae	  with	  GFP-­‐positive	  cells	  in	  the	  musculature.	  	  There	  is	  visible	  growth	  between	  7	  and	  10	  dpf	  as	  they	  develop	  into	  tumors.	  	  (C)	  Tumor	  growth	  rates,	  relative	  to	  size	  of	  tumor	  on	  day	  7.	  	  There	  is	  no	  significant	  difference	  between	  growth	  rates	  of	  the	  SUV39H1-­‐overexpressing	  tumors	  compared	  to	  control	  tumors	  (SUV39H1	  n=22,	  mCherry	  n=13,	  p=0.46).	  	  (D)	  Percentage	  of	  larvae	  within	  a	  clutch	  that	  contain	  GFP-­‐positive	  cells	  in	  the	  musculature.	  	  More	  fish	  in	  the	  mCherry	  clutches	  have	  developing	  tumors	  when	  compared	  to	  SUV39H1	  clutches	  (SUV39H1	  n=200,	  mCherry	  n=136,	  p<0.0001).	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positive	  patches	  was	  evaluated	  in	  the	  musculature.	  	  Significantly	  fewer	  patches	  were	  found	  in	  the	  SUV39H1-­‐overexpression	  clutches	  compared	  to	  controls	  (Fisher’s	  exact	  test,	  p<0.0001,	  Figure	  2.4.D).	  	  This	  study	  in	  larvae	  demonstrated	  that	  SUV39H1	  overexpression	  impacts	  the	  initiation	  of	  tumors.	  	  Once	  the	  tumor	  initiates	  in	  the	  presence	  of	  SUV39H1	  overexpression,	  it	  grows	  at	  the	  same	  rate;	  the	  main	  difference	  SUV39H1	  causes	  is	  to	  prevent	  tumors	  from	  initiating.	  	   To	  further	  analyze	  GFP	  expression,	  we	  took	  5	  and	  7	  dpf	  mosaic	  embryos	  that	  expressed	  high	  levels	  of	  mylz2-­‐mCherry	  and	  performed	  in	  situ	  hybridizations	  (ISH)	  for	  GFP	  mRNA.	  	  This	  analysis	  by	  ISH	  was	  required	  because	  the	  levels	  of	  fluorescence	  were	  too	  low	  to	  detect	  by	  microscopy	  (data	  not	  shown).	  	  Analysis	  of	  these	  fish	  by	  flow	  cytometry	  revealed	  minimal	  expression	  of	  GFP	  in	  control	  and	  SUV39H1-­‐overexpressing	  5	  and	  7	  dpf	  larvae,	  which	  confirms	  our	  visualization	  of	  GFP	  protein	  (Figure	  2.S2).	  	  Surprisingly,	  some	  larval	  fish	  displayed	  GFP	  mRNA	  expression	  throughout	  the	  musculature.	  	  Though	  the	  levels	  of	  GFP	  varied	  between	  fish	  at	  5	  dpf,	  the	  SUV39H1-­‐overexpressing	  and	  control	  larvae	  appeared	  to	  have	  similar	  ranges	  of	  GFP	  mRNA	  expression,	  with	  all	  fish	  having	  at	  least	  some	  expression	  (Figure	  2.5.A-­‐D,I).	  	  However,	  at	  7	  dpf,	  the	  SUV39H1-­‐overexpressing	  larvae	  had	  much	  less	  GFP	  expression	  compared	  to	  controls,	  with	  about	  a	  third	  of	  fish	  (10/29)	  no	  longer	  expressing	  GFP	  at	  all	  (Figure	  2.5.E-­‐I).	  	  As	  expected,	  ISHs	  for	  KRAS	  or	  SUV39H1	  mostly	  localized	  to	  putative	  tumors.	  	  KRAS	  expression	  levels	  were	  similar	  between	  5	  and	  7	  dpf	  in	  both	  SUV39H1	  and	  control	  larvae,	  with	  fewer	  fish	  having	  tumors	  in	  the	  SUV39H1	  cohort	  (Figure	  2.S3).	  	  This	  result	  allows	  us	  to	  conclude	  that	  SUV39H1	  is	  not	  simply	  suppressing	  KRASG12D	  directly	  to	  block	  tumor	  initiation.	  	  Whole-­‐mount	  	  







Figure	  2.5.	  	  rag2-­GFP	  mRNA	  analysis	  reveals	  difference	  between	  5	  and	  7	  dpf	  
larval	  fish.	  	  (A-­D)	  In	  situ	  hybridization	  for	  GFP	  mRNA	  in	  5	  dpf	  fish	  injected	  with	  of	  
rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1	  or	  mCherry,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry,	  then	  selected	  for	  mCherry-­‐high	  embryos.	  	  Pictures	  represent	  the	  range	  of	  expression	  seen,	  which	  is	  similar	  between	  SUV39H1	  and	  control	  fish.	  	  Brackets	  and	  arrowheads	  note	  patches	  of	  expression	  	  (E-­H)	  In	  situ	  hybridization	  for	  GFP	  mRNA	  in	  7	  dpf	  siblings	  of	  5	  dpf	  injected	  fish.	  	  Pictures	  represent	  the	  range	  of	  expression	  seen,	  which	  is	  lower	  in	  the	  SUV39H1	  fish	  compared	  to	  control	  fish	  (4X	  images).	  	  (I)	  Table	  with	  numerical	  representation	  of	  GFP	  expression.	  	  All	  5	  dpf	  and	  mCherry	  7	  dpf	  larvae	  have	  GFP	  expression;	  only	  in	  the	  7	  dpf	  SUV39H1	  larvae	  is	  GFP	  not	  expressed	  in	  some	  fish,	  suggesting	  that	  SUV39H1	  is	  acting	  between	  5	  and	  7	  dpf.	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Figure	  2.5	  (Continued)	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TUNEL	  analysis	  revealed	  no	  differences	  in	  apoptotic	  levels	  between	  SUV39H1	  and	  control	  larvae	  (7	  dpf,	  Figure	  2.S4).	  	  We	  conclude	  that	  SUV39H1	  is	  acting	  between	  days	  5	  and	  7	  as	  the	  first	  tumors	  initiate,	  likely	  repressing	  a	  tumor	  program	  to	  prevent	  tumor	  initiation,	  rather	  than	  a	  muscle-­‐specific	  program.	  	   To	  try	  to	  reveal	  what	  factors	  SUV39H1	  could	  be	  repressing	  in	  the	  initiation	  of	  RMS,	  we	  performed	  global	  gene	  expression	  analysis	  on	  5	  and	  7	  dpf	  rag2-­‐hKRASG12D,	  
rag2-­‐hSUV39H1/mCherry	  embryos	  highly	  mosaic	  for	  mylz2-­‐mCherry.	  	  The	  5	  dpf	  larvae	  revealed	  no	  differences,	  as	  expected.	  	  The	  7	  dpf	  larvae	  revealed	  a	  gene	  set	  differentially	  expressed	  between	  SUV39H1-­‐overexpressing	  and	  control	  fish	  (top	  downregulated	  genes	  in	  Figure	  2.6.A).	  	  Of	  particular	  note	  is	  that	  cyclin	  B1	  is	  downregulated	  in	  the	  SUV39H1-­‐expressing	  fish	  (Figure	  2.6.A).	  	  This	  may	  be	  indicative	  of	  SUV39H1	  silencing	  a	  tumorigenic	  program	  through	  suppressing	  mitosis	  entry.	  	  To	  confirm	  this	  mechanism,	  we	  performed	  chromatin	  immunoprecipitation	  followed	  by	  massively	  parallel	  DNA	  sequencing	  (ChIP-­‐seq)	  for	  HA	  in	  C2C12	  cells	  transfected	  with	  HA-­‐Suv39h1.	  	  Peaks	  revealed	  that	  Suv39h1	  is	  bound	  in	  the	  first	  intron	  of	  cyclin	  B1	  (Figure	  2.6).	  	  Though	  the	  input	  has	  the	  same	  peak	  shape,	  the	  HA-­‐Suv39h1	  peaks	  in	  the	  first	  intron	  have	  been	  detected	  by	  peak	  calling	  with	  MACS	  (p=10-­‐3;	  18000	  peaks)	  and	  SICER	  (FDR=10-­‐5;	  7000	  peaks).	  	  Additional	  ChIP-­‐seq	  for	  H3K9	  trimethylation	  levels	  revealed	  the	  H3K9me3	  mark	  in	  the	  first	  intron	  and	  5	  kb	  upstream	  of	  the	  cyclin	  B1	  gene	  (Figure	  2.6.B).	  	  Our	  studies	  establish	  that	  overexpression	  of	  SUV39H1	  directly	  silences	  cyclin	  B1,	  and	  this	  cell	  cycle	  defect	  may	  cause	  the	  lower	  incidence	  of	  tumors	  that	  initiate	  with	  SUV39H1	  overexpression.








Figure	  2.6.	  Global	  gene	  expression	  analysis	  and	  ChIP-­seq	  reveals	  Suv39h1	  acts	  
through	  silencing	  of	  the	  cyclin	  B1	  locus.	  	  (A)	  Table	  of	  top	  downregulated	  annotated	  genes	  in	  rag2-­‐KRASG12D,	  rag2-­‐SUV39H1	  7	  dpf	  larvae	  as	  compared	  to	  rag2-­‐KRASG12D,	  rag2-­‐mCherry	  control	  larvae.	  	  Of	  particular	  interest	  was	  cyclin	  B1.	  	  (B)	  HA-­‐Suv39h1	  was	  transfected	  into	  C2C12	  muscle	  cells,	  and	  ChIP-­‐seq	  was	  performed	  for	  HA.	  	  Peak	  calling	  determined	  peaks	  in	  the	  first	  intron	  of	  cyclin	  B1	  (MACS:	  p=10-­‐3,	  18000	  peaks;	  SICER:	  FDR=10-­‐5,	  7000	  peaks).	  	  ChIP-­‐seq	  was	  also	  performed	  for	  H3K9me3	  in	  wild-­‐type	  C2C12	  cells.	  	  These	  peaks	  were	  found	  in	  the	  first	  intron	  and	  5	  kb	  upstream	  of	  the	  cyclin	  B1	  gene.	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Figure	  2.6	  (Continued)	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Discussion	  	   In	  this	  chapter,	  we	  describe	  an	  overexpression	  screen	  of	  chromatin-­‐modifying	  factors	  that	  revealed	  SUV39H1	  as	  a	  suppressor	  of	  rhabdomyosarcoma	  formation	  in	  zebrafish.	  	  This	  effect	  is	  specific	  to	  the	  histone	  methyltransferase	  activity	  of	  SUV39H1,	  as	  point	  mutations	  in	  the	  SET	  domain	  lacked	  the	  suppressive	  effect.	  	  The	  SUV39H1-­‐overexpressing	  mature	  tumors	  have	  no	  differences	  in	  tumor	  proliferation	  and	  muscle	  differentiation	  status.	  	  Our	  studies	  establish	  that	  the	  larval	  fish	  with	  ectopic	  SUV39H1	  initiate	  fewer	  tumors.	  	  This	  decreased	  initiation	  likely	  acts	  through	  a	  cell	  cycle	  pathway.	  	   The	  requirement	  for	  the	  wild-­‐type	  SET	  domain	  in	  our	  model	  is	  striking	  since	  this	  was	  not	  the	  case	  of	  HMTs	  in	  a	  zebrafish	  melanoma	  model.	  	  When	  SETDB1	  was	  found	  to	  accelerate	  melanoma,	  two	  methyltransferase-­‐deficient	  SETDB1	  mutants	  also	  had	  an	  accelerated	  tumor	  incidence	  curve,	  likely	  because	  the	  complex	  still	  had	  methyltransferase	  activity	  [181].	  	  This	  suggests	  that	  our	  result	  is	  more	  sensitive	  to	  the	  loss	  of	  SUV39H1	  methyltransferase	  activity.	  	   Previous	  studies	  involving	  SUV39H1	  have	  demonstrated	  its	  role	  as	  a	  tumor	  suppressor	  involving	  senescence.	  	  SUV39H1	  was	  demonstrated	  to	  associate	  with	  pRb	  as	  well	  as	  HDAC1,	  and	  a	  senescence	  response	  in	  melanocytes	  that	  acts	  through	  these	  two	  proteins	  is	  mediated	  by	  SUV39H1	  heterochromatization	  [94,	  99,	  263].	  	  In	  a	  murine	  model	  of	  Ras-­‐driven	  T	  cell	  lymphoma,	  SUV39H1-­‐dependent	  senescent	  growth	  arrest	  prevents	  the	  onset	  of	  tumorigenesis;	  this	  senescence	  is	  likely	  dependent	  on	  H3K9	  methylation	  on	  specific	  growth	  genes	  [186].	  	  Additionally,	  loss	  of	  SUV39H1	  in	  Rb	  heterozygote	  mice	  leads	  to	  the	  development	  of	  C	  cell	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adenocarcinomas,	  along	  with	  frequent	  expression	  of	  proliferation	  markers,	  suggesting	  that	  SUV39H1	  suppresses	  tumors	  through	  senescence	  [264].	  	  If	  oncogenic	  NRAS	  was	  transduced	  into	  cell	  lines	  derived	  from	  Rb	  deficient	  tumors,	  senescence	  was	  induced	  and	  SUV39H1	  was	  recruited	  to	  chromatin	  [264].	  	  Loss	  of	  SUV39H1	  in	  a	  myc-­‐driven	  model	  of	  murine	  B	  cell	  lymphomas	  led	  to	  faster	  onset	  of	  disease,	  whereas	  SUV39H1	  wild-­‐type	  mice	  displayed	  increased	  levels	  of	  senescence	  and	  growth	  arrest	  [265].	  	  It	  has	  been	  suggested	  that	  the	  SUV39H1-­‐mediated	  H3K9me3	  mark	  on	  heterochromatin	  is	  a	  widespread	  mark	  of	  the	  senescence	  program	  and	  that	  this	  program	  could	  be	  targeted	  for	  cancer	  therapies	  [265].	  	  SUV39H1	  is	  also	  known	  to	  silence	  S	  phase	  genes	  as	  well	  as	  p21,	  both	  of	  which	  will	  induce	  growth	  arrest	  [100,	  101,	  261,	  262,	  266].	  	  The	  mechanism	  demonstrated	  in	  our	  work	  on	  RMS	  is	  similar	  to	  these	  studies.	  	  There	  was	  a	  delayed	  onset	  of	  tumorigenesis	  with	  SUV39H1	  overexpression,	  complimentary	  to	  the	  more	  aggressive	  onset	  observed	  with	  loss	  of	  SUV39H1	  in	  these	  studies.	  	  These	  experiments	  are	  consistent	  with	  the	  notion	  that	  SUV39H1	  may	  be	  a	  tumor	  suppressor	  [185,	  186].	  	   Global	  gene	  expression	  analysis	  comparing	  rag2-­‐hKRASG12D/rag2-­‐hSUV39H1	  with	  rag2-­‐hKRASG12D/rag2-­‐mCherry	  7dpf	  larvae	  revealed	  that	  cyclin	  B1	  is	  downregulated	  in	  the	  SUV39H1-­‐overexpressing	  tumors.	  	  SUV39H1	  is	  already	  known	  to	  silence	  cyclins	  E	  and	  A	  [99].	  	  Silencing	  of	  cyclin	  B1	  may	  explain	  how	  SUV39H1	  promotes	  senescence	  and	  growth	  arrest.	  	  Quiescence	  can	  often	  be	  mediated	  by	  cyclin	  B1	  downregulation,	  as	  in	  CD34-­‐negative	  hematopoietic	  stem	  cells	  and	  quiescent	  NIH3T3	  cells	  [267,	  268].	  	  Sp1,	  a	  cell	  growth	  and	  survival	  transcription	  factor,	  has	  been	  shown	  to	  associate	  with	  SUV39H1	  upon	  hydrogen	  peroxide	  treatment	  in	  an	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epithelial	  carcinoma	  cell	  line,	  leading	  to	  growth	  arrest	  through	  the	  silencing	  of	  Sp1	  target	  genes,	  including	  cyclin	  B1	  [269].	  	  SUV39H1	  overexpression	  likely	  silences	  cyclin	  B1,	  leading	  to	  growth	  arrest	  and	  decreased	  tumor	  initiation.	  	   A	  number	  of	  protocadherins,	  or	  cadherin-­‐like	  cell	  adhesion	  proteins,	  were	  found	  to	  be	  downregulated	  in	  the	  SUV39H1-­‐expressing	  fish	  upon	  larval	  microarray	  analysis.	  	  Though	  most	  protocadherins	  (PCDHs)	  seem	  to	  have	  tumor	  suppressive	  functions	  with	  reduced	  expression	  in	  tumors,	  PCDH11-­‐gamma	  is	  known	  as	  a	  proto-­‐oncogene	  [270].	  	  It	  is	  upregulated	  in	  apoptosis-­‐resistant	  cell	  variants	  of	  a	  prostate	  carcinoma	  line,	  and	  overexpression	  induces	  anchorage-­‐independent	  growth	  and	  tumors	  [271].	  	  Though	  PCDH11-­‐gamma	  was	  not	  specifically	  on	  our	  list,	  the	  established	  precedent	  that	  protocadherins	  can	  function	  as	  oncogenes	  opens	  the	  possibility	  that	  the	  dysregulated	  protocadherins	  could	  have	  oncogenic	  properties,	  and	  suppression	  by	  SUV39H1	  may	  contribute	  to	  blockage	  of	  RMS	  initiation	  in	  the	  zebrafish.	  	   Being	  able	  to	  visualize	  the	  development	  of	  RMS	  with	  a	  fluorescent	  protein	  was	  critical	  to	  these	  studies.	  	  Identifying	  tumors	  as	  soon	  as	  they	  arose	  in	  the	  fish	  by	  fluorescence,	  rather	  than	  waiting	  for	  them	  to	  be	  large	  enough	  to	  be	  observed	  by	  eye,	  enabled	  us	  to	  hone	  in	  on	  the	  earliest	  steps	  of	  tumor	  initiation.	  	  It	  made	  the	  already	  rapid	  tumor	  model	  even	  quicker,	  with	  significant	  tumor	  curves	  able	  to	  be	  completed	  by	  20	  dpf.	  	  Using	  this	  early	  tumor	  model	  will	  have	  future	  applications	  as	  a	  screening	  tool,	  further	  expanding	  on	  the	  power	  of	  zebrafish	  genetics	  and	  numbers.	  	   Performing	  ISHs	  for	  the	  developing	  tumors	  in	  larval	  fish	  revealed	  an	  unexpected	  finding.	  	  ISHs	  done	  against	  KRAS	  or	  SUV39H1	  mRNA	  either	  had	  minimal	  
60	  	  	  	  
staining	  or	  staining	  in	  patches	  that	  represented	  the	  forming	  tumors	  (Figure	  2.S3).	  	  However,	  ISHs	  performed	  for	  GFP	  mRNA	  driven	  by	  the	  rag2	  promoter	  resulted	  in	  staining	  throughout	  the	  musculature	  at	  various	  levels	  between	  individual	  fish,	  rather	  than	  just	  at	  the	  tumor	  location	  (Figure	  2.5).	  	  This	  result	  was	  surprising	  since	  we	  could	  rarely	  visualize	  any	  fluorescence	  on	  a	  standard	  dissecting	  scope	  at	  5	  dpf,	  and	  often	  at	  6	  to	  7	  dpf	  it	  was	  only	  a	  few	  isolated	  cells	  in	  a	  distinct	  patch.	  	  FACS	  analysis	  for	  the	  presence	  of	  GFP	  protein	  confirmed	  the	  low	  to	  absent	  GFP	  fluorescence	  (Figure	  2.S2).	  	  The	  ISHs	  demonstrate	  that	  rag2-­‐GFP	  mRNA	  expresses	  in	  satellite	  cells	  at	  low	  levels	  throughout	  the	  musculature.	  	  Only	  when	  GFP	  protein	  levels	  accumulate,	  such	  as	  in	  a	  developing	  tumor,	  then	  fluorescence	  is	  detected.	  	   In	  conclusion,	  we	  performed	  a	  screen	  of	  chromatin-­‐modifying	  factors	  for	  their	  effects	  on	  tumorigenesis	  in	  RMS,	  using	  zebrafish	  as	  a	  model	  organism.	  	  SUV39H1	  was	  determined	  to	  be	  a	  suppressor	  of	  RMS	  formation,	  dependent	  on	  its	  histone	  methyltransferase	  activity,	  suppressing	  tumor	  initiation	  likely	  by	  suppressing	  cyclin	  B1	  and	  causing	  cell	  cycle	  arrest.	  	  These	  studies	  support	  previous	  work	  that	  SUV39H1	  is	  a	  marker	  of	  senescence	  and	  will	  warrant	  further	  examination	  of	  the	  role	  of	  SUV39H1	  in	  muscle	  differentiation.	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Supplemental	  Figures	  
	  
Figure	  2.S1.	  	  Human	  RMS	  samples	  contain	  upregulation	  of	  chromatin-­
modifying	  factors.	  	  (A)	  List	  of	  protein	  domains	  resulting	  in	  a	  list	  of	  chromatin-­‐modifying	  factors.	  	  (B)	  Gene	  set	  enrichment	  analysis	  results	  show	  significant	  enrichment	  for	  chromatin	  factor	  gene	  lists	  in	  human	  embryonal	  RMS	  versus	  normal	  human	  juvenile	  muscle.	  	  (C)	  Gene	  set	  enrichment	  analysis	  results	  show	  significant	  enrichment	  for	  chromatin	  factor	  gene	  lists	  in	  human	  alveolar	  RMS	  versus	  normal	  human	  juvenile	  muscle	  (p<0.05	  for	  B,C).	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Figure	  2.S2.	  	  GFP	  analysis	  by	  FACS	  reveals	  minimal	  GFP	  protein	  expression,	  
with	  no	  differences	  between	  fish.	  	  (A-­C)	  FACS	  analysis	  for	  GFP	  mRNA	  in	  5	  dpf	  fish	  injected	  with	  of	  rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1	  or	  mCherry,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry,	  then	  selected	  for	  mCherry-­‐high	  embryos,	  compared	  to	  wild-­‐type	  fish.	  	  The	  analysis	  reveals	  a	  small	  number	  of	  dimly	  expressing	  cells	  present	  in	  both	  injected	  samples.	  	  (D-­F)	  FACS	  analysis	  for	  GFP	  of	  sibling	  fish	  at	  7	  dpf.	  	  Both	  injected	  samples	  have	  very	  low	  amounts	  of	  GFP.	  	  







Figure	  2.S3.	  KRAS	  and	  SUV39H1	  expression	  generally	  localizes	  to	  developing	  
tumors.	  	  (A)	  In	  rag2-­‐hKRASG12D,	  rag2-­‐mCherry,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry-­‐positive	  5	  dpf	  fish,	  KRAS	  expression	  mostly	  localizes	  in	  distinct	  patches,	  likely	  where	  tumors	  are	  forming.	  	  (B)	  The	  same	  occurs	  for	  rag2-­SUV39H1	  5	  dpf	  fish.	  	  (C,D)	  Some	  5	  dpf	  fish	  do	  not	  show	  much	  KRAS	  expression	  at	  all,	  as	  those	  fish	  are	  likely	  not	  forming	  tumors	  yet.	  	  (E-­H)	  In	  7	  dpf	  larvae,	  KRAS	  expression	  is	  similar,	  with	  patches	  of	  expression	  in	  some	  fish,	  likely	  in	  developing	  tumors,	  and	  minimal	  expression	  in	  others.	  	  (I,	  L)	  As	  expected,	  there	  is	  no	  SUV39H1	  mRNA	  expression	  in	  control	  fish.	  	  
(J,K,M)	  Similar	  to	  KRAS	  expression,	  SUV39H1	  expression	  is	  observed	  in	  patches	  of	  tumors	  forming	  or	  not	  visualized	  at	  all.	  	  In	  all	  panels,	  arrowheads	  note	  patches	  of	  expression	  (8X	  images).	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Figure	  2.S3	  (Continued)	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Figure	  2.S4.	  SUV39H1	  overexpression	  does	  not	  lead	  to	  increased	  apoptosis.	  	  (A)	  In	  rag2-­‐hKRASG12D,	  rag2-­‐mCherry,	  and	  mylz2-­‐mCherry-­‐positive	  7	  dpf	  fish,	  there	  is	  minimal	  programmed	  cell	  death,	  as	  noted	  through	  TUNEL	  staining.	  	  (B)	  Similar	  levels	  are	  seen	  in	  rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1,	  and	  mylz2-­‐mCherry-­‐positive	  7	  dpf	  fish,	  suggesting	  the	  tumor	  initiating	  cells	  are	  not	  simply	  dying	  off	  (5X	  images).	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Addendum	  
The	  role	  of	  chromatin	  in	  muscle	  development	  	   Epigenetic	  structure	  is	  known	  to	  be	  important	  during	  muscle	  development.	  	  It	  begins	  on	  the	  DNA	  level,	  as	  DNA	  demethylation	  is	  a	  critical	  step	  committing	  cells	  to	  the	  myogenic	  lineage.	  	  If	  DNA	  methylation	  is	  blocked	  using	  either	  5-­‐azacytidine	  or	  antisense	  nucleotides	  against	  dnmt1,	  this	  can	  convert	  fibroblasts	  to	  muscle	  cells	  [272,	  273].	  	  Genome-­‐wide	  demethylation	  occurs	  in	  myoblasts	  upon	  differentiation	  induction,	  but	  some	  of	  the	  specific	  loci	  likely	  targeted	  are	  the	  regulatory	  regions	  of	  MyoD	  and	  myogenin	  [274-­‐276].	  	  Once	  the	  cells	  are	  committed	  muscle	  progenitors,	  many	  of	  the	  differentiation	  genes	  remain	  repressed	  through	  their	  chromatin	  structure,	  ensuring	  no	  premature	  differentiation	  occurs.	  	  In	  precursors,	  MyoD	  and	  its	  associated	  transcription	  factor	  MEF2	  interact	  with	  histone	  deacetylases	  (HDACs),	  the	  repressive	  YY1	  protein,	  and	  HMTs	  associated	  with	  silencing	  [277-­‐283].	  	  Overexpression	  of	  EZH2,	  an	  H3K27	  HMT,	  can	  inhibit	  muscle	  differentiation	  by	  keeping	  muscle	  creatine	  kinase	  and	  myosin	  heavy	  chain	  repressed	  [282].	  	  Overexpression	  of	  SUV39H1	  directly	  represses	  MyoD	  and	  therefore	  differentiation,	  and	  G9a,	  an	  H3K9me2	  HMT,	  similarly	  blocks	  differentiation	  through	  methylation	  on	  MyoD	  target	  promoters	  and	  MyoD	  itself	  [252,	  283].	  	   The	  chromatin	  landscape	  changes	  dramatically	  once	  muscle	  differentiation	  is	  ready	  to	  commence.	  	  MyoD	  and	  MEF2	  no	  longer	  associate	  with	  repressive	  chromatin	  factors	  [284].	  	  Repressive	  chromatin	  structure	  keeps	  myogenin	  and	  muscle	  creatine	  kinase	  transcriptionally	  inactive	  until	  MyoD	  opens	  the	  structure	  [285].	  	  This	  is	  mediated	  through	  recruitment	  of	  the	  SWI/SNF	  chromatin	  remodeling	  complex	  by	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MyoD,	  loss	  of	  which	  prevents	  muscle	  differentiation	  [286].	  	  Additionally,	  MyoD	  directly	  binds	  the	  HAT	  p300,	  forming	  a	  complex	  with	  p300	  and	  PCAF,	  another	  HAT	  [287-­‐289].	  	  To	  ensure	  that	  MyoD	  can	  fully	  activate	  its	  target	  genes,	  p300	  acetylates	  histones	  for	  an	  open	  chromatin	  structure	  while	  PCAF	  acetylates	  MyoD	  to	  enhance	  its	  DNA	  binding	  activity	  [290,	  291].	  	  The	  epigenetic	  landscape	  aids	  in	  the	  regulation	  and	  timing	  of	  muscle	  differentiation.	  
Molecular	  characterization	  of	  SUV39H1	  in	  RMS	  To	  understand	  the	  gene	  expression	  changes	  that	  occur	  in	  our	  different	  RMS	  tumor	  types,	  microarray	  analysis	  was	  performed	  on	  six	  SUV39H1-­‐overexpressing	  tumors	  and	  six	  control	  mCherry-­‐overexpressing	  tumors.	  	  A	  variety	  of	  genes	  were	  differentially	  expressed	  between	  the	  two	  tumor	  types,	  with	  definable	  clusters	  associating	  with	  the	  different	  tumors	  types	  (Figure	  2.A1.A).	  	  The	  most	  striking	  set	  of	  genes	  were	  a	  set	  of	  transcription	  factors	  whose	  expression	  was	  down	  in	  the	  SUV39H1-­‐overexpression	  tumors	  and	  would	  be	  consistent	  with	  overexpressed	  SUV39H1	  functioning	  as	  a	  transcriptional	  repressor	  (Figure	  2.A1.B).	  	  The	  most	  notable	  factor	  on	  this	  list	  was	  Pax7,	  a	  known	  player	  in	  muscle	  differentiation	  and	  translocation	  partner	  in	  causing	  ARMS.	  	  Also,	  quantitative	  PCR	  analysis	  of	  a	  panel	  of	  endogenous	  muscle	  genes,	  along	  with	  hKRASG12D	  and	  hSUV39H1,	  revealed	  that	  expression	  of	  the	  muscle	  program	  was	  decreased	  in	  SUV39H1-­‐overexpressing	  tumors	  as	  compared	  to	  mCherry	  control	  tumors	  (Figure	  2.A2.A).	  	  However,	  when	  this	  panel	  was	  examined	  in	  the	  SUV39H1	  enzymatic	  point	  mutants,	  C326A	  and	  H324K,	  expression	  of	  some	  muscle	  genes	  was	  increased	  in	  comparison	  with	  the	  SUV39H1	  tumors	  (Figure	  2.A2.B,C).	  	  This	  fits	  with	  previously	  known	  data	  that	  	  









Figure	  2.A1.	  Global	  gene	  expression	  analysis	  reveals	  transcription	  factor	  
targets.	  	  (A)	  Heat	  maps	  for	  6	  SUV39H1-­‐overexpressing	  and	  6	  mCherry-­‐overexpressing	  tumors	  reveal	  clusters	  of	  gene	  that	  are	  differentially	  expressed	  between	  the	  two	  tumor	  types.	  	  (B)	  A	  list	  of	  transcription	  factors	  that	  are	  downregulated	  in	  the	  SUV39H1-­‐overexpressing	  tumors,	  including	  the	  muscle	  transcription	  factor	  Pax7.	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Figure	  2.A1	  (Continued)	  
	  










Figure	  2.A2.	  Gene	  expression	  analysis	  of	  muscle	  genes	  in	  SUV39H1-­
overexpressing	  tumors.	  	  (A)	  qRT-­‐PCR	  analysis	  from	  SUV39H1-­‐overexpressing	  tumors	  compared	  to	  mCherry	  tumors	  reveals	  that	  some	  of	  the	  muscle	  program	  may	  be	  transcriptionally	  down	  in	  the	  SUV39H1	  tumors.	  	  (B)	  When	  compared	  to	  SUV39H1-­‐overexpressing	  tumors,	  some	  of	  the	  muscle	  program	  is	  upregulated	  in	  SUV39H1C326A	  tumors.	  	  (C)	  When	  compared	  to	  SUV39H1-­‐overexpressing	  tumors,	  most	  of	  the	  muscle	  program	  is	  upregulated	  in	  SUV39H1H324K	  tumors.	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Figure	  2.A2	  (Continued)	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SUV39H1	  suppresses	  MyoD	  and	  differentiation	  and	  suggested	  that	  SUV39H1	  is	  impacting	  the	  muscle	  program	  [251,	  252].	  	  An	  interesting	  observation	  here	  is	  the	  RAS	  levels	  across	  tumor	  types.	  	  Though	  RAS	  levels	  appear	  to	  be	  slightly	  lower	  in	  the	  SUV39H1	  tumor	  compared	  to	  controls	  (Figure	  2.A2.A),	  they	  also	  appear	  to	  be	  lower	  in	  the	  point	  mutants	  compared	  to	  wild-­‐type	  SUV39H1	  tumors,	  yet	  the	  C326A/H324K-­‐overexpressing	  fish	  get	  more	  tumors	  than	  their	  wild-­‐type	  SUV39H1	  counterparts	  (Figure	  2.A2.B,C).	  	  Since	  RAS	  levels	  do	  not	  correlate	  with	  tumor	  incidence,	  the	  conclusion	  is	  that	  RAS	  levels	  are	  not	  responsible	  for	  the	  tumor	  suppressive	  phenotype.	  To	  determine	  if	  SUV39H1	  repression	  of	  Pax7	  was	  responsible	  for	  the	  suppressed	  tumor	  phenotype,	  we	  co-­‐injected	  rag2-­‐hKRASG12D,	  rag2-­‐mPax7	  with	  either	  rag2-­‐hSUV39H1	  or	  rag2-­‐mCherry	  in	  our	  fluorescent	  tumor	  assay	  (rag2-­‐GFP)	  along	  with	  the	  marker	  mylz2-­‐mCherry.	  	  The	  Pax7	  overexpression	  led	  to	  no	  significant	  difference	  between	  the	  suppressed	  SUV39H1	  tumor	  curve	  with	  a	  control	  vector	  and	  the	  tumor	  curve	  with	  SUV39H1	  and	  Pax7	  (p=0.1623,	  Figure	  2.A3.A),	  suggesting	  that	  Pax7	  did	  not	  mediate	  the	  suppression	  phenotype.	  	  We	  repeated	  these	  curves	  with	  myogenin	  as	  well,	  which	  also	  showed	  no	  difference	  from	  the	  suppressed	  SUV39H1-­‐overexpression	  curve	  (p=0.2609;	  Figure	  2.A3.B).	  	  These	  data	  led	  us	  to	  conclude	  that	  the	  muscle	  program	  was	  not	  the	  sole	  cause	  of	  tumor	  suppression	  by	  SUV39H1.	  
Discussion	  	   SUV39H1	  appears	  to	  play	  a	  role	  in	  muscle	  differentiation.	  	  It	  is	  known	  to	  directly	  silence	  MyoD	  and	  differentiation	  through	  H3K9me3	  [252].	  	  SUV39H1	  is	  	  






Figure	  2.A3.	  Overexpression	  of	  muscle	  transcription	  factors	  cannot	  revert	  the	  
SUV39H1-­mediated	  suppressive	  phenotype.	  	  (A)	  Injections	  into	  one-­‐cell	  stage	  embryos	  of	  rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1,	  rag2-­‐mPax7,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry,	  then	  selected	  for	  mCherry-­‐high	  embryos,	  and	  monitored	  for	  tumor	  formation	  by	  GFP	  presence,	  results	  in	  a	  suppressed	  tumor	  curve	  that	  is	  the	  same	  as	  
rag2-­‐hSUV39H1;	  rag2-­‐mCherry	  control	  curves	  (Pax7	  n=46,	  mCherry	  n=90,	  p=0.1623).	  	  (B)	  Injections	  into	  one-­‐cell	  stage	  embryos	  of	  rag2-­‐hKRASG12D,	  rag2-­‐hSUV39H1,	  rag2-­‐myog,	  rag2-­‐GFP,	  and	  mylz2-­‐mCherry,	  then	  selected	  for	  mCherry-­‐high	  embryos,	  and	  monitored	  for	  tumor	  formation	  by	  GFP	  presence,	  results	  in	  a	  suppressed	  tumor	  curve	  that	  is	  the	  same	  as	  rag2-­‐hSUV39H1;	  rag2-­‐mCherry	  control	  curves	  (myog	  n=68,	  mCherry	  n=88,	  p=0.2609).	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Figure	  2.A3	  (Continued)	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Introduction	  
Vertebrate	  Hematopoiesis	  	   All	  vertebrates	  require	  blood	  flowing	  in	  their	  bodies	  to	  carry	  oxygen	  and	  other	  nutrients	  to	  cells	  of	  all	  tissues	  and	  to	  provide	  defenses	  against	  foreign	  pathogens.	  	  Hematopoiesis,	  or	  the	  differentiation	  of	  the	  mature	  blood	  lineages	  from	  immature	  progenitors,	  occurs	  throughout	  the	  lifetime	  of	  an	  organism	  to	  regularly	  replenish	  the	  various	  cellular	  components	  of	  the	  blood.	  	  It	  occurs	  in	  two	  successive	  waves	  known	  as	  the	  primitive	  and	  definitive	  waves.	  	  The	  primitive	  wave	  produces	  hundreds	  of	  erythrocytes,	  or	  red	  blood	  cells	  (RBCs),	  in	  the	  intermediate	  cell	  mass	  (ICM)	  and	  some	  macrophages	  to	  support	  the	  developing	  embryo	  [292,	  293].	  	  The	  RBCs	  are	  defined	  by	  expression	  of	  embryonic	  globins	  and	  gata1,	  the	  erythroid	  master	  regulator	  transcription	  factor,	  whereas	  the	  macrophages	  are	  characterized	  by	  expression	  of	  pu.1,	  a	  myeloid	  master	  transcription	  factor	  [294,	  295].	  	  The	  definitive	  wave	  results	  in	  the	  production	  of	  all	  blood	  cells	  through	  the	  hematopoietic	  stem	  cells.	  	   Hematopoietic	  stem	  cells	  (HSCs)	  are	  rare	  cells	  that	  generate	  the	  entire	  blood	  system	  of	  an	  organism,	  comprised	  of	  lymphocytes,	  RBCs,	  myeloid	  cells,	  and	  thrombocytes.	  	  In	  addition	  to	  this	  ability,	  HSCs	  also	  have	  the	  capacity	  to	  self	  renew,	  maintaining	  their	  own	  population	  for	  the	  life	  of	  that	  organism.	  	  In	  the	  hematopoietic	  system,	  self-­‐renewal	  is	  traditionally	  assessed	  by	  long-­‐term	  transplantation	  capability	  [296-­‐298].	  	  A	  single	  HSC	  transplanted	  into	  a	  lethally	  irradiated	  recipient	  can	  rescue	  the	  entire	  immune	  and	  nervous	  systems	  [299].	  	  Serial	  transplants,	  where	  HSCs	  from	  a	  primary	  transplanted	  organism	  are	  then	  transplanted	  into	  a	  new	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recipient,	  are	  also	  used	  to	  demonstrate	  the	  self-­‐renewal	  capacity	  of	  an	  HSC	  [300,	  301].	  	  Extrinsic	  regulators	  in	  the	  niche	  can	  impact	  the	  self-­‐renewal	  of	  an	  HSC,	  including	  Wnt,	  Notch,	  Hedgehog,	  BMP,	  angiopoietin-­‐like	  factors,	  thrombopoietin,	  retinoic	  acid,	  and	  prostaglandins	  [302-­‐313].	  	  Though	  many	  extrinsic	  pathways	  responsible	  for	  determining	  whether	  an	  HSC	  undergoes	  self-­‐renewal	  have	  been	  revealed,	  the	  stem	  cell-­‐intrinsic	  pathways	  are	  still	  not	  completely	  understood.	  	   The	  developing	  HSCs	  in	  a	  mammalian	  embryo	  are	  initially	  found	  in	  the	  aorta-­‐gonad-­‐mesonephros	  (AGM)	  region	  [314,	  315].	  	  Similarly,	  in	  a	  zebrafish	  embryo,	  the	  first	  definitive	  HSCs	  are	  found	  in	  the	  ventral	  wall	  of	  the	  dorsal	  aorta	  by	  36	  hours	  post	  fertilization	  (hpf)	  [316,	  317].	  	  These	  can	  be	  detected	  as	  clusters	  of	  cells	  expressing	  runx1	  and	  c-­myb	  [318-­‐320].	  	  The	  HSCs	  then	  bud	  off	  from	  the	  floor	  of	  the	  aorta	  and	  enter	  circulation	  to	  migrate	  to	  their	  next	  location	  [321,	  322].	  	  For	  many,	  this	  will	  be	  the	  caudal	  hematopoietic	  tissue,	  or	  CHT,	  which	  is	  roughly	  equivalent	  to	  the	  mammalian	  fetal	  liver	  [323,	  324].	  	  Here	  the	  HSCs	  will	  differentiate	  and	  expand	  while	  also	  producing	  the	  progenitor	  cells	  that	  will	  seed	  the	  thymus	  and	  kidney,	  the	  adult	  sites	  of	  hematopoiesis	  [323,	  325].	  	  In	  zebrafish,	  the	  kidney	  marrow	  is	  the	  equivalent	  of	  the	  mammalian	  bone	  marrow,	  with	  the	  HSCs	  residing	  near	  the	  reticular	  stromal	  cells	  among	  renal	  tubules	  and	  blood	  vessels.	  	  By	  5	  days	  post	  fertilization	  (dpf),	  nearly	  all	  HSCs	  are	  found	  in	  the	  kidney	  marrow	  rather	  than	  the	  AGM,	  producing	  HSCs	  and	  blood	  cells	  for	  the	  life	  of	  the	  zebrafish	  [293].	  	  Flow	  cytometry	  analysis	  comparing	  cells	  by	  size	  (forward	  scatter)	  and	  granularity	  (side	  scatter)	  can	  be	  performed	  on	  the	  zebrafish	  kidney	  marrow	  to	  reveal	  four	  distinct	  populations,	  erythroid,	  myeloid,	  lymphoid,	  and	  precursors	  [326].	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   With	  the	  HSCs	  in	  the	  kidney	  marrow	  by	  5	  dpf,	  definite	  hematopoiesis	  is	  well	  underway	  by	  this	  timepoint	  in	  the	  zebrafish.	  	  Definitive	  erythropoiesis	  produces	  RBCs	  to	  replace	  the	  primitive	  ones	  in	  circulation	  [327].	  	  Myelopoiesis	  generates	  two	  lineages	  by	  7	  dpf,	  one	  resembling	  mammalian	  neutrophils	  and	  one	  resembling	  a	  combination	  of	  mammalian	  eosinophils	  and	  basophils	  [293,	  328].	  	  Starting	  at	  3-­‐4	  dpf,	  T	  cells	  derive	  from	  the	  kidney	  and	  develop	  in	  the	  bilateral	  thymi	  [293,	  329].	  	  B	  cells	  develop	  in	  the	  kidney	  marrow,	  commencing	  at	  19	  dpf	  [330].	  	  Lastly,	  thrombocyte	  production	  begins	  around	  36	  hpf,	  resulting	  in	  cells	  similar	  to	  mammalian	  platelets	  [331].	  
HSC	  Self-­Renewal	  and	  Chromatin	  	   Chromatin-­‐modifying	  factors	  are	  likely	  candidates	  to	  control	  cell	  intrinsic	  pathways	  regulating	  self-­‐renewal	  in	  HSCs.	  	  One	  of	  the	  most	  well	  known	  families	  of	  chromatin	  factors	  that	  have	  a	  role	  in	  hematopoiesis	  is	  the	  Polycomb	  Group	  (PcG)	  of	  proteins.	  	  The	  PcG	  proteins	  were	  first	  discovered	  in	  Drosophila	  melanogaster	  as	  regulators	  of	  homeotic	  genes	  to	  form	  the	  various	  body	  segments	  of	  the	  fruit	  fly	  [332,	  333].	  	  Similarly,	  two	  main	  complexes	  of	  PcG	  proteins	  exist	  in	  vertebrates	  that	  play	  a	  role	  in	  repressing	  chromatin.	  	  Polycomb	  repressive	  complex	  1	  (PRC1)	  consists	  of	  chromodomain	  proteins	  HPC1,	  2,	  and	  3;	  HPH1,	  2,	  and	  3;	  E3	  ubiquitin	  ligases	  RING1A	  and	  1B;	  and	  the	  two	  homologues	  BMI-­‐1	  and	  MEL18.	  	  This	  complex	  is	  typically	  responsible	  for	  maintaining	  the	  repressive	  chromatin	  structure	  [334].	  	  PRC2	  is	  composed	  of	  the	  WD40	  domain	  protein	  EED,	  HMT	  EZH2,	  zinc	  finger	  domain	  protein	  SUZ12,	  and	  PHD	  domain	  proteins	  PHF19	  and	  MTF2.	  	  PRC2	  establishes	  the	  repressive	  mark	  in	  the	  chromatin	  [335].	  	  Two	  other	  complexes	  exist,	  PRC3	  and	  PRC4,	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which	  are	  less	  well	  studied;	  their	  components	  are	  similar	  to	  PRC2,	  with	  different	  EED	  isoforms	  [336,	  337].	  	   It	  has	  been	  proposed	  that	  the	  balance	  between	  the	  two	  major	  PcG	  complexes,	  PRC1	  and	  PRC2,	  may	  impact	  whether	  a	  stem	  cell	  chooses	  to	  remain	  quiescent	  or	  to	  divide	  and	  differentiate	  [338,	  339].	  	  It	  is	  evident	  that	  these	  complexes	  play	  a	  role	  in	  HSCs,	  as	  PRC2	  members	  EZH2	  and	  SUZ12	  are	  highly	  expressed	  in	  zebrafish	  and	  murine	  HSCs	  [340,	  341].	  	  Additionally,	  overexpression	  of	  BMI-­‐1,	  of	  the	  PRC1	  complex,	  in	  murine	  HSCs	  promotes	  symmetrical	  divisions	  and	  a	  higher	  repopulation	  potential;	  this	  increased	  self-­‐renewal	  capacity	  is	  not	  seen	  when	  BMI-­‐1	  is	  overexpressed	  in	  more	  mature	  progenitor	  cells	  instead	  [342].	  	   Two	  studies	  characterized	  the	  role	  of	  BMI-­‐1	  in	  the	  self-­‐renewal	  of	  murine	  HSCs.	  	  The	  first	  showed	  that	  BMI-­‐1-­‐/-­‐	  mice	  contain	  half	  as	  many	  adult	  HSCs	  as	  opposed	  to	  heterozygote	  or	  wild	  type	  mice,	  as	  determined	  by	  flow	  cytometry.	  	  The	  few	  HSCs	  found	  in	  BMI-­‐1-­‐/-­‐	  mice	  have	  no	  detectable	  self-­‐renewal	  since	  they	  cannot	  reconstitute	  the	  blood	  lineages	  upon	  transplantation	  [343].	  	  A	  second	  study	  showed	  that	  AML	  cells,	  formed	  from	  BMI-­‐1-­‐/-­‐	  fetal	  liver	  cells,	  were	  derived	  from	  only	  two	  to	  four	  clones;	  the	  idea	  that	  proliferative	  capacity	  was	  unaffected	  but	  there	  were	  fewer	  leukemic	  stem	  cells	  (L-­‐HSCs)	  due	  to	  a	  self-­‐renewal	  defect	  was	  confirmed	  when	  this	  leukemia	  did	  not	  transplant	  into	  another	  recipient	  [344].	  	  Additionally,	  BMI-­‐1	  acts	  to	  protect	  HSCs	  from	  exhaustion	  caused	  by	  expression	  of	  Ink4a	  and	  Arf,	  as	  knocking	  out	  Ink4a	  and	  Arf	  in	  an	  HSC-­‐depleted	  BMI-­‐1	  knockout	  mouse	  can	  rescue	  HSC	  self-­‐renewal	  [345].	  	  It	  is	  apparent	  that	  BMI-­‐1	  plays	  a	  role	  in	  the	  self-­‐renewal	  of	  HSCs.	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   Other	  members	  of	  the	  PcG	  have	  been	  implicated	  to	  play	  a	  role	  in	  HSC	  self-­‐renewal	  as	  well.	  	  RAE28,	  an	  HPH	  protein	  and	  member	  of	  PRC1,	  appears	  to	  play	  an	  integral	  part	  in	  self-­‐renewal.	  	  Murine	  fetal	  liver	  cells	  lacking	  RAE28	  cannot	  reconstitute	  the	  blood	  system	  upon	  transplantation,	  implying	  a	  self-­‐renewal	  defect;	  mice	  without	  RAE28	  also	  seem	  to	  have	  decreased	  numbers	  of	  HSCs	  and	  decreased	  stem	  cell	  activity	  [346,	  347].	  	  An	  additional	  PRC1	  member,	  MEL18,	  seems	  to	  have	  contrasting	  effects.	  	  Loss	  of	  MEL18	  increases	  HSC	  quiescence	  and	  promotes	  self-­‐renewal;	  thus,	  MEL18	  appears	  to	  negatively	  regulate	  HSC	  reconstitution	  capabilities	  [348].	  	  Many	  PcG	  factors	  are	  impacting	  HSC	  self-­‐renewal,	  both	  positively	  and	  negatively.	  	   Trithorax	  proteins,	  whose	  functions	  generally	  oppose	  that	  of	  the	  PcG	  proteins	  by	  activating	  transcription,	  are	  also	  known	  to	  play	  a	  role	  in	  HSC	  self-­‐renewal	  [349].	  	  For	  example,	  MLL,	  the	  trithorax	  homolog,	  is	  the	  mixed	  lineage	  leukemia	  gene	  that	  acts	  as	  a	  transcriptional	  activator,	  with	  one	  of	  its	  major	  targets	  being	  the	  homeobox	  genes.	  	  MLL	  is	  often	  found	  in	  leukemic	  cells	  as	  part	  of	  a	  fusion	  gene	  generated	  by	  chromosomal	  translocations	  during	  oncogenesis;	  it	  has	  over	  fifty	  translocation	  partners.	  	  Over	  half	  of	  all	  infant	  acute	  leukemias	  and	  10%	  of	  common	  AMLs	  contain	  MLL	  translocations	  or	  duplications	  [350].	  	  The	  MLL-­‐AF9	  translocation,	  for	  example,	  can	  initiate	  transformation	  in	  a	  myeloid	  progenitor	  cell	  by	  turning	  on	  a	  self-­‐renewal	  associated	  gene	  signature	  and	  inducing	  self-­‐renewal	  capacities	  in	  the	  progenitor	  cell;	  therefore,	  overexpression	  of	  MLL	  can	  increase	  self-­‐renewal	  [351].	  	  Conversely,	  embryo	  and	  chimera	  studies	  demonstrated	  that	  MLL-­‐deficient	  cells	  have	  decreased	  self-­‐renewal	  and	  cannot	  contribute	  to	  the	  pool	  of	  HSCs	  in	  an	  organism;	  without	  MLL,	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the	  cells	  enter	  the	  cell	  cycle	  and	  are	  depleted,	  so	  the	  role	  of	  MLL	  is	  likely	  to	  maintain	  quiescence	  [352,	  353].	  	  It	  is	  clear	  that	  MLL	  plays	  a	  key	  role	  in	  regulating	  HSC	  self-­‐renewal.	  	   Methylation	  also	  participates	  in	  the	  intrinsic	  control	  of	  self-­‐renewal	  in	  HSCs.	  	  Combinatorial	  knockdown	  of	  both	  Dnmt3a	  and	  Dnmt3b,	  de	  novo	  DNA	  methyltransferases,	  impaired	  the	  self-­‐renewal	  of	  murine	  HSCs,	  as	  assayed	  through	  long-­‐term	  transplantation,	  despite	  the	  knockout	  HSCs	  having	  normal	  differentiation	  capacities	  [354].	  	  A	  more	  recent	  study	  demonstrated	  the	  opposite	  phenotype	  by	  conditionally	  depleting	  Dnmt3a	  alone.	  	  They	  showed	  that	  Dnmt3a	  plays	  a	  role	  in	  silencing	  HSC	  regulatory	  genes	  to	  keep	  the	  balance	  between	  self-­‐renewal	  and	  differentiation	  [355].	  	  Despite	  the	  technical	  differences	  in	  the	  studies,	  which	  may	  have	  led	  to	  the	  differing	  results,	  both	  groups	  would	  agree	  that	  the	  Dnmt3	  factors	  play	  some	  role	  in	  HSC	  self-­‐renewal.	  	  This	  is	  also	  confirmed	  since	  Dnmt3a	  mutations	  are	  found	  in	  about	  20%	  of	  AML	  cases	  [229,	  230].	  	  Disruption	  of	  Dnmt1	  in	  the	  hematopoietic	  system	  leads	  to	  impaired	  HSCs	  that	  cannot	  self-­‐renew	  or	  produce	  the	  appropriate	  progenitor	  cells	  for	  standard	  hematopoiesis	  to	  take	  place	  [356,	  357].	  	  Histone	  methylation	  is	  also	  likely	  important	  for	  HSC	  self-­‐renewal,	  as	  murine	  HSCs	  express	  Fbxl10,	  or	  F-­‐box	  and	  leucine-­‐rich	  repeat	  protein	  10,	  a	  histone	  H3K36	  demethylase;	  forced	  expression	  of	  Fbxl10	  produced	  more	  multipotent	  cells	  in	  colony-­‐forming	  assays	  and	  in	  long-­‐term	  serial	  transplantation	  assays	  [358].	  	   Many	  other	  types	  of	  chromatin-­‐modifying	  factors	  also	  have	  been	  shown	  to	  impact	  HSC	  self-­‐renewal.	  	  Hmgb3,	  a	  high	  mobility	  group	  protein	  that	  can	  bind	  DNA,	  is	  preferentially	  expressed	  in	  HSCs;	  knockdown	  of	  the	  gene	  in	  mice	  produces	  more	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HSCs	  at	  the	  expense	  of	  differentiation,	  due	  to	  activation	  of	  the	  Wnt	  pathway,	  suggesting	  it	  plays	  a	  key	  role	  in	  the	  regulation	  of	  self-­‐renewal	  [359].	  	  Conditional	  knockout	  of	  Mi-­‐2beta,	  an	  ATPase	  and	  component	  of	  the	  Nucleosome	  Remodeling	  Deacetylase	  (NuRD)	  complex,	  leads	  HSCs	  to	  enter	  the	  cell	  cycle	  and	  produce	  only	  erythroid	  progenitors,	  revealing	  that	  Mi-­‐2beta	  contributes	  to	  both	  self-­‐renewal	  and	  lineage	  priming	  [360].	  	  Deletion	  of	  murine	  MOZ,	  a	  histone	  acetyltransferase	  known	  to	  interact	  with	  key	  blood	  transcription	  factors	  Runx1	  and	  PU.1,	  results	  in	  embryonic	  death,	  caused	  by	  lack	  of	  HSCs	  and	  therefore	  all	  hematopoiesis	  [361,	  362].	  	  MOZ	  is	  also	  a	  frequent	  translocation	  partner	  found	  in	  leukemias,	  and	  its	  translocation	  with	  TIF2	  can	  induce	  self-­‐renewal	  in	  hematopoietic	  progenitor	  cells	  during	  oncogenesis	  [363].	  	   Chromatin-­‐modifying	  factors	  are	  increasingly	  becoming	  known	  as	  regulators	  of	  hematopoiesis	  and	  HSC	  self-­‐renewal.	  	  However,	  since	  the	  few	  factors	  tested	  come	  from	  a	  wide	  variety	  of	  families,	  it	  is	  likely	  that	  many	  more	  with	  important	  roles	  remain	  to	  be	  discovered.	  	  Here	  we	  describe	  a	  series	  of	  novel	  screening	  approaches	  to	  determine	  what	  factors,	  when	  overexpressed	  in	  the	  hematopoietic	  system,	  have	  an	  impact	  on	  HSCs	  and	  hematopoiesis.	  	  A	  F1	  transgenic	  screening	  strategy	  was	  determined	  to	  be	  the	  best	  approach	  in	  targeting	  the	  desired	  tissue.	  	  Our	  results	  will	  have	  future	  applications	  to	  target	  the	  hematopoietic	  system	  as	  well	  as	  other	  tissues.	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Materials	  and	  Methods	  
Zebrafish	  Zebrafish	  were	  maintained	  and	  developmentally	  staged	  as	  previously	  described	  according	  to	  IACUC	  guidelines	  [255].	  	  The	  Animal	  Care	  and	  Use	  Committee,	  Children’s	  Hospital	  Boston	  approved	  all	  animal	  protocols.	  
Vectors	  and	  Cloning	  The	  plasmid	  containing	  the	  zebrafish	  globin	  locus	  control	  region	  (LCR),	  globin	  alpha-­‐A1	  promoter,	  and	  GFP	  was	  obtained	  from	  N.	  Hsia	  [364].	  	  To	  obtain	  this	  plasmid	  containing	  just	  the	  core	  200	  bp	  of	  the	  LCR,	  the	  following	  primers	  were	  used	  to	  amplify	  the	  core	  sequence	  by	  High	  Fidelity	  PCR	  and	  add	  the	  respective	  restriction	  enzyme	  sites:	  5’-­‐	  GGGGTACCCCAAGTGCAGAGTCATGGAGGGCT-­‐3’	  and	  5’	  GGACTAGTCCAAGTGATGAGTCAGCTGTTTGT-­‐3’.	  	  After	  gel	  extraction	  of	  this	  PCR	  reaction,	  the	  core	  fragment	  and	  the	  original	  plasmid	  were	  digested	  using	  KpnI	  and	  SpeI	  enzymes	  and	  treated	  with	  Antarctic	  Phosphatase,	  and	  the	  core	  fragment	  was	  ligated	  in	  place	  of	  the	  original	  6.2	  kb	  LCR.	  	  The	  non-­‐Tol2	  beta-­actin-­‐GFP	  and	  dsRed	  plasmids	  were	  obtained	  from	  D.	  Langenau.	  	  The	  p5E-­‐lmo2	  construct	  was	  obtained	  from	  O.	  Tamplin.	  	  The	  p5E-­‐ubiquitin	  construct	  was	  obtained	  from	  C.	  Kaufman	  [365].	  	  The	  non-­‐Tol2	  rag2	  destination	  vector	  was	  obtained	  from	  N.	  Storer.	  	  The	  Tol2-­‐plmo2	  Gateway	  destination	  vector	  (#367)	  as	  well	  as	  the	  pCS2	  Gateway	  destination	  vector	  (#201)	  was	  obtained	  from	  the	  Lawson	  lab.	  	  The	  Tol2	  multisite	  destination	  vectors	  without	  and	  with	  cmlc2-­‐GFP	  (#394,	  395),	  the	  p5E-­‐beta	  actin	  (#299),	  the	  p5E-­‐multiple	  cloning	  site	  (#228),	  the	  pME	  vectors	  with	  GFP	  and	  mCherry	  (#383,	  386),	  and	  the	  p3E-­‐polyA	  vector	  (#302)	  were	  obtained	  from	  the	  Tol2Kit	  [366].	  	  The	  Tol2	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beta-­actin-­‐GFP	  and	  mCherry	  plasmids	  were	  cloned	  through	  multisite	  Gateway	  reactions	  using	  LR	  Clonase	  II	  Plus	  (Invitrogen)	  with	  vectors	  394,	  299,	  383/386,	  and	  302.	  	  The	  p5E-­‐rag2	  construct	  was	  cloned	  by	  digesting	  vector	  228	  and	  a	  non-­‐Tol2	  
rag2-­‐BMI-­‐1	  with	  XhoI	  and	  BamHI	  enzymes	  and	  treating	  with	  Antarctic	  Phosphatase.	  	  Quick	  ligation	  of	  the	  components	  put	  the	  rag2	  promoter	  into	  the	  p5E	  vector.	  	  The	  Tol2-­‐rag2-­‐ORF	  plasmids	  were	  cloned	  through	  multisite	  Gateway	  reactions	  using	  LR	  Clonase	  II	  Plus	  (Invitrogen)	  with	  vectors	  395,	  p5E-­‐rag2,	  the	  desired	  ORF,	  and	  302.	  The	  Tol2-­‐lmo2-­‐ORF	  plasmids	  were	  cloned	  through	  multisite	  Gateway	  reactions	  using	  LR	  Clonase	  II	  Plus	  (Invitrogen)	  with	  vectors	  395,	  p5E-­‐lmo2,	  the	  desired	  ORF,	  and	  302.	  	  All	  open	  reading	  frames	  were	  obtained	  from	  the	  Ultimate	  ORF	  Clone	  collection	  (Invitrogen),	  with	  the	  exception	  of	  mMyc	  (C.	  Xu),	  MLL-­‐AF9	  (M.	  Stubbs	  from	  the	  Armstrong	  lab),	  runx1	  (E.	  Trompouki),	  and	  BMI-­‐1	  (N.	  Storer).	  
Microinjection	  All	  non-­‐Tol2	  constructs	  were	  linearized	  with	  XhoI,	  purified	  by	  phenol:chloroform	  extraction,	  and	  precipitated	  in	  ethanol.	  	  These	  purified	  constructs	  were	  diluted	  to	  50	  ng/uL	  in	  0.5x	  TE	  +	  0.1	  M	  KCl	  for	  injections,	  when	  one	  nL	  of	  this	  stock	  would	  be	  injected	  into	  one-­‐cell	  stage	  embryos.	  	  All	  Tol2	  constructs	  were	  injected	  at	  a	  total	  of	  25	  ng/uL	  with	  15	  ng/uL	  transposase	  mRNA	  in	  0.5x	  TE	  +	  0.1	  M	  KCl;	  one	  nL	  of	  this	  dilution	  was	  injected	  into	  one	  cell	  stage	  embryos.	  	  Transposase	  was	  made	  by	  linearizing	  the	  pCS-­‐TPase	  vector	  with	  NotI,	  synthesizing	  mRNA	  with	  the	  SP6	  mMessage	  mMachine	  kit	  (Ambion),	  and	  purifying	  with	  the	  RNeasy	  mini	  kit	  (Qiagen).	  	  All	  pCS	  constructs	  for	  chromatin	  factor	  mRNA	  injections	  were	  linearized	  with	  NotI,	  then	  gel	  extracted.	  	  This	  extracted	  DNA	  served	  as	  a	  template	  for	  the	  SP6	  synthesis	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reaction	  using	  the	  mMessage	  mMachine	  kit	  (Ambion);	  the	  synthesized	  mRNA	  was	  purified	  using	  the	  RNeasy	  mini	  kit	  (Qiagen).	  	  The	  purified	  mRNA	  was	  diluted	  with	  water	  to	  a	  concentration	  of	  40	  ng/uL	  for	  injections	  of	  1	  nL,	  2	  nL,	  or	  3	  nL	  to	  yield	  40	  pg,	  80	  pg,	  and	  120	  pg.	  	  All	  zebrafish	  used	  for	  microinjection	  were	  of	  the	  AB	  strain.	  
Identification	  of	  known	  and	  putative	  chromatin	  modifying	  factors	  Human	  chromatin	  modifying	  factors	  were	  identified	  using	  CREMOFAC,	  SMART	  domain,	  CDD,	  and	  Pfam	  databases.	  
In	  Situ	  Hybridization	  and	  Histopathology	  Whole	  mount	  in	  situ	  hybridizations	  (ISHs)	  were	  performed	  as	  previously	  described	  [259,	  260].	  	  Antisense	  mRNA	  probes	  were	  synthesized	  from	  digested	  plasmids	  [260].	  	  For	  the	  chromatin	  factors,	  the	  antisense	  probes	  were	  synthesized	  from	  the	  pCS2-­‐ORF	  vectors	  for	  each	  factor.	  	  The	  vectors	  were	  linearized	  with	  either	  EcoRI	  or	  BamHI,	  using	  one	  enzyme	  if	  the	  other	  site	  was	  present	  in	  the	  ORF.	  	  After	  phenol:chloroform	  extraction,	  the	  DIG-­‐labeled	  probes	  were	  synthesized	  using	  T7	  polymerase	  and	  purified	  using	  the	  RNeasy	  kit	  (Qiagen).	  	  Whole-­‐mount	  double	  fluorescent	  ISH	  was	  performed	  as	  previously	  described	  using	  the	  TSA	  Plus	  Fluorescein	  and	  TSA	  Plus	  Cy3	  kits	  for	  tyramide	  amplification	  (Perkin	  Elmer)	  [367].	  	  For	  ISH	  on	  the	  adult	  thymus,	  fish	  were	  euthanized	  and	  fixed	  in	  4%	  paraformaldehyde	  overnight	  at	  4°C.	  	  Paraffin	  embedding,	  sectioning,	  H&E	  staining,	  and	  RNA	  in	  situ	  hybridization	  were	  performed	  according	  to	  standard	  techniques	  by	  the	  Brigham	  &	  Women’s	  Pathology	  Core.	  	  RNA	  in	  situ	  probes	  were	  synthesized	  in	  the	  same	  manner	  as	  for	  whole	  mount	  ISHs.	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Results	  
In	  vivo	  Hematopoietic	  Stem	  Cell	  Competition	  Assay	  The	  gold	  standard	  for	  assessing	  self-­‐renewal	  capabilities	  of	  an	  HSC	  is	  the	  transplantation	  assay.	  	  However,	  when	  performing	  a	  transplant,	  several	  other	  factors	  are	  involved	  in	  determining	  whether	  the	  HSC	  successfully	  repopulates	  the	  recipient’s	  blood	  system.	  	  First,	  the	  HSC	  must	  successfully	  home	  and	  migrate	  to	  the	  marrow;	  second,	  it	  must	  interact	  properly	  with	  the	  niche	  in	  the	  marrow,	  allowing	  for	  engraftment.	  	  Homing,	  migration,	  and	  niche	  interactions	  represent	  an	  additional	  set	  of	  factors,	  each	  with	  their	  own	  regulation.	  	  Furthermore,	  performing	  transplants	  can	  be	  laborious	  and	  tedious,	  not	  ideal	  for	  high-­‐throughput	  screening.	  	  In	  order	  to	  focus	  on	  self-­‐renewal	  in	  an	  efficient	  in	  vivo	  setting,	  we	  proposed	  creating	  a	  competitive	  assay	  to	  monitor	  HSC	  competition	  during	  embryonic	  development.	  	  This	  assay	  would	  be	  parallel	  to	  transplants	  but	  in	  the	  context	  of	  development	  instead,	  as	  the	  HSCs	  would	  compete	  with	  each	  other	  in	  the	  AGM	  rather	  than	  the	  marrow	  and	  engraftment	  would	  still	  be	  read	  out	  in	  the	  differentiated	  lineages.	  	  If	  an	  HSC	  has	  a	  competitive	  advantage	  over	  other	  HSCs	  as	  they	  arise	  in	  the	  AGM,	  we	  would	  read	  out	  this	  increased	  self-­‐renewal	  in	  the	  downstream	  lineages,	  such	  as	  the	  RBCs	  (Figure	  3.1).	  	  This	  concept	  was	  feasible	  because	  definitive	  HSCs	  are	  rare	  within	  the	  fish,	  such	  that	  if	  the	  self-­‐renewal	  of	  a	  few	  HSCs	  increased,	  the	  downstream	  effects	  would	  present	  in	  a	  large	  proportion	  of	  the	  blood	  lineage.	  We	  set	  out	  to	  construct	  a	  transgenic	  system	  to	  overexpress	  an	  array	  of	  chromatin-­‐modifying	  factors	  in	  individual	  HSCs	  within	  the	  same	  animal	  and	  then	  determine	  which	  factors	  are	  important	  for	  self-­‐renewal.	  	  This	  system	  required	  a	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Figure	  3.1.	  Conceptual	  schematic	  for	  in	  vivo	  stem	  cell	  competition	  assay.	  	  (A)	  Different	  HSCs	  present	  in	  the	  AGM	  of	  a	  developing	  zebrafish	  each	  can	  differentiate	  into	  a	  full	  set	  of	  mature	  blood	  cells.	  	  If	  one	  of	  these	  HSCs	  were	  carrying	  a	  construct	  driving	  GFP	  expression	  by	  the	  globin	  locus,	  it	  would	  result	  in	  GFP-­‐positive	  erythrocytes.	  	  A	  different	  HSC	  could	  contain	  a	  construct	  with	  mCherry	  driven	  by	  the	  globin	  locus,	  resulting	  in	  mCherry-­‐positive	  erythrocytes	  instead.	  	  (B)	  With	  the	  base	  strategy	  presented	  in	  (A),	  the	  HSC	  capable	  of	  producing	  GFP-­‐positive	  erythrocytes	  could	  also	  contain	  a	  factor	  that	  would	  give	  this	  HSC	  a	  competitive	  advantage	  over	  the	  other.	  	  This	  would	  lead	  to	  an	  increased	  number	  of	  these	  HSCs,	  relative	  to	  the	  other,	  which	  could	  be	  read	  out	  as	  an	  increase	  in	  GFP-­‐positive	  erythrocytes	  as	  opposed	  to	  the	  mCherry-­‐positive	  erythrocytes.	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Figure	  3.1	  (Continued)	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method	  to	  express	  the	  factor	  of	  choice	  in	  the	  HSC	  as	  well	  as	  a	  method	  to	  assess	  “engraftment”	  downstream.	  	  Using	  an	  HSC/progenitor	  specific	  promoter,	  the	  expression	  of	  chromatin	  factors	  would	  be	  driven	  in	  the	  HSCs.	  	  Utilizing	  an	  RBC-­‐specific	  promoter	  to	  drive	  two	  or	  more	  fluorescent	  proteins	  in	  this	  differentiated	  lineage	  served	  as	  the	  engraftment	  readout.	  	  Ideally	  these	  two	  components	  would	  be	  placed	  on	  a	  single	  vector	  to	  ensure	  the	  HSC	  receiving	  the	  chromatin	  factor	  always	  also	  received	  the	  same	  fluorescent	  color	  for	  accurate	  readout.	  	  Then,	  the	  different	  RBCs,	  formed	  from	  different	  HSCs,	  would	  be	  marked	  in	  vivo	  by	  different	  fluorescent	  proteins.	  	  The	  presence	  of	  multicolor	  peripheral	  blood	  in	  an	  adult	  fish	  would	  thus	  imply	  equal	  “engraftment”	  among	  the	  competing	  HSCs	  during	  development;	  however,	  if	  one	  color	  is	  more	  prominent	  than	  the	  other(s),	  this	  would	  suggest	  an	  impact	  on	  competition	  during	  development	  and	  therefore	  self-­‐renewal.	  	  For	  example,	  we	  would	  start	  with	  a	  two	  color	  system	  using	  GFP	  and	  mCherry	  in	  the	  RBCs,	  where	  GFP	  marked	  RBCs	  derived	  from	  an	  HSC	  overexpressing	  a	  factor	  and	  mCherry	  marked	  RBCs	  derived	  from	  an	  HSC	  with	  overexpressing	  a	  control	  factor.	  	  If	  this	  factor	  of	  interest	  were	  to	  enhance	  self-­‐renewal,	  a	  clonal	  expansion	  of	  those	  HSCs	  would	  occur;	  this	  would	  lead	  to	  a	  clonal	  expansion	  of	  the	  fluorescent	  color	  it	  was	  co-­‐expressed	  with	  (here,	  GFP)	  further	  down	  in	  the	  blood	  lineage.	  	  A	  simple	  way	  to	  monitor	  this	  expansion	  is	  to	  analyze	  fluorescence	  expression	  by	  FACS	  or	  simply	  by	  looking	  at	  circulation	  in	  vivo	  in	  the	  tail	  of	  a	  live	  zebrafish.	  	  Factors	  with	  no	  HSC	  impact	  should	  have	  equal	  numbers	  of	  green	  and	  red	  RBCs.	  	  However,	  if	  the	  candidate	  factor	  confers	  a	  competitive	  advantage	  or	  enhances	  self-­‐renewal	  of	  the	  HSC,	  the	  green	  RBCs	  will	  expand	  relative	  to	  the	  red	  ones	  (Figure	  3.1).	  	  Similarly,	  if	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the	  proportion	  of	  GFP-­‐positive	  erythrocytes	  were	  less	  than	  half,	  this	  would	  suggest	  that	  the	  candidate	  factor	  had	  a	  negative	  influence	  on	  HSC	  development.	  	  The	  applications	  of	  this	  assay	  include	  an	  assessment	  of	  the	  role	  of	  various	  genes	  in	  the	  self-­‐renewal	  of	  stem	  cells,	  the	  elimination	  of	  the	  need	  to	  perform	  time-­‐consuming	  transplants,	  and	  a	  true	  assessment	  of	  self-­‐renewal	  without	  migration,	  homing,	  and	  niche	  considerations.	  We	  began	  developing	  a	  multi-­‐fluorescence	  based	  system	  to	  readout	  RBCs	  arising	  from	  genetically	  modified	  HSCs.	  	  This	  utilized	  a	  globin	  LCR	  vector,	  consisting	  of	  the	  hemoglobin	  locus	  control	  region	  adjacent	  to	  the	  globin	  alpha	  A1	  (adult	  1)	  promoter	  driving	  a	  fluorophore	  of	  interest	  [364].	  	  When	  transiently	  injected	  into	  one-­‐cell	  stage	  zebrafish	  embryos,	  this	  promoter	  and	  regulatory	  element	  drives	  robust	  fluorophore	  expression	  in	  the	  erythrocyte	  lineage.	  	  The	  original	  vector	  was	  6.2	  kb	  and	  therefore	  lacked	  maneuverability,	  so	  we	  characterized	  a	  core	  200	  bp	  sequence	  of	  the	  LCR	  that	  retained	  robust	  erythrocyte	  expression	  that	  was	  used	  for	  subsequent	  studies.	  	  This	  200	  bp	  includes	  an	  important	  DNase	  hypersensitive	  site	  as	  well	  as	  several	  GATA1	  and	  NFE2	  binding	  motifs.	  In	  addition	  to	  needing	  fluorescent	  transgenes	  to	  mark	  different	  HSC-­‐specific	  progeny,	  expression	  of	  modifiers	  in	  the	  HSCs	  was	  also	  needed.	  	  Potential	  modifiers	  of	  HSC	  function	  would	  be	  expressed	  in	  the	  HSC	  under	  the	  control	  of	  the	  lmo2	  promoter.	  	  We	  obtained	  Tol2	  transposon	  vectors	  containing	  the	  lmo2	  promoter	  in	  front	  of	  Gateway	  recombination	  sites.	  	  The	  Gateway	  system	  would	  allow	  ease	  of	  cloning	  in	  a	  set	  of	  factors	  of	  interest	  to	  be	  screened	  in	  the	  in	  vivo	  competition	  assay	  over	  traditional	  restriction	  digests	  and	  ligations.	  	  The	  Tol2	  transposon	  system	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would	  permit	  efficient	  transgenesis	  of	  up	  to	  11	  kb	  of	  cargo	  through	  single-­‐copy	  integrations	  when	  the	  transposons	  were	  co-­‐injected	  with	  transposase	  mRNA	  [368].	  	  We	  also	  obtained	  around	  one	  hundred	  open	  reading	  frames	  of	  human	  chromatin-­‐modifying	  factors	  from	  Invitrogen	  that	  were	  Gateway	  compatible.	  With	  all	  the	  pieces	  in	  place,	  we	  needed	  to	  show	  that	  this	  in	  vivo	  competition	  assay	  would	  be	  technically	  feasible.	  	  To	  test	  both	  linearized	  plasmid	  and	  transposon	  constructs	  for	  segregation,	  we	  injected	  vectors	  of	  each	  type	  with	  the	  beta-­actin	  promoter	  driving	  GFP	  and	  dsRed/mCherry.	  	  In	  the	  case	  of	  co-­‐injections	  of	  both	  linearized	  plasmids	  and	  transposons,	  there	  was	  colocalization	  of	  the	  red	  and	  green	  color	  (Figure	  3.2).	  	  This	  meant	  that	  if	  the	  cells	  received	  one	  vector,	  they	  were	  getting	  both	  vectors.	  	  The	  concept	  for	  the	  in	  vivo	  competition	  assay	  relied	  on	  the	  different	  fluorophore	  vectors	  landing	  in	  different	  cells.	  	  This	  proof	  of	  principle	  experiment	  displayed	  that	  the	  assay	  would	  not	  work	  as	  planned,	  and	  we	  would	  need	  a	  new	  assay	  to	  assess	  effects	  on	  HSC	  self-­‐renewal	  in	  vivo.	  
Test	  of	  F0	  Ubiquitous	  Overexpression	  In	  looking	  for	  another	  approach	  to	  assess	  the	  impact	  of	  overexpressing	  chromatin-­‐modifying	  factors	  on	  HSC	  biology,	  we	  first	  examined	  the	  possibilities	  of	  ubiquitous	  overexpression	  in	  the	  F0	  generation	  of	  embryos.	  	  There	  were	  some	  immediate	  concerns	  that	  ubiquitous	  overexpression	  of	  a	  chromatin-­‐modifying	  factor	  would	  result	  in	  an	  embryo	  too	  universally	  affected	  to	  evaluate.	  	  We	  tested	  two	  methods	  of	  ubiquitous	  overexpression,	  expression	  of	  the	  factor	  by	  injecting	  full-­‐length	  mRNA	  and	  by	  injecting	  a	  DNA	  construct	  driving	  expression	  of	  the	  factor	  with	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Figure	  3.2.	  Ubiquitous	  DNA	  vectors	  colocalize	  in	  the	  zebrafish	  embryo,	  
regardless	  of	  vector	  type.	  	  beta-­actin-­‐GFP	  and	  beta-­actin-­‐dsRed	  linearized	  plasmids	  (panels	  A,B,E,F,I,J)	  showed	  colocalization	  when	  co-­‐injected.	  	  Similarly,	  Tol2-­‐beta-­actin-­‐GFP	  and	  Tol2-­‐beta-­actin-­‐mCherry	  constructs	  co-­‐injected,	  along	  with	  transposase	  mRNA,	  also	  showed	  colocalization	  of	  fluorescent	  cells	  (panels	  
C,D,G,H,K,L).	  	  Fish	  were	  examined	  for	  fluorescence	  at	  1	  dpf	  (A-­‐D),	  9	  dpf	  (E-­‐H),	  and	  23	  dpf	  (I-­‐L).	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the	  ubiquitin	  promoter.	  	  The	  chromatin	  factor	  mRNAs	  were	  injected	  at	  40,	  80,	  and	  120	  pg	  into	  the	  yolk	  of	  one	  and	  two	  cell	  stage	  embryos,	  since	  each	  mRNA	  would	  have	  a	  different	  optimal	  dose.	  	  The	  embryos	  were	  then	  fixed	  at	  36	  hpf	  in	  4%	  paraformaldehyde,	  and	  in	  situ	  hybridization	  was	  performed	  on	  them	  for	  c-­myb	  and	  
runx1,	  markers	  of	  the	  HSCs	  at	  this	  timepoint.	  	  The	  following	  factors	  were	  screened	  for	  effects	  on	  c-­myb/runx1	  expression	  by	  mRNA	  overexpression:	  HMGA1,	  CBX1,	  ING3,	  ING4,	  MBD3,	  BMI-­‐1,	  C20orf20,	  CBX5,	  ING5,	  TNFAIP6,	  TERF1,	  BRD7,	  BRD2,	  CBX8,	  BRPF3,	  ARID3A,	  ARID3B,	  SUV39H1,	  SUV39H2,	  CBX3,	  CBX6,	  CBX7,	  CDYL2,	  RFX5,	  ZHX1,	  ELF3,	  N-­‐PAC,	  BRPF1,	  PCAF,	  HMGN1,	  and	  MBD1.	  The	  ubiquitin-­‐driving	  chromatin	  factor	  constructs	  were	  made	  as	  Tol2	  transposons.	  	  It	  was	  thought	  that	  using	  the	  transposon	  system	  would	  lead	  to	  more	  efficient	  expression	  that	  linearized	  vectors.	  	  The	  transposon	  carrying	  ubiquitin-­‐chromatin	  factor	  and	  the	  transposase	  mRNA	  were	  injected	  into	  the	  cell	  of	  one	  cell	  stage	  embryos	  at	  25	  ng/uL	  and	  15	  ng/uL,	  respectively.	  	  Similar	  to	  the	  mRNA	  injections,	  these	  embryos	  were	  fixed	  at	  36	  hpf	  and	  stained	  by	  in	  situ	  hybridization	  (ISH)	  for	  c-­myb	  and	  runx1	  probes.	  	  The	  following	  factors	  were	  screened	  for	  effects	  on	  c-­myb/runx1	  expression	  by	  ubiquitin	  overexpression:	  BMI-­‐1,	  CBX6,	  SCL,	  HDAC3,	  HDAC8,	  HDAC10,	  HDAC11,	  ING3,	  ING4,	  MLL-­‐AF9,	  runx1,	  CBX3,	  CBX5,	  CBX7,	  CBX8,	  CDYL2,	  and	  CBX1.	  We	  examined	  these	  options	  more	  closely	  using	  BMI-­‐1	  as	  the	  factor	  of	  choice.	  	  Upon	  performing	  the	  injections	  with	  either	  BMI-­‐1	  mRNA	  or	  a	  Tol2	  based	  ubiquitin-­‐BMI-­‐1	  construct	  with	  transposase,	  these	  embryos	  were	  fixed	  as	  usual	  at	  36	  hpf.	  	  Rather	  than	  staining	  for	  the	  blood	  markers,	  however,	  we	  performed	  the	  ISHs	  using	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probe	  for	  BMI-­‐1	  (Figure	  3.3).	  	  The	  mRNA-­‐injected	  embryos	  showed	  a	  diffuse,	  ubiquitous	  overexpression	  of	  BMI-­‐1,	  with	  the	  higher	  doses	  having	  slightly	  darker	  staining	  than	  the	  low	  dose	  of	  40	  pg	  (Figure	  3.3.C-­‐D).	  	  The	  ubiquitin-­‐based	  injections,	  being	  a	  DNA	  construct,	  were	  more	  mosaic,	  revealing	  distinct	  but	  random	  patches	  of	  BMI-­‐1	  expression	  over	  the	  entire	  embryo	  (Figure	  3.3.B).	  	  Based	  on	  the	  overexpression	  quality,	  the	  mRNA	  strategy	  was	  more	  likely	  to	  be	  getting	  into	  every	  cell,	  including	  the	  blood	  cells	  we	  wanted	  to	  study.	  	  However,	  we	  had	  some	  concerns	  that	  producing	  quality	  mRNA	  in	  a	  high-­‐throughout	  manner	  for	  each	  factor	  we	  wanted	  to	  screen	  would	  be	  troublesome.	  	  On	  the	  other	  hand,	  producing	  quality	  DNA	  vector,	  such	  as	  the	  ubiquitin	  transposons,	  was	  not	  difficult	  at	  all,	  as	  a	  standard	  miniprep	  was	  of	  sufficient	  quality;	  some	  larger	  ORFs	  we	  were	  unable	  to	  synthesize	  as	  mRNA	  but	  could	  easily	  produce	  a	  DNA-­‐based	  vector.	  	  Yet,	  this	  strategy	  did	  not	  guarantee	  the	  desired	  factor	  would	  be	  expressed	  in	  a	  blood	  cell.	  	  The	  one	  thing	  both	  strategies	  had	  in	  common	  was	  that	  neither	  was	  cell	  intrinsic;	  if	  we	  saw	  a	  phenotype,	  we	  would	  be	  unable	  to	  determine	  if	  it	  was	  due	  to	  an	  effect	  in	  the	  HSC,	  progenitor	  cell,	  mature	  blood	  cell,	  the	  niche,	  or	  any	  other	  cell	  in	  the	  embryo.	  	  Neither	  option	  presented	  itself	  as	  the	  best	  way	  to	  screen	  for	  a	  self-­‐renewal	  phenotype,	  which	  was	  the	  confirmation	  we	  needed	  to	  perform	  the	  screen	  in	  the	  F1	  generation.	  
F1	  Transgenic	  Screen	  in	  Hematopoietic	  Stem	  and	  Progenitor	  Cells	  In	  order	  to	  best	  address	  the	  question	  of	  how	  overexpression	  of	  a	  particular	  factor	  affects	  the	  self-­‐renewal	  of	  HSCs	  in	  a	  vertebrate,	  we	  developed	  an	  F1	  transgenic	  screening	  approach.	  	  Having	  an	  F1	  approach	  allows	  the	  factor	  of	  interest	  to	  be	  overexpressed	  stably	  in	  the	  desired	  tissue	  of	  choice,	  eliminating	  issues	  of	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Figure	  3.3.	  Transient	  injections	  to	  overexpress	  chromatin	  factors.	  	  Embryos	  were	  injected	  with	  either	  BMI-­‐1	  mRNA	  or	  a	  DNA	  ubiquitin-­‐BMI-­‐1	  construct.	  	  At	  36	  hpf,	  ISH	  was	  performed	  to	  BMI-­‐1.	  	  When	  compared	  to	  uninjected	  controls	  (A),	  the	  DNA	  construct	  (B)	  resulted	  in	  a	  patchy,	  mosaic	  expression	  pattern.	  	  In	  contrast,	  two	  different	  doses	  of	  mRNA	  (C,D)	  revealed	  a	  diffuse,	  ubiquitous	  expression	  pattern.	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variability	  and	  inconsistent	  expression.	  	  Additionally,	  targeting	  the	  expression	  of	  the	  factor	  of	  interest	  to	  the	  desired	  cells	  allows	  for	  a	  cell	  intrinsic	  assessment,	  thus	  eliminating	  the	  need	  to	  do	  cell	  autonomy	  studies	  later.	  	  The	  major	  disadvantage	  to	  this	  system	  as	  a	  screening	  tool	  is	  the	  lag	  time	  waiting	  for	  the	  next	  generation.	  	  However,	  this	  loss	  in	  time	  is	  gained	  later	  when	  a	  factor	  proves	  worthy	  of	  further	  study,	  and	  more	  embryos	  can	  be	  obtained	  weekly	  by	  setting	  up	  the	  founders.	  	  Any	  studies	  that	  would	  require	  the	  development	  of	  a	  transgenic	  line	  can	  commence	  sooner	  because	  the	  line	  has	  already	  been	  made.	  
	   The	  F1	  screen	  we	  performed	  was	  in	  the	  HSC/progenitor	  compartment.	  	  This	  screen	  was	  designed	  utilizing	  the	  Tol2Kit	  vector	  #395,	  a	  Tol2	  destination	  vector	  containing	  the	  cardiac	  myosin	  light	  chain	  2	  (cmlc2)	  promoter	  driving	  GFP	  as	  well	  as	  multisite	  Gateway	  recombination	  sites	  [366].	  	  This	  vector	  allowed	  the	  use	  of	  the	  
cmlc2-­‐GFP	  as	  a	  transgenesis	  marker;	  fish	  carrying	  the	  transgene	  had	  GFP-­‐positive	  hearts.	  	  The	  Gateway	  sites	  allowed	  the	  recombination	  into	  the	  vector	  of	  the	  5’	  lmo2	  promoter,	  the	  middle	  chromatin-­‐modifying	  factor	  ORF	  of	  interest,	  and	  the	  3’	  poly-­‐A	  tail	  to	  be	  in	  tandem	  with	  the	  cmlc2-­‐GFP.	  A	  proof	  of	  principle	  was	  executed	  first	  with	  a	  vector	  carrying	  cmlc2-­‐GFP,	  
lmo2-­mCherry,	  where	  we	  anticipated	  that	  embryos	  with	  GFP-­‐positive	  hearts	  would	  have	  mCherry-­‐positive	  blood.	  	  The	  first	  clutch	  from	  an	  F0	  incross	  yielded	  58	  GFP-­‐positive	  embryos,	  none	  of	  which	  were	  mCherry-­‐positive	  by	  eye.	  	  Some	  of	  these	  embryos	  were	  fixed	  at	  36	  hpf	  and	  were	  examined	  by	  in	  situ	  hybridization	  for	  mCherry	  expression.	  	  12/14	  were	  negative,	  while	  2/14	  did	  show	  some	  expression	  in	  the	  hematopoietic	  compartment.	  	  More	  F0	  incrosses	  yielded	  more	  GFP-­‐positive	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embryos.	  	  From	  this	  larger	  cohort	  of	  clutches,	  we	  saw	  three	  groups	  of	  embryos	  (Figure	  3.4).	  	  In	  the	  first	  set,	  we	  observed	  that	  all	  the	  GFP-­‐positive	  embryos	  were	  also	  mCherry-­‐positive	  in	  the	  blood,	  as	  expected.	  	  These	  also	  stained	  well	  for	  mCherry	  mRNA	  by	  ISH.	  	  In	  the	  second	  set,	  none	  of	  the	  GFP-­‐positive	  embryos	  were	  mCherry-­‐positive.	  	  When	  these	  embryos	  underwent	  ISH,	  they	  had	  a	  very	  small	  number	  of	  cells	  in	  the	  posterior	  blood	  island	  (PBI)	  stain	  positive	  for	  mCherry	  mRNA.	  	  The	  third	  set	  contained	  a	  mixture;	  most	  GFP-­‐positive	  embryos	  were	  mCherry-­‐negative,	  yet	  a	  few	  were	  mCherry-­‐positive.	  	  Upon	  performing	  the	  ISH	  on	  this	  clutch,	  a	  few	  had	  strong	  mCherry	  staining,	  likely	  the	  ones	  that	  could	  be	  visualized.	  	  About	  one-­‐third	  had	  some	  moderate	  staining,	  and	  the	  rest	  had	  essentially	  no	  staining	  at	  all.	  	  The	  correlation	  between	  GFP	  and	  mCherry	  expression	  did	  not	  seem	  to	  be	  as	  clear	  cut	  as	  desired,	  so	  investigation	  continued	  with	  a	  few	  selected	  cmlc2-­‐GFP,	  lmo2-­‐chromatin-­‐modifying	  factor	  lines	  that	  had	  already	  been	  injected.	  The	  following	  four	  lines	  were	  examined	  more	  in	  depth:	  cmlc2-­‐GFP,	  lmo2-­‐CBX1;	  cmlc2-­‐GFP,	  lmo2-­‐CBX7;	  cmlc2-­‐GFP,	  lmo2-­‐ING3;	  and	  cmlc2-­‐GFP,	  lmo2-­‐CDYL2.	  	  For	  each	  transgenic	  line,	  F0	  fish	  were	  incrossed,	  GFP-­‐positive	  embryos	  were	  segregated,	  and	  those	  embryos	  were	  fixed	  at	  22-­‐24	  hpf.	  	  GFP-­‐negative	  siblings	  were	  also	  fixed	  at	  the	  same	  time	  as	  negative	  controls.	  	  ISHs	  were	  completed	  on	  these	  embryos	  with	  probes	  to	  their	  respective	  chromatin-­‐modifying	  factor.	  	  In	  general,	  at	  22-­‐24	  hpf,	  it	  appears	  that	  expression	  of	  both	  CBX1	  and	  CBX7	  was	  highly	  correlated	  with	  GFP	  expression.	  	  All	  embryos	  had	  some	  expression	  in	  the	  expected	  pattern,	  though	  sometimes	  the	  levels	  of	  expression	  varied	  greatly	  between	  weak	  and	  robust	  	  






Figure	  3.4.	  HSC	  F1	  screen	  strategy	  and	  proof	  of	  principle.	  	  (A)	  A	  Tol2-­‐based	  vector,	  containing	  the	  transgenesis	  marker	  cmlc2-­‐GFP	  with	  lmo2	  driving	  the	  chromatin	  factor	  of	  interest,	  was	  co-­‐injected	  with	  transposase	  mRNA	  into	  wild-­‐type	  embryos.	  	  These	  F0	  fish	  were	  grown	  up	  to	  adulthood,	  incrossed,	  and	  the	  subsequent	  F1	  embryos	  were	  scored	  for	  GFP-­‐positive	  hearts.	  	  Those	  with	  GFP-­‐positive	  hearts	  were	  fixed	  at	  either	  22	  hpf	  or	  36	  hpf	  for	  subsequent	  ISH	  for	  beta-­E3-­globin	  or	  
runx1/c-­myb,	  respectively.	  	  (B-­D)	  This	  was	  first	  tested	  with	  a	  proof	  of	  principle	  using	  mCherry	  as	  the	  factor	  of	  interest.	  	  Three	  groups	  of	  F1	  GFP-­‐positive	  embryos	  would	  appear:	  mCherry-­‐positive	  by	  eye	  (B),	  mCherry-­‐negative	  by	  eye	  (C),	  and	  some	  of	  each	  (D).	  	  ISH	  for	  mCherry	  on	  these	  three	  groups	  revealed	  robust	  expression	  when	  mCherry	  was	  seen	  by	  eye	  and	  little	  to	  none	  when	  it	  was	  not	  visualized.	  	  Arrowheads	  indicate	  patches	  of	  expression.	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(Figure	  3.5.A-­‐D).	  	  However,	  almost	  all	  GFP-­‐positive	  had	  ICM	  expression	  of	  CBX1	  or	  CBX7,	  as	  would	  be	  expected	  at	  this	  time	  point.	  	  We	  also	  wondered	  if	  the	  variation	  in	  expression	  levels	  correlated	  to	  GFP	  intensity,	  as	  we	  observed	  differences	  in	  the	  GFP	  intensity	  in	  the	  hearts	  of	  these	  embryos.	  	  	  There	  was	  minimal	  correlation	  between	  higher	  expressing	  GFP	  levels	  in	  the	  heart	  and	  higher/lower	  chromatin	  factor	  expression	  levels	  (Figure	  3.5.E-­‐F).	  	  The	  two	  other	  lines,	  cmlc2-­‐GFP,	  lmo2-­‐ING3	  and	  
cmlc2-­‐GFP,	  lmo2-­‐CDYL2,	  displayed	  similar	  results,	  with	  greater	  than	  95%	  of	  the	  embryos	  with	  GFP-­‐positive	  hearts	  having	  some	  expression	  of	  the	  chromatin	  factor	  by	  ISH.	  	  However,	  only	  25-­‐50%	  of	  those	  embryos	  were	  classified	  as	  having	  good	  expression,	  which	  was	  defined	  as	  robust	  expression	  throughout	  both	  the	  PBI	  and	  intermediate	  cell	  mass	  (ICM;	  Figure	  3.5.G).	  	  It	  was	  unknown	  how	  much	  of	  this	  was	  implicit	  in	  the	  transgenic	  fish	  and	  how	  much	  was	  ISH	  and	  probe-­‐dependent.	  	  Since	  we	  were	  seeing	  expression	  of	  some	  level	  in	  nearly	  100%	  of	  embryos,	  we	  concluded	  that	  the	  screen	  of	  chromatin	  factor	  expression	  in	  the	  blood	  could	  officially	  commence.	  	  However,	  we	  decided	  to	  modify	  the	  approach	  so	  that	  we	  would	  know	  the	  general	  levels	  of	  expression	  of	  the	  overexpression	  factor	  within	  each	  clutch.	  	  Therefore,	  each	  clutch	  was	  segregated	  into	  GFP-­‐positive	  and	  GFP-­‐negative	  embryos,	  and	  each	  of	  those	  groups	  was	  fixed	  in	  thirds	  for	  three	  different	  ISHs.	  	  One	  ISH	  occurred	  on	  22	  hpf	  embryos	  for	  betaE3	  globin	  (primitive	  RBCs),	  the	  second	  ISH	  occurred	  on	  36	  hpf	  embryos	  for	  runx1/c-­myb	  (definitive	  HSCs),	  and	  the	  last	  ISH	  occurred	  on	  22	  hpf	  embryos	  with	  a	  probe	  for	  the	  chromatin	  factor	  being	  tested	  (Figure	  3.6.A-­‐F).	  	  The	  GFP-­‐negative	  siblings	  acted	  as	  a	  control	  for	  each	  clutch,	  and	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Figure	  3.5.	  HSC	  F1	  screen	  for	  first	  few	  factors	  is	  more	  promising	  than	  mCherry.	  	  ISH	  were	  performed	  for	  the	  injected	  chromatin	  factor	  to	  examine	  expression	  levels.	  	  Representative	  pictures	  from	  CBX1	  ISHs	  (A,B)	  and	  CBX7	  ISHs	  (C,D)	  are	  shown;	  there	  is	  expression,	  but	  levels	  vary.	  	  (E,F)	  Expression	  levels	  do	  not	  correlate	  with	  GFP	  levels	  in	  the	  heart	  by	  eye,	  as	  embryos	  separated	  into	  low	  and	  high	  GFP	  look	  similar.	  	  Arrowheads	  indicate	  patches	  of	  expression.	  	  (G)	  The	  table	  shows	  all	  data	  from	  the	  first	  four	  chromatin	  factors	  examined	  for	  their	  expression	  levels;	  most	  have	  some	  expression,	  but	  it	  is	  not	  necessarily	  high	  levels	  of	  expression.	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Figure	  3.6.	  HSC	  F1	  Screening.	  	  Representative	  images	  from	  a	  full	  set	  of	  data	  from	  a	  representative	  chromatin	  factor,	  ING3.	  	  For	  each	  factor,	  clutches	  were	  split	  into	  thirds	  to	  complete	  ISH	  for	  the	  factor	  itself	  (A,B;	  22	  hpf),	  beta-­E3-­globin(C,D;	  22	  hpf),	  and	  runx1/c-­myb	  (E,F;	  36	  hpf).	  	  (G-­J)	  Double	  fluorescent	  ISH	  were	  also	  tested	  to	  avoid	  having	  to	  split	  clutches	  and	  perform	  the	  ISH	  for	  the	  blood	  marker	  and	  factor	  in	  a	  single	  embryo,	  shown	  here	  for	  CBX7.	  	  Arrowheads	  indicate	  patches	  of	  expression.	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we	  felt	  it	  was	  important	  to	  know	  the	  expression	  levels	  of	  the	  chromatin	  factor	  in	  each	  clutch	  since	  it	  was	  variable.	  	   To	  eliminate	  the	  need	  to	  perform	  three	  separate	  ISH	  for	  each	  set	  of	  embryos,	  we	  explored	  the	  possibility	  of	  performing	  double	  fluorescent	  ISH	  [367].	  	  The	  double	  ISH	  would	  enable	  the	  visualization	  of	  both	  the	  blood	  marker	  and	  the	  chromatin	  factor	  in	  the	  same	  embryo.	  	  The	  fluorescent	  ISH	  would	  permit	  the	  visualization	  of	  each	  probe	  with	  a	  different	  fluorophore,	  since	  both	  genes	  were	  being	  expressed	  in	  the	  same	  region	  and	  could	  not	  be	  separated	  with	  traditional	  two-­‐color	  ISH.	  	  This	  was	  tried	  with	  several	  chromatin	  factor	  probes	  that	  were	  successful	  in	  traditional	  ISH,	  including	  CBX1	  and	  CBX7.	  	  The	  only	  chromatin	  factor	  probe	  to	  produce	  any	  signal	  in	  the	  fluorescent	  ISH	  was	  CBX7,	  probably	  the	  strongest	  chromatin	  factor	  probe	  we	  had.	  	  However,	  in	  the	  double	  fluorescent	  ISH,	  it	  stained	  the	  ICM	  very	  minimally	  (Figure	  3.6G-­‐J).	  	  The	  procedure	  works	  best	  for	  probes	  that	  are	  strong,	  so	  we	  concluded	  that	  this	  set	  of	  probes	  was	  likely	  too	  weak	  to	  perform	  the	  fluorescent	  ISH	  in	  a	  high-­‐throughput	  manner.	  	  Therefore,	  we	  continued	  the	  screen	  as	  previously,	  splitting	  each	  clutch	  to	  perform	  three	  sets	  of	  traditional	  ISH.	  Twenty-­‐seven	  different	  chromatin-­‐modifying	  factors	  were	  fully	  examined	  in	  the	  F1	  generation	  as	  embryos	  for	  effects	  on	  blood	  development.	  	  They	  were:	  CBX1,	  CBX7,	  ING3,	  CDYL2,	  ID2,	  HDAC9,	  BMI-­‐1,	  CBX3,	  HMGA1,	  ARID3B,	  ARID3A,	  ING4,	  PCAF,	  HDAC10,	  MBD3,	  ING5,	  CBX5,	  CITED2,	  SUV39H1,	  HDAC3,	  C20orf20,	  CCDC71,	  CTCF,	  SATB2,	  BRPF3,	  N-­‐PAC,	  and	  CHRAC1.	  	  Several	  others,	  including	  CBX6,	  UHRF2,	  and	  MLL-­‐AF9,	  had	  no	  blood	  phenotype	  but	  the	  ISH	  for	  the	  factor	  itself	  was	  unsuccessful	  (Figure	  3.7).	  	  The	  only	  factor	  to	  display	  any	  phenotype	  was	  CBX5,	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Figure	  3.7.	  Expression	  levels	  for	  each	  chromatin	  factor	  examined	  in	  the	  F1	  
screen.	  	  Of	  the	  GFP-­‐positive	  embryos	  collected	  per	  factor	  (GFP	  positive),	  there	  was	  a	  wide	  variety	  of	  percentages	  for	  whether	  the	  factors	  were	  expressed	  highly	  (CF	  exp	  good)	  or	  even	  at	  all	  (CF	  positive).	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which	  looked	  to	  have	  fewer	  HSCs	  by	  runx1/c-­myb	  staining	  on	  the	  first	  few	  GFP-­‐positive	  embryos	  compared	  to	  negative	  siblings	  (Figure	  3.8.A-­‐D).	  	  This	  seemed	  interesting	  because	  CBX5,	  along	  with	  Myb	  and	  Hmgb3,	  is	  known	  to	  be	  important	  for	  leukemic	  stem	  cell	  maintenance	  [369].	  	  However,	  the	  phenotype	  did	  not	  repeat	  from	  new	  founders,	  leading	  us	  to	  conclude	  that	  the	  effect	  was	  not	  specific	  to	  CBX5.	  	  At	  this	  point,	  we	  decided	  not	  to	  continue	  screening	  the	  remaining	  thirty	  factors	  that	  had	  been	  injected	  as	  F0s	  because	  it	  seemed	  unlikely	  that	  we	  would	  see	  an	  interesting	  phenotype.	  
F0	  Transgenic	  Screen	  in	  Lymphoid	  Cells	  	   In	  parallel	  with	  the	  F0	  ubiquitous	  overexpression	  studies,	  we	  also	  attempted	  an	  F0	  screen	  in	  the	  lymphoid	  progenitor	  compartment.	  	  This	  screen	  was	  designed	  using	  the	  rag2	  promoter,	  the	  recombination	  activating	  gene	  2	  that	  expresses	  in	  developing	  lymphocytes	  (Figure	  3.9.A-­‐E).	  	  This	  approach	  was	  desirable	  as	  rag2	  expresses	  in	  the	  common	  lymphocyte	  progenitor,	  maintaining	  this	  as	  a	  stem	  and	  progenitor	  cell	  screen.	  	  It	  was	  also	  desirable	  because	  we	  had	  a	  positive	  control	  with	  
rag2-­mMyc,	  known	  to	  induce	  T-­‐ALL	  in	  zebrafish;	  since	  this	  was	  our	  best	  hypothesis	  at	  the	  phenotype	  we	  could	  expect	  this	  screen	  was	  also	  a	  screen	  looking	  for	  leukemias/lymphomas	  [173].	  	  The	  chromatin-­‐modifying	  factors	  were	  recombined	  using	  the	  Gateway	  system	  behind	  the	  rag2	  promoter,	  then	  sequenced	  for	  verification.	  	  Each	  rag2-­chromatin	  factor	  linearized	  construct	  was	  co-­‐injected	  into	  one	  cell	  stage	  AB	  wild-­‐type	  fish	  along	  with	  a	  linearized	  construct	  of	  rag2-­‐GFP,	  with	  each	  construct	  injected	  at	  50	  ng/uL.	  	  Injected	  constructs	  of	  good	  quality	  ORFs	  included	  the	  following	  factors:	  BMI-­‐1,	  MLL-­‐AF9,	  HDAC9,	  CBX1,	  CBX6,	  CBX7,	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Figure	  3.8.	  CBX5	  overexpression	  may	  reduce	  HSCs	  in	  the	  AGM.	  	  (A-­D)	  From	  one	  founder,	  CBX5	  overexpression	  in	  the	  HSC	  compartment	  resulted	  in	  a	  reduction	  of	  HSCs,	  as	  shown	  by	  runx1/c-­myb	  staining	  at	  36	  hpf	  over	  two	  clutches	  (clutch	  1,	  A,B;	  clutch	  2,	  C,D).	  	  Arrowheads	  indicate	  patches	  of	  expression.	  	  (E-­G)	  Even	  from	  this	  one	  founder,	  levels	  of	  CBX5	  expression	  varied	  greatly,	  as	  assessed	  by	  CBX5	  staining	  at	  22	  hpf.	  	  However,	  these	  results	  did	  not	  repeat	  with	  another	  founder.	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Figure	  3.9.	  F0	  transient	  co-­injection	  approach	  utilizing	  the	  rag2	  promoter	  
leads	  to	  co-­expression	  in	  T	  cells.	  	  (A,B)	  Co-­‐injection	  of	  linearized	  constructs	  rag2-­‐GFP	  and	  rag2-­‐mCherry	  demonstrates	  that	  by	  5	  dpf,	  both	  proteins	  are	  expressed	  in	  T	  cells	  in	  the	  thymus.	  	  (C-­E)	  In	  adulthood,	  both	  constructs	  are	  still	  expressed	  in	  T	  cells	  in	  the	  thymus.	  	  (F)	  An	  adult	  fish,	  injected	  as	  an	  embryo	  with	  rag2-­‐BMI-­‐1	  and	  rag2-­‐GFP.	  	  The	  T	  cells	  look	  normal	  by	  fluorescent	  visualization.	  	  (G-­J)	  In	  situ	  hybridization	  of	  the	  fish	  shown	  in	  (F)	  for	  BMI-­‐1,	  which	  is	  expressed	  in	  the	  GFP-­‐positive	  but	  not	  GFP-­‐negative	  section.	  	  This	  shows	  that	  GFP-­‐positive	  cells	  do	  in	  fact	  express	  the	  factor	  co-­‐injected	  with	  GFP.	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SUV39H1,	  WHSC1L1/NSD3,	  WHSC1/NSD2,	  CBX5,	  CBX3,	  CBX8,	  HRX/MLLT11,	  MLL5,	  EZH2,	  PRDM1,	  CHD2,	  CDYL1,	  CDYL2,	  and	  SUV39H2.	  	  A	  subset	  of	  these	  was	  also	  injected	  into	  p53-­‐/-­‐	  fish	  as	  well	  as	  wild-­‐type.	  	  At	  5	  dpf,	  the	  injected	  embryos	  were	  examined	  for	  presence	  of	  the	  GFP	  in	  the	  thymus,	  and	  those	  with	  GFP-­‐positive	  cells	  in	  the	  thymic	  region	  were	  grown	  to	  adulthood.	  	  To	  prove	  that	  the	  presence	  of	  GFP	  also	  meant	  the	  presence	  of	  the	  co-­‐injected	  chromatin	  factor,	  we	  first	  injected	  rag2-­mCherry	  with	  rag2-­‐GFP	  and	  showed	  that	  both	  colors	  were	  present	  (Figures	  3.9.A-­‐E).	  	  We	  also	  performed	  ISH	  staining	  for	  BMI-­‐1	  on	  adults	  co-­‐injected	  with	  rag2-­BMI-­‐1	  and	  rag2-­GFP	  that	  had	  GFP-­‐positive	  thymi.	  	  BMI-­‐1	  mRNA	  was	  detected	  in	  the	  thymi	  of	  fish	  with	  GFP-­‐positive	  thymi	  but	  not	  in	  those	  that	  were	  negative	  (Figure	  3.9.F-­‐J).	  When	  the	  F0	  fish	  reached	  adulthood,	  they	  were	  screened	  for	  fluorescence	  once	  every	  3-­‐4	  weeks	  for	  a	  lymphocyte	  expansion	  or	  a	  putative	  tumor.	  	  The	  positive	  control	  for	  this	  assay	  was	  mMyc	  [173].	  	  When	  co-­‐injected	  with	  rag2-­‐GFP,	  the	  GFP-­‐positive	  T	  cells	  invade	  the	  entire	  fish	  by	  just	  a	  few	  weeks	  of	  life,	  causing	  T-­‐ALL	  (Figure	  3.10).	  	  Based	  on	  this,	  our	  hypothesis	  was	  that	  some	  chromatin-­‐modifying	  factors	  might	  also	  lead	  to	  a	  lymphocyte	  expansion	  or	  even	  outright	  tumor	  development.	  	  The	  factors	  most	  likely	  were	  BMI-­‐1	  and	  the	  oncogenic	  fusion	  protein	  MLL-­‐AF9.	  The	  F0	  transient	  screen	  has	  several	  underlying	  issues.	  	  The	  largest	  one	  was	  simply	  obtaining	  a	  useful	  number	  of	  fish.	  	  Only	  about	  5%	  of	  injected	  embryos	  would	  have	  GFP-­‐positive	  T	  cells,	  which	  is	  reasonable	  in	  transience	  for	  a	  subset	  of	  the	  blood	  compartment,	  already	  such	  a	  small	  percentage	  of	  the	  embryo	  at	  60/8000,	  or	  0.75%,	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Figure	  3.10.	  Proof	  of	  principle	  experiment	  with	  mMyc.	  	  (A)	  Embryos	  injected	  with	  rag2-­‐mMyc	  and	  rag2-­‐GFP	  express	  GFP	  by	  5	  dpf.	  	  (B)	  Some	  zebrafish	  show	  signs	  of	  T-­‐cell	  acute	  lymphoblastic	  lymphoma	  by	  21	  dpf.	  	  (C,D)	  The	  disease	  continues	  to	  take	  over	  the	  larval	  and	  adult	  fish.	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early	  gastrula	  cells	  [370].	  	  This	  means	  that	  95%	  of	  the	  injected	  embryos	  were	  discarded	  at	  5	  dpf.	  	  Of	  the	  5%	  remaining,	  the	  vast	  majority	  of	  these	  would	  no	  longer	  have	  GFP-­‐positive	  thymi	  at	  8	  weeks	  of	  life,	  when	  they	  were	  next	  scored	  for	  fluorescence.	  	  This	  correlates	  with	  the	  fact	  that	  rag2	  is	  expressed	  in	  developing	  lymphocytes	  only,	  rather	  than	  mature	  ones.	  	  However,	  for	  the	  screen,	  it	  meant	  that	  we	  were	  usually	  scoring	  less	  than	  five	  fish	  from	  the	  initial	  injection	  of	  five	  hundred	  embryos,	  which	  were	  often	  all	  non-­‐fluorescent,	  in	  hopes	  that	  they	  developed	  an	  expansion	  of	  developing	  lymphocytes	  due	  to	  the	  chromatin	  factor’s	  presence.	  	  Such	  a	  low	  number	  of	  GFP-­‐positive	  fish,	  even	  as	  embryos,	  really	  takes	  away	  the	  advantage	  of	  numbers	  that	  zebrafish	  offers.	  	  The	  other	  major	  issue	  with	  this	  screen	  was	  that	  it	  was	  more	  of	  an	  oncogenesis	  screen	  than	  self-­‐renewal	  screen.	  	  We	  were	  screening	  for	  an	  expansion	  of	  cells,	  but	  what	  we	  were	  really	  looking	  for	  was	  cancer.	  	  This	  was	  too	  much	  to	  ask	  of	  a	  chromatin	  factor	  on	  its	  own	  to	  do;	  even	  injections	  of	  BMI-­‐1	  and	  MLL-­‐AF9,	  with	  known	  oncogenic	  roles,	  were	  unable	  to	  result	  in	  a	  phenotype.	  
F1	  Transgenic	  Screen	  in	  Lymphoid	  Cells	  Based	  on	  the	  above	  conclusions	  on	  the	  F0	  lymphoid	  screen,	  we	  moved	  to	  an	  F1	  transgenic	  approach,	  paralleled	  to	  the	  HSC	  F1	  screen	  described	  above.	  	  It	  was	  based	  on	  the	  same	  transgenic	  technology,	  utilizing	  the	  395	  Tol2kit	  vector.	  	  This	  time,	  rather	  than	  the	  lmo2	  promoter,	  we	  used	  the	  rag2	  promoter	  to	  drive	  expression	  of	  the	  desired	  chromatin	  factors	  in	  the	  lymphoid	  progenitor	  and	  developing	  T	  cells	  of	  the	  fish	  embryo	  (Figure	  3.11.A).	  	  Twenty-­‐five	  factors	  were	  subcloned	  into	  the	  395	  vector	  and	  subsequently	  injected	  into	  rag2-­‐dsRed	  stable	  line	  along	  with	  transposase	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Figure	  3.11.	  T	  cell	  F1	  screen	  strategy	  and	  proof	  of	  principle.	  	  (A)	  A	  Tol2-­‐based	  vector,	  containing	  the	  transgenesis	  marker	  cmlc2-­‐GFP	  with	  rag2	  driving	  the	  chromatin	  factor	  of	  interest,	  was	  co-­‐injected	  with	  transposase	  mRNA	  into	  Rag2-­‐dsRed	  embryos.	  	  These	  F0	  fish	  were	  grown	  up	  to	  adulthood,	  incrossed,	  and	  the	  subsequent	  F1	  embryos	  were	  scored	  for	  GFP-­‐positive	  hearts.	  	  Those	  with	  GFP-­‐positive	  hearts	  were	  grown	  up	  and	  examined	  for	  effects	  on	  the	  dsRed-­‐positive	  T	  cells.	  	  (B-­E)	  This	  was	  first	  tested	  as	  a	  proof	  of	  principle	  with	  mCherry	  as	  the	  factor	  of	  interest	  (injected	  into	  wild-­‐type	  embryos),	  to	  show	  that	  GFP-­‐positive	  hearts	  did	  correlate	  with	  T	  cell	  expression	  of	  the	  mCherry	  at	  6	  dpf	  (B,C)	  and	  23	  dpf	  (D,E).	  	  (F,G)	  The	  second	  proof	  of	  principle	  put	  mMyc	  in	  as	  the	  injected	  factor,	  and	  the	  F1	  fish	  with	  GFP-­‐positive	  hearts	  did	  indeed	  contract	  T-­‐ALL	  by	  28	  dpf.	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mRNA.	  	  These	  fish	  have	  red	  thymi,	  thus	  enabling	  the	  tracking	  of	  the	  thymus	  in	  the	  event	  of	  a	  lymphocytic	  expansion.	  	  GFP-­‐positive	  embryos	  were	  analyzed	  at	  7	  dpf	  for	  impacts	  on	  the	  red	  thymi	  and	  were	  examined	  into	  adulthood	  for	  the	  development	  of	  a	  lymphoproliferative	  disease	  or	  cancer	  as	  noted	  by	  the	  fluorescent	  thymi	  (Figure	  3.11.A).	  The	  Tol2-­‐F1	  system	  was	  tested	  for	  proof	  of	  principle	  during	  the	  vector	  development	  stage.	  	  The	  first	  vector	  injected	  was	  cmlc2-­GFP;	  rag2-­‐mCherry	  into	  wild-­‐type	  fish	  as	  a	  proof	  of	  principle.	  	  An	  F0	  incross	  of	  fish	  injected	  with	  this	  vector	  yielded	  26	  GFP-­‐positive	  embryos.	  	  Normally,	  T	  cells	  tagged	  with	  a	  fluorescent	  protein	  from	  the	  rag2	  promoter	  can	  be	  visualized	  beginning	  at	  4	  dpf;	  however,	  when	  these	  GFP-­‐positive	  fish	  were	  examined	  at	  6	  dpf,	  no	  red	  fluorescence	  was	  seen.	  	  We	  looked	  at	  these	  same	  F1	  fish	  again	  when	  they	  were	  20	  to	  30	  dpf,	  and	  about	  fifty	  percent	  of	  the	  larvae	  had	  mCherry-­‐positive	  thymi.	  By	  the	  time	  the	  fish	  were	  about	  6	  weeks	  old,	  24/26	  of	  the	  F1	  clutch	  had	  red	  thymi	  (Figure	  3.11.B-­‐E).	  	  Several	  other	  clutches	  followed	  suit,	  all	  with	  near	  100%	  correlation	  between	  GFP	  and	  mCherry	  expression.	  	  It	  was	  assumed	  that	  mCherry	  was	  too	  dim	  to	  visualize	  in	  such	  a	  small	  number	  of	  cells	  in	  the	  6	  dpf	  embryo,	  and	  that	  the	  cmlc2-­‐GFP	  transgenesis	  marker	  would	  be	  a	  successful	  informant	  of	  the	  embryos	  carrying	  the	  rag2-­chromatin-­‐modifying	  factor.	  The	  second	  proof	  of	  principle	  experiment	  that	  was	  completed	  was	  to	  inject	  the	  395	  vector	  carrying	  cmlc2-­‐GFP;	  rag2-­‐mMyc,	  a	  positive	  control	  known	  to	  induce	  T	  cell	  lymphomas	  commencing	  by	  21	  dpf	  in	  F0	  fish,	  into	  the	  rag2-­‐dsRed	  stable	  line.	  	  When	  these	  injected	  F0s	  were	  first	  incrossed,	  a	  clutch	  containing	  five	  GFP-­‐positive	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embryos	  was	  grown	  up.	  	  At	  28	  dpf,	  three	  of	  the	  five	  larvae	  had	  developed	  myc-­‐induced	  lymphoma	  (Figure	  3.11.F-­‐G).	  	  Combined	  with	  the	  aforementioned	  mCherry	  experiments,	  it	  seemed	  that	  the	  vector	  development	  was	  successful	  and	  the	  screen	  of	  chromatin-­‐modifying	  factors	  could	  commence.	  Injections	  into	  the	  rag2-­‐dsRed	  stable	  line	  with	  twenty-­‐seven	  different	  chromatin	  factors	  commenced.	  	  The	  following	  factors	  were	  injected:	  HMGA1,	  CBX1,	  ING3,	  ING4,	  MBD3,	  BMI-­‐1,	  C20orf20,	  CBX5,	  HDAC9,	  HDAC8,	  SMARCD1,	  ING5,	  TNFAIP6,	  TERF1,	  BRD7,	  CBX8,	  ARID3A,	  ARID3B,	  SMARCD3,	  SMARCAL1,	  SMARCAD1,	  MBD1,	  SATB2,	  MLLT11,	  MLLT3,	  HDAC11,	  and	  CBX7.	  	  This	  list	  of	  factors	  were	  selected	  because	  either	  their	  expression	  is	  up	  or	  down	  in	  lmo2-­‐positive	  and	  cd41-­‐positive	  cells	  (A.	  DiBiase,	  personal	  communication)	  or	  they	  are	  members	  of	  the	  SWI/SNF	  complex,	  known	  to	  play	  a	  regulatory	  role	  in	  T	  lymphocyte	  development	  [371].	  	  F0	  injections	  were	  completed,	  and	  F1	  embryos	  were	  screened	  for	  GFP-­‐positive	  hearts.	  	  These	  F1	  fish	  were	  examined	  into	  adulthood.	  	  None	  ever	  displayed	  any	  interesting	  phenotypes	  of	  lymphoproliferation	  or	  lymphoid	  tumors	  (Figure	  3.12).	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Figure	  3.12.	  Representative	  factors	  screened	  in	  the	  F1	  assay	  for	  T	  cells.	  	  Representative	  F1	  adults	  for	  BMI-­‐1	  (A,B,	  72	  dpf),	  MLL-­‐AF9	  (C,D,	  72	  dpf),	  CBX1	  (E,F,	  44	  dpf),	  and	  SATB2	  (G,H,	  51	  dpf)	  that	  had	  GFP-­‐positive	  hearts	  and	  were	  therefore	  expressing	  the	  factor	  of	  interest	  in	  T	  cells.	  	  However,	  all	  of	  these	  had	  no	  abnormal	  phenotype	  in	  their	  dsRed-­‐positive	  T	  cells.	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Discussion	  	   In	  this	  chapter,	  we	  describe	  the	  development	  of	  a	  novel	  F1	  transgenic	  screening	  approach	  that	  was	  used	  as	  a	  method	  of	  overexpression	  screening.	  	  The	  goal	  was	  to	  develop	  an	  in	  vivo	  assay	  that	  could	  act	  as	  a	  surrogate	  for	  transplantations	  as	  a	  self-­‐renewal	  assay.	  	  When	  this	  approach	  was	  not	  possible	  technically	  due	  to	  cosegregation	  of	  plasmids,	  we	  turned	  to	  F0	  transgenics;	  lastly,	  to	  overcome	  expression	  issues	  with	  F0	  transgenics,	  we	  developed	  an	  F1	  system.	  	  This	  approach	  capitalizes	  on	  the	  ease	  of	  generating	  F1	  transgenics	  in	  zebrafish,	  particularly	  in	  a	  tissue	  like	  the	  blood	  that	  consists	  of	  relatively	  few	  cells.	  	  We	  used	  it	  in	  the	  context	  of	  both	  HSCs	  and	  lymphoid	  progenitors.	  	   The	  only	  strong	  modifier	  detected	  by	  the	  F1	  HSC	  screen	  initially	  was	  CBX5,	  which	  decreased	  the	  number	  of	  runx1/c-­myb	  positive	  cells.	  	  This	  HSC	  phenotype	  did	  not	  consistently	  repeat	  with	  CBX5	  overexpression	  from	  new	  founder	  fish	  yet	  still	  remains	  an	  interesting	  putative	  hit.	  	  CBX5,	  or	  HP1alpha,	  is	  an	  epigenetic	  repressor	  of	  the	  heterochromatin	  protein	  family.	  	  It	  is	  enriched	  in	  heterochromatin	  and	  associated	  with	  centromeres.	  	  CBX5	  has	  an	  N	  terminal	  chromo	  domain,	  so	  it	  binds	  methylated	  lysines	  on	  histones,	  likely	  responsible	  for	  its	  transcriptional	  repressive	  properties.	  	  It	  also	  has	  a	  C	  terminal	  chromoshadow	  domain	  that	  allows	  it	  to	  homodimerize	  and	  interacts	  with	  other	  proteins;	  key	  interactions	  with	  essential	  kinetochore	  proteins	  suggest	  how	  CBX5	  has	  a	  role	  in	  the	  formation	  of	  functional	  kinetochores.	  	  As	  a	  strong	  repressor	  associated	  with	  heterochromatin,	  it	  seems	  logical	  that	  overexpression	  of	  CBX5	  could	  repress	  either	  runx1/c-­myb	  directly	  or	  indirectly.	  	  Expression	  of	  CBX5	  turns	  on	  gradually	  through	  early	  development,	  likely	  
123	  	  	  	  
keeping	  heterochromatin	  sustained	  throughout	  cell	  fate	  decisions;	  it	  is	  also	  highly	  expressed	  in	  embryonic	  stem	  cells.	  	  It	  has	  been	  suggested	  that	  CBX5	  acts	  as	  a	  marker	  of	  cell	  type	  commitment,	  increasing	  the	  heterochromatin	  in	  cells	  once	  they	  have	  reached	  their	  appropriate	  fate	  so	  that	  the	  differentiation	  genes	  are	  repressed	  [372].	  	  By	  overexpressing	  CBX5	  in	  stem	  and	  progenitor	  cells,	  we	  may	  have	  disrupted	  the	  cell	  fate	  balance,	  leading	  to	  fewer	  HSCs.	  	  However,	  CBX5	  is	  also	  known	  to	  play	  a	  critical	  role	  in	  the	  maintenance	  of	  leukemic	  stem	  cells	  (LSCs),	  part	  of	  an	  embryonic	  stem	  cell-­‐like	  set	  of	  genes	  that	  maintain	  self-­‐renewal.	  	  Along	  with	  Myb	  and	  Hmgb3,	  Cbx5	  overexpression	  induces	  bone	  marrow	  stem	  and	  progenitor	  cell	  immortalization	  without	  requiring	  overexpression	  of	  the	  Hoxa/Meis	  pathway	  [369].	  	  Though	  this	  study	  showed	  that	  overexpression	  led	  to	  self-­‐renewal	  rather	  than	  the	  decrease	  we	  observed	  in	  HSC	  numbers	  in	  the	  zebrafish	  embryo,	  it	  suggests	  that	  CBX5	  does	  play	  a	  role	  in	  self-­‐renewal	  that	  our	  screen	  may	  have	  found.	  	   This	  F1	  transgenic	  overexpression	  screening	  approach	  has	  several	  applications.	  	  In	  this	  chapter,	  we	  showed	  how	  it	  could	  be	  used	  for	  overexpression	  screening	  of	  factors	  in	  a	  tissue	  that	  was	  difficult	  to	  inject	  into	  as	  an	  F0.	  	  This	  could	  be	  applied	  to	  other	  difficult	  to	  reach	  tissues,	  such	  as	  connective	  tissues,	  neural	  crest,	  or	  germ	  cells.	  	  Having	  this	  as	  a	  tool	  to	  stably	  overexpress	  a	  gene	  of	  interest	  in	  a	  cell	  autonomous	  manner	  would	  permit	  interesting	  hypothesis-­‐driven	  studies.	  	  This	  could	  be	  done	  as	  an	  alternative	  to	  transplants	  as	  the	  only	  cell	  autonomy	  assay.	  	  Knockdown	  studies	  are	  often	  complemented	  by	  overexpression	  studies,	  and	  this	  is	  a	  straightforward	  system	  to	  overexpress	  a	  factor	  in	  vivo.	  	  This	  system	  could	  also	  be	  used	  to	  study	  toxic	  factors,	  like	  dominant	  negatives,	  whose	  ubiquitous	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overexpression	  in	  an	  F0	  embryo	  would	  be	  lethal.	  	  However,	  getting	  the	  transgene	  in	  the	  germline	  of	  the	  F0	  would	  not	  necessarily	  be	  lethal,	  thus	  permitting	  study	  in	  the	  F1	  generation.	  	  Similarly,	  this	  could	  also	  be	  performed	  in	  lethal	  mutants,	  if	  the	  transgene	  was	  injected	  into	  heterozygotes,	  as	  a	  method	  to	  rescue	  the	  mutants	  and	  allow	  study	  at	  an	  age	  when	  the	  embryos	  would	  normally	  not	  be	  alive	  anymore.	  	  This	  could	  replace	  the	  main	  rescue	  technique	  of	  mRNA	  injections,	  whose	  rescue	  is	  only	  transient	  due	  to	  mRNA	  instability	  and	  not	  cell	  intrinsic.	  	  As	  we	  were	  finishing	  up	  this	  project,	  a	  paper	  demonstrating	  this	  was	  published;	  they	  rescued	  the	  vlad	  tepes	  mutant	  (gata1)	  using	  a	  Tol2	  transposon	  system	  [373].	  	  However,	  they	  also	  only	  used	  transient	  transgenics,	  and	  it’s	  likely	  their	  results	  would	  have	  been	  more	  consistent	  using	  embryos	  from	  the	  next	  generation.	  	   Having	  these	  stable	  lines	  developed	  has	  already	  proved	  useful.	  	  Fluorescence-­‐activated	  cell	  sorting	  was	  performed	  on	  the	  kidney	  marrows	  of	  adult	  F1	  fish	  for	  about	  ten	  of	  the	  chromatin	  factors	  (H.	  Huang,	  personal	  communication).	  	  One,	  HMGA1,	  had	  an	  interesting	  phenotype	  of	  an	  increased	  population	  of	  precursors	  cells	  in	  the	  marrow.	  	  This	  is	  consistent	  with	  a	  previous	  study	  that	  found	  that	  knocking	  down	  HMGA1	  in	  embryonic	  stem	  cells	  resulted	  in	  a	  decrease	  in	  T	  cell	  precursors.	  	  Loss	  of	  HMGA1	  also	  altered	  the	  differentiation	  of	  precursors,	  with	  a	  reduction	  in	  monocytes	  and	  macrophages	  and	  an	  increase	  in	  megakaryocyte	  precursors	  and	  erythrocytes	  [374].	  	  Another	  study	  additionally	  revealed	  that	  expression	  of	  HMGA1	  in	  lymphoid	  cells	  undergoing	  tumorigenesis	  led	  to	  expression	  of	  hematopoietic	  pathways;	  HMGA1-­‐expressing	  tumor	  cells	  were	  also	  enriched	  for	  stem	  cell	  genes	  [375].	  	  These	  results	  suggest	  that	  HMGA1	  may	  play	  a	  role	  in	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maintaining	  HSCs	  or	  hematopoietic	  precursors	  that	  may	  have	  been	  detectable	  using	  the	  F1	  transgenic	  fish	  created	  here.	  	   In	  conclusion,	  we	  developed	  a	  F1	  transgenic	  screening	  system	  that	  successfully	  expressed	  the	  factors	  of	  interest	  in	  the	  tissue	  of	  interest.	  	  This	  will	  have	  future	  applications	  as	  we	  targeted	  the	  hematopoietic	  system,	  a	  highly	  studied	  system	  that	  makes	  up	  a	  small	  proportion	  of	  the	  developing	  embryo.	  	  Being	  able	  to	  simply	  target	  this	  tissue	  that	  can	  be	  difficult	  to	  access	  by	  transient	  microinjection	  will	  be	  useful	  for	  further	  study.	  	  Though	  we	  were	  unable	  to	  use	  it	  along	  with	  in	  situ	  hybridizations	  to	  identify	  chromatin	  modifying-­‐factors	  that	  strongly	  impacted	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   The	  cellular	  chromatin	  state	  contributes	  to	  the	  critical	  regulation	  of	  processes	  such	  as	  transcription,	  DNA	  repair,	  and	  DNA	  replication.	  	  When	  the	  epigenetic	  state	  is	  altered,	  these	  functions	  can	  be	  deregulated	  and,	  in	  extreme	  cases,	  lead	  to	  tumorigenesis.	  	  The	  studies	  in	  this	  dissertation	  utilized	  the	  zebrafish	  as	  a	  screening	  tool	  for	  a	  set	  of	  chromatin-­‐modifying	  factors	  in	  both	  cancer	  and	  hematopoiesis.	  	  Using	  a	  rhabdomyosarcoma	  (RMS)	  model,	  the	  H3K9	  histone	  methyltransferase	  (HMT)	  SUV39H1	  was	  found	  to	  be	  a	  suppressor	  of	  tumor	  initiation.	  	  This	  effect	  appears	  to	  act	  through	  a	  cell	  cycle	  or	  growth	  arrest	  pathway	  rather	  than	  the	  muscle	  differentiation	  program.	  	  This	  dissertation	  also	  describes	  the	  development	  of	  a	  F1	  transgenic	  screening	  approach	  to	  uncover	  novel	  roles	  of	  chromatin	  factors	  in	  hematopoietic	  development.	  	  These	  studies	  have	  contributed	  to	  the	  current	  knowledge	  about	  the	  interplay	  of	  chromatin	  and	  cancer	  as	  well	  as	  zebrafish	  screening	  technology.	  
	  
Zebrafish	  Assay	  Development	  
Cancer	  Initiation	  Assay	  	   To	  perform	  a	  screen	  for	  the	  involvement	  of	  chromatin	  factors	  in	  RMS	  formation,	  a	  triple	  co-­‐injection	  strategy	  was	  used	  to	  minimize	  variability.	  	  This	  screen	  took	  advantage	  of	  the	  ease	  of	  creating	  transient	  transgenics	  in	  the	  zebrafish.	  	  This	  system	  is	  particularly	  unusual	  since	  we	  drive	  expression	  of	  hKRASG12D	  using	  a	  large	  exogenous	  fragment	  containing	  the	  rag2	  promoter,	  which	  has	  been	  shown	  to	  express	  in	  muscle	  satellite	  cells	  even	  though	  the	  endogenous	  rag2	  promoter	  is	  not	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expressed	  in	  these	  cells	  [155].	  	  Being	  able	  to	  knock-­‐in	  oncogenic	  KRAS	  into	  its	  own	  locus	  would	  resolve	  this	  issue	  and	  represent	  a	  system	  more	  like	  human	  cancer,	  but	  unfortunately	  that	  technology	  does	  not	  exist	  in	  the	  zebrafish.	  	  In	  the	  mouse,	  knock-­‐in	  technology	  has	  permitted	  the	  development	  of	  an	  ARMS	  mouse	  expressing	  a	  Pax3-­‐FKHR	  translocation	  conditionally	  from	  the	  Pax3	  locus	  and	  an	  RMS	  mouse	  expressing	  KRASG12V	  from	  the	  endogenous	  KRAS	  locus	  [376,	  377].	  	   In	  this	  dissertation	  we	  transitioned	  from	  making	  longer	  tumor	  curves	  to	  50	  dpf	  based	  on	  visual	  tumor	  formation	  to	  using	  a	  larval	  tumor	  curve	  monitored	  by	  fluorescence	  to	  20	  dpf.	  	  Our	  previous	  method	  of	  scoring	  until	  50	  dpf	  limited	  how	  many	  factors	  could	  be	  screened.	  	  In	  contrast,	  by	  shortening	  the	  screening	  process	  from	  50	  to	  20	  dpf,	  we	  have	  established	  a	  larval	  tumor	  development	  assay	  based	  on	  initial	  RMS	  tumor	  development	  that	  will	  prove	  useful	  for	  future	  cancer	  drug	  discovery.	  	  Rather	  than	  trying	  to	  treat	  adult	  fish	  with	  tumors,	  RMS	  screening	  could	  be	  completed	  in	  the	  larval	  stages,	  enabling	  a	  larger	  cohort	  of	  fish	  to	  be	  screened	  at	  one	  time.	  	  In	  fact,	  a	  small-­‐scale	  assay	  on	  a	  few	  chemicals	  looking	  for	  effects	  on	  tumor	  growth	  was	  performed	  as	  a	  secondary	  screen	  and	  demonstrated	  that	  two	  chemicals	  suppressed	  growth	  (X.	  Le,	  personal	  communication).	  	  A	  method	  to	  expand	  this	  to	  a	  large-­‐scale	  screen	  will	  be	  discussed	  further	  below.	  
In	  vivo	  HSC	  competition	  assay	  for	  defining	  the	  role	  of	  chromatin	  factors	  	   The	  first	  concept	  to	  screen	  chromatin-­‐modifying	  factors	  in	  the	  blood	  system	  was	  to	  develop	  an	  in	  vivo	  HSC	  competition	  assay.	  	  This	  was	  technically	  unfeasible	  because	  injected	  plasmids	  always	  co-­‐segregated,	  whether	  using	  linearized	  plasmids	  or	  the	  Tol2	  transposon	  system.	  	  This	  would	  not	  allow	  for	  plasmids	  injected	  together	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to	  integrate	  in	  separate	  HSCs	  and	  thus	  to	  be	  able	  to	  read	  out	  different	  HSCs	  in	  vivo	  (Figure	  3.1).	  	  It	  was	  already	  known	  that	  plasmids	  injected	  together	  co-­‐segregated	  in	  tumors	  [246];	  however,	  it	  was	  not	  necessarily	  known	  in	  regular	  tissues.	  	  We	  opted	  to	  move	  on	  to	  a	  different	  strategy	  rather	  than	  develop	  a	  method	  to	  get	  plasmids	  to	  undergo	  independent	  segregation.	  	  This	  may	  have	  been	  possible	  using	  another	  transposon	  system,	  such	  as	  the	  Tdr2	  [378].	  	  It	  also	  may	  have	  been	  feasible	  by	  injecting	  one	  HSC	  factor	  with	  one	  RBC	  color	  into	  one	  cell	  of	  a	  two-­‐cell	  stage	  embryo	  and	  injecting	  the	  control	  factor	  and	  other	  RBC	  color	  into	  the	  other	  cell.	  	  Some	  studies	  have	  previously	  been	  successful	  with	  this	  technique,	  obtaining	  a	  fish	  embryo	  with	  different	  phenotypes	  on	  the	  different	  lateral	  sides	  of	  the	  fish	  [379].	  	  However,	  the	  assay	  would	  be	  tedious	  to	  perform,	  and	  the	  transient	  injections	  would	  likely	  prove	  difficult	  to	  hit	  HSCs	  in	  both	  halves	  of	  the	  fish.	  	  To	  do	  this	  as	  a	  screen	  with	  enough	  doubly	  fluorescent	  injected	  fish	  would	  have	  been	  challenging.	  
F0	  Transgenic	  Approaches	  	   Generating	  transient	  F0	  transgenics	  in	  the	  blood	  is	  a	  process	  severely	  limited	  by	  numbers;	  even	  the	  best	  micro-­‐injection	  technique	  will	  only	  deliver	  transgene	  to	  the	  developing	  blood	  cells	  a	  low	  percentage	  of	  the	  time,	  as	  only	  60	  out	  of	  the	  8000	  early	  gastrula	  cells,	  or	  0.75%,	  are	  fated	  to	  become	  blood	  [370].	  	  Transient	  transgenics	  also	  often	  contain	  inconsistent	  expression	  levels	  of	  the	  gene	  of	  interest	  from	  fish	  to	  fish,	  since	  each	  individual	  fish	  is	  a	  unique	  injection	  and	  likely	  has	  integrated	  the	  transgene	  in	  a	  different	  genomic	  location.	  	  Examining	  the	  F1	  generation	  instead	  solved	  these	  issues.	  	  The	  transgene	  must	  integrate	  into	  the	  germline	  rather	  than	  the	  tissue	  of	  choice,	  which	  for	  the	  hematopoietic	  system	  was	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an	  easier	  task.	  	  Even	  with	  only	  a	  few	  founders,	  this	  system	  is	  preferable	  as	  fish	  can	  be	  mated	  weekly	  to	  produce	  more	  F1	  offspring.	  	  In	  transient	  fish,	  if	  only	  5%	  of	  the	  F0	  clutch	  has	  hematopoietic	  expression,	  then	  those	  are	  the	  only	  embryos	  available	  for	  analysis	  until	  the	  next	  round	  of	  injections.	  	  Also,	  taking	  multiple	  clutches	  from	  the	  same	  founder	  is	  preferable	  because	  they	  will	  all	  have	  the	  transgene	  integrated	  in	  the	  same	  place	  and,	  therefore,	  have	  similar	  expression	  levels.	  	  Driven	  behind	  the	  promoter	  of	  choice,	  the	  desired	  factor	  is	  expressed	  cell	  intrinsically,	  whereas	  F0	  transient	  injections	  more	  often	  contain	  ectopic	  expression	  in	  larger	  tissues	  such	  as	  the	  musculature	  or	  nervous	  system.	  	  The	  main	  downside	  to	  the	  F1	  strategy	  is	  the	  generation	  lag	  time,	  having	  to	  wait	  until	  the	  F0	  potential	  founders	  are	  sexually	  mature.	  	  In	  zebrafish,	  this	  can	  be	  as	  low	  as	  45	  days	  of	  life,	  shorter	  than	  many	  species,	  and	  is	  worth	  waiting	  for	  a	  better	  experiment.	  	  It	  is	  still	  shorter	  than	  making	  full	  stable	  lines,	  yet	  if	  a	  factor	  is	  found	  that	  requires	  a	  stable	  line,	  a	  benefit	  is	  that	  founders	  have	  already	  been	  identified,	  thus	  saving	  a	  step.	  
F1	  Transgenic	  Approaches	  	   The	  F1	  transgenic	  screen	  performed	  in	  T	  cells	  analyzed	  twenty-­‐seven	  different	  chromatin	  factors;	  none	  resulted	  in	  the	  T	  cell	  expansion	  phenotype	  we	  hypothesized	  would	  occur.	  	  There	  are	  several	  possible	  reasons	  for	  this	  outcome.	  	  First,	  we	  may	  not	  have	  screened	  enough	  or	  the	  best	  candidate	  genes.	  	  We	  chose	  to	  screen	  from	  a	  list	  of	  genes	  that	  were	  up-­‐	  or	  down-­‐regulated	  in	  hematopoietic	  progenitor	  cells.	  	  However,	  we	  were	  screening	  for	  a	  lymphoid	  phenotype,	  and	  this	  set	  of	  genes	  may	  not	  have	  been	  particularly	  critical	  to	  lymphoid	  development.	  	  The	  other	  screened	  genes	  are	  from	  the	  SWI/SNF	  complex,	  which	  is	  known	  to	  play	  a	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regulatory	  role	  in	  T	  cell	  development	  [371].	  	  We	  may	  not	  have	  been	  expressing	  these	  genes	  at	  the	  right	  stage	  of	  development	  to	  see	  a	  phenotype.	  	  Second,	  this	  screen	  may	  have	  served	  well	  as	  a	  modifier	  screen	  instead.	  	  We	  simply	  injected	  these	  chromatin	  factors	  and	  then	  screened	  for	  a	  cancer-­‐like	  phenotype.	  	  Without	  co-­‐injecting	  an	  oncogene,	  injecting	  into	  p53-­‐/-­‐	  fish,	  or	  exposing	  the	  fish	  to	  another	  cancer-­‐inducing	  agent,	  the	  fish	  were	  very	  unlikely	  to	  spontaneously	  develop	  tumors	  from	  the	  overexpression	  of	  a	  single	  chromatin	  factor.	  	  It	  is	  reasonable	  to	  think	  that	  in	  the	  proper	  background,	  with	  overexpression	  of	  an	  oncogene	  or	  loss	  of	  a	  tumor	  suppressor,	  overexpression	  of	  one	  of	  these	  chromatin	  factors	  could	  have	  provided	  the	  additional	  hit	  needed	  to	  induce	  T	  cell	  expansion	  or	  generate	  an	  accelerated	  (or	  suppressed)	  tumor	  curve.	  	  This	  likely	  would	  not	  have	  addressed	  our	  interest	  in	  self-­‐renewal	  but	  would	  have	  been	  an	  interesting	  tumorigenesis	  model	  to	  study.	  	  Third,	  T	  cells	  have	  such	  a	  rigorous	  selection	  process	  that	  any	  T	  cells	  with	  aberrant	  chromatin	  factor	  expression	  may	  have	  been	  selected	  against.	  	  We	  know	  by	  ISH	  that	  the	  injected	  factor	  was	  present	  in	  the	  thymus	  (Figure	  3.9.G-­‐J),	  but	  that	  does	  not	  guarantee	  that	  these	  cells	  made	  protein	  and	  survived	  long	  enough	  to	  disrupt	  thymic	  homeostasis.	  	   The	  F1	  transgenic	  screen	  performed	  in	  hematopoietic	  progenitor	  cells	  also	  did	  not	  yield	  any	  reproducible	  phenotypes	  from	  the	  thirty	  factors	  that	  were	  fully	  screened.	  	  Similarly,	  this	  list	  was	  enhanced	  for	  factors	  whose	  expression	  was	  up-­‐	  or	  down-­‐regulated	  in	  progenitor	  cells	  as	  well	  as	  chromatin	  factors	  that	  produced	  a	  hematopoietic	  phenotype	  upon	  knockdown	  in	  the	  embryo	  (H.	  Huang	  and	  K.	  Kathrein,	  personal	  communication).	  	  It	  was	  unexpected	  that	  none	  of	  these	  anticipated	  genes	  seemed	  to	  have	  an	  effect	  on	  either	  globin	  or	  runx1/c-­myb	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expression.	  	  We	  did	  see	  a	  wide	  variety	  of	  expression	  levels	  when	  performing	  expression	  analysis	  of	  the	  injected	  chromatin	  factor	  by	  ISH.	  	  Some	  factors	  seemed	  to	  express	  very	  strongly	  and	  others	  very	  weakly	  (Figure	  3.7).	  	  Part	  of	  this	  could	  be	  due	  to	  ISH	  and	  probe	  variability;	  each	  probe	  was	  made	  from	  the	  open	  reading	  frame	  for	  each	  gene,	  so	  it	  is	  likely	  that	  some	  just	  worked	  better	  than	  others,	  depending	  on	  size	  and	  nucleotide	  sequence.	  	  Some	  factors	  may	  have	  expressed	  better	  due	  to	  genomic	  location	  of	  integration	  or	  interaction	  with	  other	  genes.	  	  Outcrossing	  the	  founders	  rather	  than	  incrosses	  helped	  increase	  the	  expression	  level	  variability,	  suggesting	  that	  differing	  integration	  locations	  between	  different	  fish	  caused	  some	  of	  the	  issues.	  	   A	  stronger	  promoter	  may	  have	  been	  necessary	  to	  provide	  more	  consistently	  robust	  expression	  levels.	  	  In	  fact,	  another	  project	  in	  the	  lab	  took	  this	  advice,	  using	  the	  draculin	  promoter	  for	  a	  hematopoietic	  overexpression	  screen	  (J.	  Ganis,	  personal	  communication).	  	  The	  draculin	  promoter	  drives	  strongly	  in	  all	  blood	  lineages	  from	  early	  in	  development,	  and	  genes	  involved	  in	  globin	  switching	  were	  successfully	  screened	  using	  this	  method.	  	  Additionally,	  a	  cancer	  screen	  in	  the	  lab	  is	  looking	  at	  the	  role	  of	  chromatin-­‐modifying	  factors	  in	  melanoma,	  using	  the	  mitf	  promoter	  to	  drive	  expression	  (E.	  van	  Rooijen,	  personal	  communication).	  	  The	  mitf	  promoter	  drives	  strongly	  and	  specifically	  in	  melanocytes,	  making	  this	  an	  ideal	  choice	  for	  a	  melanoma	  screen.	  	  Higher	  overexpression	  levels	  with	  a	  stronger	  promoter	  may	  have	  yielded	  the	  phenotypes	  we	  were	  looking	  for	  in	  our	  screen.	  	  The	  screen	  may	  have	  also	  produced	  weak	  modifiers	  of	  hematopoietic	  development,	  but	  these	  went	  undetected,	  either	  due	  to	  regular	  ISH	  variability	  or	  the	  inconsistent	  factor	  expression	  levels	  behind	  a	  weaker	  promoter.	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Overexpression	  as	  a	  screening	  tool	  	   Overexpression	  in	  a	  state	  of	  normal	  development	  may	  not	  be	  the	  best	  approach	  for	  screening	  factors.	  	  Knocking	  down	  chromatin	  factors	  in	  zebrafish	  had	  produced	  many	  interesting	  phenotypes	  for	  primitive	  RBC	  development	  and	  definitive	  HSC	  development	  (H.	  Huang	  and	  K.	  Kathrein,	  personal	  communication).	  	  By	  removing	  a	  specific	  factor	  that	  is	  necessary	  for	  a	  certain	  step	  in	  development,	  this	  is	  more	  likely	  to	  produce	  a	  phenotype	  in	  the	  embryo.	  	  The	  main	  reason	  this	  would	  not	  result	  in	  a	  disruption	  of	  hematopoiesis	  is	  compensatory	  genes.	  	  However,	  with	  overexpression,	  you	  may	  need	  a	  non-­‐physiological	  level	  of	  overexpression	  to	  disrupt	  the	  balance	  of	  factors	  in	  the	  cell	  so	  much	  to	  create	  a	  phenotype.	  	  Many	  of	  these	  factors	  are	  ubiquitously	  expressed,	  so	  adding	  a	  little	  more	  would	  not	  disrupt	  the	  blood	  tissues	  dramatically.	  	  Many	  also	  act	  only	  in	  complexes,	  so	  without	  overexpressing	  their	  complex	  partners	  at	  the	  same	  time,	  the	  extra	  single	  factor	  in	  the	  cell	  would	  essentially	  be	  inactive	  despite	  its	  expression.	  	  These	  reasons	  imply	  that	  overexpression	  may	  not	  be	  the	  best	  screening	  tool	  to	  discover	  novel	  roles	  of	  known	  genes	  in	  development.	  	  Overexpressing	  screening	  in	  cancer	  seems	  to	  be	  more	  successful,	  likely	  because	  disrupted	  cells	  are	  being	  selected	  for	  during	  tumorigenesis.	  	  
Understanding	  the	  role	  of	  SUV39H1	  in	  cell	  cycle	  and	  growth	  arrest	  
Cell	  cycle	  analysis	  	   There	  are	  a	  number	  of	  tools	  available	  that	  can	  enhance	  our	  understanding	  of	  the	  dynamics	  of	  the	  SUV39H1	  suppression	  of	  RMS	  initiation.	  	  Further	  cell	  cycle	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analysis	  is	  warranted	  on	  the	  5	  and	  7	  dpf	  tumor	  forming	  larvae.	  	  We	  have	  preliminary	  data	  through	  FACS	  analysis	  that	  indicates	  the	  SUV39H1-­‐overexpressing	  larvae	  may	  have	  a	  slightly	  higher	  proportion	  of	  cells	  in	  G1	  phase,	  implicating	  a	  cell	  cycle	  arrest.	  	  Further	  analysis	  could	  be	  accomplished	  through	  the	  use	  of	  the	  FUCCI	  system,	  or	  the	  fluorescence	  ubiquitination	  cell	  cycle	  indicator	  [380].	  	  This	  system	  would	  permit	  the	  real	  time	  following	  of	  cell	  divisions	  as	  the	  tumors	  develop.	  	  It	  has	  RFP	  fused	  to	  cdt1,	  which	  is	  present	  in	  G1	  and	  ubiquitinated	  for	  destruction	  in	  S/G2/M,	  and	  GFP	  fused	  to	  geminin,	  which	  is	  ubiquitinated	  for	  destruction	  in	  G1	  but	  present	  in	  S/G2/M.	  	  Depending	  on	  whether	  the	  cells	  are	  red	  or	  green,	  their	  cell	  cycle	  stage	  can	  be	  determined;	  they	  can	  also	  appear	  as	  yellow	  during	  the	  G1-­‐S	  transition,	  as	  levels	  of	  cdt1	  are	  decreasing	  and	  geminin	  are	  rising.	  	  This	  system	  would	  ideally	  require	  the	  development	  of	  transgenic	  lines	  expressing	  the	  two	  fusion	  proteins,	  and	  then	  microinjections	  of	  the	  rag2-­‐hKRASG12D,	  rag2-­hSUV39H1/mCherry	  constructs	  could	  be	  executed	  into	  the	  stable	  fish	  lines.	  	  It	  may	  also	  be	  possible	  in	  transient	  transgenics,	  though	  this	  would	  require	  the	  microinjections	  of	  six	  constructs.	  	  Using	  FUCCI	  would	  take	  advantage	  of	  the	  transparent	  fish	  for	  fluorescent	  cell	  cycle	  imaging.	  	  Additional	  cell	  cycle	  assessment	  could	  be	  performed	  through	  markers	  such	  as	  PCNA	  or	  MCM5,	  which	  can	  also	  be	  done	  in	  the	  zebrafish	  as	  fluorescent	  transgenics	  [381].	  	   Since	  cyclin	  B1	  was	  a	  gene	  of	  interest	  observed	  as	  downregulated	  in	  the	  SUV39H1-­‐overexpressing	  7	  dpf	  larvae	  by	  microarray	  and	  was	  found	  to	  be	  bound	  by	  SUV39H1	  in	  C2C12	  cells,	  it	  may	  be	  interesting	  to	  determine	  its	  role	  in	  the	  suppression	  of	  these	  tumors.	  	  We	  could	  overexpress	  the	  cyclin	  B1	  ORF	  with	  the	  rag2	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promoter	  to	  restrict	  expression	  to	  the	  developing	  SUV39H1	  tumors.	  	  This	  would	  allow	  us	  to	  determine	  if	  reinstating	  cyclin	  B1	  expression	  would	  restore	  the	  SUV39H1	  tumor	  curves	  to	  the	  control	  state.	  	  This	  is	  likely	  to	  occur	  however,	  since	  increasing	  expression	  of	  cyclin	  B1	  would	  likely	  push	  the	  cells	  into	  mitosis.	  	  Cell	  cycle	  analysis	  of	  control	  tumors,	  SUV39H1	  tumors,	  and	  SUV39H1/cyclin	  B1	  tumors	  may	  present	  insights	  into	  how	  SUV39H1	  is	  suppressing	  tumor	  initiation	  through	  cyclin	  B1.	  	   Previous	  studies	  in	  the	  zebrafish	  have	  shown	  that	  cyclin	  B1	  plays	  a	  central	  role	  regarding	  B-­‐myb,	  a	  transcription	  factor	  that	  interacts	  with	  cell	  cycle	  regulators.	  	  A	  mutant	  for	  bmyb	  was	  revealed	  in	  a	  large-­‐scale	  mutagenesis	  screen	  as	  having	  an	  increased	  number	  of	  mitotic	  cells,	  noted	  by	  increased	  phospho-­‐H3	  staining.	  	  The	  
bmyb	  mutant	  zebrafish	  had	  decreased	  cell	  proliferation	  and	  defects	  in	  progression	  through	  the	  G2/M	  phase,	  which	  could	  be	  rescued	  by	  the	  overexpression	  of	  cyclin	  B1	  mRNA	  [165].	  	  A	  chemical	  genetic	  screen	  led	  to	  the	  discovery	  of	  persynthamide	  as	  a	  suppressor	  of	  the	  bmyb	  mutant;	  persynthamide	  caused	  a	  delay	  in	  S	  phase	  progression,	  leaving	  extra	  time	  for	  cyclin	  B1	  mRNA	  to	  accumulate	  in	  the	  cells	  and	  to	  push	  the	  cells	  through	  mitosis	  [382].	  	  These	  studies	  suggest	  that	  cyclin	  B1	  levels	  can	  be	  manipulated	  in	  vivo	  to	  rescue	  cell	  cycle	  defects,	  and	  overexpression	  of	  cyclin	  B1	  or	  treatment	  with	  persynthamide	  may	  be	  interesting	  experiments	  to	  try	  in	  our	  SUV39H1-­‐overexpressing	  RMS	  model.	  
Senescence	  	   To	  look	  at	  growth	  arrest	  further	  in	  this	  RMS	  model,	  we	  would	  need	  to	  examine	  markers	  of	  senescence.	  	  The	  gold	  standard	  for	  senescence	  currently	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remains	  senescence-­‐associated	  beta-­‐Galactosidase	  (SA-­‐beta-­‐gal)	  [383].	  	  In	  the	  zebrafish,	  senescence	  has	  been	  analyzed	  by	  SA-­‐beta-­‐gal	  staining	  in	  cryosections	  and	  on	  scales;	  this	  could	  be	  performed	  in	  tumor	  sections	  as	  well	  as	  potentially	  in	  the	  larval	  fish	  [181,	  384].	  	  Newer	  markers	  for	  senescence	  are	  constantly	  being	  discovered,	  and	  some	  of	  these	  could	  be	  tested,	  including	  p15,	  Dec1,	  DcR2,	  cathepsin	  D,	  and	  eEF1B2	  [385,	  386].	  	  Interestingly,	  it	  has	  been	  proposed	  that	  in	  some	  tumors	  such	  as	  C	  cell	  adenocarcinomas,	  the	  H3K9me3	  mark	  itself	  is	  a	  marker	  of	  senescence,	  which	  seems	  likely	  to	  be	  true	  in	  our	  SUV39H1-­‐overexpressing	  RMS	  cells	  [264].	  	   Our	  results	  add	  to	  the	  growing	  field	  of	  knowledge	  regarding	  how	  cellular	  senescence	  plays	  into	  tumorigenesis.	  	  It	  has	  been	  known	  for	  some	  time	  that	  oncogene	  expression	  can	  induce	  senescence	  and	  has	  more	  recently	  been	  shown	  that	  senescence	  is	  a	  mechanism	  to	  prevent	  tumor	  formation	  [186,	  385,	  387-­‐389].	  	  Our	  results	  with	  SUV39H1	  demonstrate	  this	  effect,	  where	  overexpression	  of	  the	  enzyme	  in	  the	  presence	  of	  oncogenic	  KRAS	  likely	  directly	  suppresses	  cyclin	  B1	  to	  cause	  growth	  arrest.	  	  As	  a	  consequence	  of	  growth	  arrest,	  fewer	  tumors	  form,	  leading	  to	  the	  suppressed	  phenotype	  we	  initially	  observed.	  	  This	  may	  have	  therapeutic	  implications,	  particularly	  since	  SUV39H1	  associates	  with	  HDACs	  and	  DNMTs	  [94,	  123].	  	  In	  a	  complementary	  study	  to	  ours,	  loss	  of	  SUV39H1	  led	  to	  a	  loss	  of	  senescence	  and	  therefore	  tumor	  development;	  this	  effect	  could	  be	  phenocopied	  by	  treatment	  with	  HDAC	  inhibitors	  or	  DNMT	  inhibitors	  [186].	  	  This	  result	  suggests	  that	  by	  enhancing	  SUV39H1	  or	  its	  HDAC	  and	  DNMT	  partners,	  tumor	  development	  would	  be	  halted.	  	  We	  demonstrated	  reduced	  tumor	  formation	  with	  SUV39H1	  overexpression,	  and	  it	  may	  be	  interesting	  to	  overexpress	  HDACs	  or	  DNMTs	  in	  our	  model.	  	  In	  fact,	  the	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only	  one	  tested	  in	  our	  screen,	  HDAC3,	  was	  a	  minor	  suppression	  of	  RMS	  formation,	  suggesting	  a	  similar	  mechanism	  is	  at	  play	  in	  our	  model.	  	  SUV39H1	  is	  also	  known	  to	  interact	  with	  Rb,	  and	  Rb	  is	  uniquely	  required	  during	  senescence	  to	  repress	  growth-­‐related	  genes	  [99,	  100,	  390].	  	  This	  also	  implicates	  SUV39H1	  in	  the	  regulation	  of	  senescence.	  	  In	  general,	  following	  up	  with	  the	  role	  of	  SUV39H1	  in	  senescence	  could	  strengthen	  the	  conclusions	  from	  our	  RMS	  model.	  
Transgene	  expression	  	   A	  question	  regarding	  overexpression	  of	  chromatin	  factors	  and	  tumor	  suppression	  is	  the	  expression	  of	  the	  oncogenic	  transgene;	  this	  is	  particularly	  valid	  in	  our	  model	  since	  SUV39H1	  is	  a	  transcriptional	  repressor.	  	  However,	  hKRASG12D	  expression	  in	  the	  tumors	  does	  not	  correlate	  with	  tumor	  incidence	  among	  control,	  SUV39H1,	  and	  SUV39H1	  mutant	  tumors	  within	  the	  tumors	  that	  form	  (Figure	  2.A2).	  	  To	  demonstrate	  that	  SUV39H1	  has	  not	  directly	  suppressed	  the	  rag2-­‐hKRASG12D	  transgene	  in	  larvae	  as	  the	  mechanism	  for	  decreased	  tumor	  initiation,	  assessing	  how	  SUV39H1	  impacts	  the	  integration	  of	  this	  transgene	  would	  be	  interesting.	  	  To	  study	  this,	  we	  will	  use	  a	  transgenic	  approach,	  comparing	  the	  effects	  of	  rag2-­‐hSUV39H1	  on	  fluorescent	  transgenes	  driven	  by	  different	  promoters	  to	  ensure	  that	  SUV39H1	  does	  not	  specifically	  silence	  the	  rag2	  promoter.	  	  Additionally,	  our	  result	  that	  mRNA	  expression	  of	  GFP	  driven	  by	  the	  rag2	  promoter	  is	  the	  same	  in	  SUV39H1	  and	  control	  larvae	  at	  5	  dpf	  demonstrates	  that	  SUV39H1	  does	  not	  suppress	  the	  rag2	  promoter	  activity	  (Figure	  2.5).	  	  
SUV39H1	  and	  the	  muscle	  program	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   Even	  though	  we	  concluded	  that	  the	  impact	  of	  SUV39H1	  on	  the	  muscle	  program	  was	  not	  solely	  responsible	  for	  the	  suppressive	  phenotype,	  it	  still	  may	  be	  interesting	  to	  follow	  up	  this	  part	  of	  the	  project.	  	  Our	  lab	  has	  KRASG12D-­‐driven	  models	  of	  RMS	  initiated	  in	  various	  muscle	  cell	  types	  at	  different	  stages	  of	  differentiation.	  	  The	  tumor-­‐initiating	  cell	  directly	  correlates	  to	  the	  differentiation	  state	  of	  the	  tumor	  that	  eventually	  develops;	  for	  example,	  driving	  the	  KRAS	  oncogene	  using	  promoters	  that	  express	  earlier	  in	  muscle	  differentiation,	  such	  as	  rag2-­‐	  or	  cadherin	  15	  (cdh15)-­‐KRASG12D,	  gives	  rise	  to	  undifferentiated	  RMS	  whereas	  tumors	  arising	  in	  cells	  expressing	  myosin	  light	  polypeptide	  2	  (mylz2)-­‐KRASG12D	  are	  highly	  differentiated	  [257].	  	  Repeating	  the	  experiments	  with	  SUV39H1	  driven	  in	  RMS	  of	  various	  differentiation	  states	  may	  allow	  further	  assessment	  of	  its	  effects	  on	  the	  muscle	  program.	  	  For	  example,	  a	  tumor	  expressed	  from	  the	  mylz2-­‐hKRASG12D,	  mylz2-­‐hSUV39H1	  transgenes	  may	  permit	  us	  to	  see	  the	  change	  from	  a	  differentiated	  control	  tumor	  to	  an	  undifferentiated	  SUV39H1	  tumor.	  	  This	  observation	  would	  not	  have	  been	  possible	  in	  the	  rag2	  tumors,	  as	  they	  already	  start	  in	  an	  undifferentiated	  state.	  	  This	  result	  would	  indicate	  that	  SUV39H1	  could	  impact	  the	  muscle	  program	  in	  the	  tumor.	  	  Assessing	  tumor	  rates	  driven	  by	  cdh15-­‐hKRASG12D,	  cdh15-­‐hSUV39H1	  would	  be	  of	  particular	  appeal,	  since	  cdh15	  expresses	  early	  in	  the	  muscle	  lineage,	  like	  rag2.	  	  SUV39H1	  would	  be	  expected	  to	  suppress	  this	  model	  of	  RMS	  with	  a	  similar	  mechanism	  as	  our	  current	  model,	  since	  these	  tumors	  should	  have	  the	  same	  muscle	  differentiation	  properties	  as	  rag2	  tumors.	  	   Another	  fascinating	  experiment	  would	  be	  to	  perform	  chromatin	  immunoprecipitation	  followed	  by	  massively	  parallel	  DNA	  sequencing	  (ChIP-­‐seq)	  for	  
139	  	  	  	  
a	  muscle	  master	  regulator	  like	  MyoD	  rather	  than	  for	  SUV39H1	  or	  other	  HMTs	  themselves.	  	  In	  a	  recent	  study,	  it	  was	  demonstrated	  that	  different	  master	  regulators	  co-­‐bind	  with	  signal	  transduction	  factors	  at	  lineage-­‐specific	  genomic	  enhancers,	  depending	  on	  the	  cell	  lineage.	  	  For	  example,	  Wnt	  and	  BMP	  factors	  bind	  with	  erythroid	  factors	  at	  erythroid	  enhancers	  in	  an	  erythroleukemia	  context	  yet	  bind	  with	  myeloid	  regulators	  at	  myeloid	  enhancers	  in	  a	  monocytic	  environment	  [391].	  	  This	  suggests	  that	  the	  master	  regulator	  is	  organizing	  the	  cellular	  state	  into	  the	  right	  context,	  with	  one	  of	  the	  likely	  mechanisms	  opening	  the	  chromatin	  at	  the	  desired	  genomic	  locations	  and	  ensuring	  others	  are	  closed.	  	  In	  fact,	  some	  chromatin	  complexes	  are	  known	  to	  interact	  with	  cellular	  regulators	  directly	  [392,	  393].	  	  Since	  MyoD	  is	  known	  to	  associate	  with	  repressive	  chromatin	  factors	  in	  precursors	  and	  chromatin	  activators	  in	  differentiating	  cells,	  it	  is	  likely	  that	  MyoD	  is	  acting	  in	  the	  same	  manner	  as	  the	  hematopoietic	  regulators.	  	  Performing	  ChIP-­‐seq	  with	  MyoD	  would	  directly	  inform	  us	  of	  the	  most	  important	  genes	  involved	  in	  muscle	  or	  RMS	  development	  that	  MyoD	  is	  trying	  to	  open	  or	  close.	  	  In	  the	  context	  of	  the	  SUV39H1-­‐overexpressing	  tumors,	  we	  could	  compare	  what	  MyoD	  binds	  in	  control	  and	  SUV39H1	  tumors	  to	  determine	  where	  it	  cannot	  bind	  when	  ectopic	  SUV39H1	  promotes	  the	  closure	  of	  chromatin.	  	  These	  data	  would	  directly	  elucidate	  the	  SUV39H1	  target	  genes	  that	  MyoD	  is	  unable	  to	  control,	  leading	  to	  tumor	  suppression.	  	  
H3K9	  methylation	  and	  cancer	  	   An	  intriguing	  follow-­‐up	  study	  on	  this	  project	  may	  be	  to	  fully	  examine	  the	  role	  of	  H3K9	  methylation	  in	  RMS	  formation.	  	  In	  addition	  to	  SUV39H1	  suppressing	  tumor	  
140	  	  	  	  
development,	  H3K9	  HMT	  SETDB1	  also	  suppressed	  RMS	  formation	  in	  zebrafish	  (data	  not	  shown).	  	  This	  is	  of	  particular	  interest	  since	  SUV39H1	  and	  SETDB1	  act	  in	  the	  same	  complex	  [95].	  	  Though	  we	  did	  not	  examine	  them,	  it	  is	  likely	  the	  other	  HMTs	  in	  this	  complex,	  such	  as	  G9a	  and	  GLP,	  could	  also	  suppress	  RMS	  formation	  upon	  overexpression.	  	  Along	  with	  the	  data	  presented	  that	  SUV39H1	  suppression	  relies	  on	  an	  active	  SET	  domain,	  having	  two	  H3K9	  HMTs	  with	  a	  similar	  phenotype	  suggests	  that	  there	  is	  a	  specific	  set	  of	  genes	  that	  are	  being	  repressed	  when	  these	  enzymes	  are	  overexpressed	  to	  cause	  the	  decrease	  in	  tumor	  formation.	  	  Interestingly,	  when	  either	  of	  these	  genes	  is	  overexpressed	  in	  a	  zebrafish	  melanoma	  model,	  they	  accelerate	  tumor	  formation	  rather	  than	  suppress	  [181].	  	  This	  implies	  that	  they	  are	  methylating	  a	  different	  set	  of	  target	  genes	  in	  skin	  as	  opposed	  to	  muscle.	  	  Trying	  to	  assess	  this	  difference	  could	  also	  prove	  interesting.	  	   The	  most	  appealing	  experiment	  to	  determine	  the	  role	  of	  the	  H3K9	  methyl	  mark	  in	  causing	  RMS	  suppression	  would	  be	  ascertaining	  what	  genes	  are	  silenced.	  	  In	  our	  model	  system,	  since	  the	  tumors	  form	  so	  early,	  it	  is	  possible	  to	  perform	  ChIP-­‐seq	  in	  injected	  embryos	  to	  determine	  the	  target	  genes	  of	  the	  enzymes.	  	  This	  is	  feasible	  if	  the	  injected	  SUV39H1	  and	  SETDB1	  are	  Flag-­‐tagged,	  allowing	  for	  ease	  of	  pull-­‐down.	  	  This	  would	  require	  1500-­‐2000	  embryos,	  making	  it	  technically	  feasible	  to	  perform	  by	  pooling	  a	  few	  rounds	  of	  injected	  embryos	  (E.	  Paik,	  personal	  communication).	  	  Additionally,	  other	  H3K9	  HMTs	  could	  be	  examined,	  including	  G9a	  and	  GLP,	  which	  act	  in	  a	  complex	  together	  [95].	  	  The	  fish	  could	  also	  be	  treated	  with	  histone	  methylation	  inhibitors,	  to	  determine	  if	  decreased	  methylation	  would	  promote	  tumor	  formation,	  though	  this	  could	  be	  in	  conflict	  with	  known	  LSD1	  demethylase	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overexpression	  in	  human	  RMS,	  though	  the	  enzymes	  may	  target	  a	  different	  set	  of	  genes	  [253,	  254].	  	  We	  could	  test	  the	  effects	  of	  LSD1	  overexpression	  in	  our	  model	  as	  well.	  	   A	  secondary	  screen	  to	  identify	  the	  critical	  target	  genes	  that	  result	  from	  ChIP-­‐seq	  analysis	  may	  be	  necessary.	  	  It	  is	  possible	  that	  the	  tumor	  suppressive	  activity	  of	  SUV39H1	  is	  dependent	  on	  several	  candidate	  genes.	  	  To	  solve	  this	  problem,	  putative	  target	  genes	  may	  need	  to	  be	  analyzed	  in	  combinatorial	  pools.	  	  Pooling	  of	  factors	  for	  screening	  has	  been	  successfully	  performed	  in	  the	  zebrafish	  (E.	  van	  Rooijen,	  personal	  communication).	  	  It	  is	  possible	  that	  the	  single	  gene	  approach	  limited	  our	  analysis	  involving	  Pax7	  and	  myogenin,	  where	  neither	  gene	  alone	  was	  able	  to	  rescue	  the	  suppressed	  SUV39H1	  tumor	  curve.	  	  In	  combination	  with	  reduced	  expression	  of	  a	  cell	  cycle	  or	  growth	  arrest	  factor,	  reduced	  levels	  of	  Pax7	  or	  myogenin	  may	  still	  participate	  in	  the	  tumor	  suppression.	  	  These	  experiments	  would	  improve	  our	  understanding	  of	  how	  misregulation	  of	  H3K9	  methylation	  contributes	  to	  RMS	  pathogenesis.	  	   A	  potential	  mechanism	  for	  the	  SUV39H1	  suppression	  of	  RMS	  formation	  involves	  Hox	  genes.	  	  Hox	  genes	  play	  an	  initial	  role	  in	  muscle	  development	  by	  specifying	  the	  somites	  [394].	  	  Furthermore,	  Hox	  genes	  were	  found	  to	  be	  among	  the	  targets	  of	  SETDB1	  overexpression	  in	  melanoma	  [181].	  	  Therefore,	  Hox	  genes	  are	  a	  potential	  target	  of	  SUV39H1	  overexpression	  in	  the	  muscle.	  	  In	  our	  system,	  it	  seems	  unlikely	  this	  would	  be	  impacting	  embryonic	  muscle	  development,	  as	  SUV39H1	  driven	  by	  the	  rag2	  promoter	  should	  be	  expressed	  well	  after	  somite	  formation.	  	  However,	  the	  Hox	  genes	  are	  known	  to	  have	  differing	  roles	  in	  muscle	  regeneration,	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so	  they	  potentially	  still	  could	  impact	  our	  RMS	  tumors	  [395].	  In	  fact,	  repression	  of	  certain	  Hox	  genes	  may	  be	  required	  for	  quiescence,	  so	  further	  investigation	  of	  this	  mechanism	  in	  our	  tumors	  may	  be	  necessary	  [395,	  396].	  	  
Chromatin-­modifying	  factors	  in	  cancer	  	   Increasingly,	  chromatin-­‐modifying	  factors	  are	  being	  revealed	  as	  having	  key	  roles	  in	  tumor	  development,	  and	  the	  zebrafish	  is	  playing	  a	  major	  part	  in	  these	  discoveries.	  	  A	  study	  last	  year	  found	  that	  overexpression	  of	  SETDB1,	  another	  HMT,	  accelerates	  formation	  of	  hBRAFV600E,	  p53-­‐/-­‐	  tumors	  in	  zebrafish	  [181].	  	  This	  study	  represents	  an	  elegant	  experimental	  design,	  where	  a	  set	  of	  genes	  from	  a	  region	  known	  to	  be	  amplified	  in	  human	  melanomas	  could	  be	  examined	  in	  zebrafish	  to	  find	  the	  gene	  causing	  the	  phenotype	  and	  moved	  back	  to	  human	  cell	  lines	  to	  obtain	  the	  most	  relevant	  data.	  	  Another	  screen	  is	  ongoing	  in	  our	  lab	  utilizing	  the	  same	  model	  of	  melanoma	  to	  determine	  accelerator	  roles	  of	  other	  chromatin-­‐modifying	  factors.	  	  Using	  the	  same	  set	  of	  ORFs	  used	  in	  this	  dissertation,	  SATB2	  was	  revealed	  to	  be	  an	  accelerator	  of	  melanoma	  (E.	  van	  Rooijen,	  personal	  communication).	  	  Future	  screens	  utilizing	  our	  library	  of	  chromatin	  factors	  ORFs	  could	  discover	  novel	  roles	  of	  chromatin	  factors	  in	  other	  tumor	  types	  as	  well.	  	   In	  addition,	  many	  different	  steps	  in	  embryonic	  and	  regenerative	  muscle	  development	  are	  regulated	  by	  chromatin-­‐modifying	  factors.	  	  It	  is	  likely	  that	  many	  more	  perform	  important	  functions,	  but	  they	  currently	  remain	  undiscovered.	  	  Utilizing	  the	  capability	  of	  the	  zebrafish	  for	  high-­‐throughput	  screens,	  a	  morpholino	  injection-­‐based	  screen	  could	  be	  performed,	  knocking	  down	  every	  chromatin	  factor	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in	  the	  zebrafish.	  	  The	  morphant	  embryos	  could	  be	  assessed	  for	  problems	  with	  muscle	  development,	  ranging	  from	  somite	  development	  to	  muscle	  regulatory	  factor	  expression	  to	  slow	  and	  fast	  fiber	  formation.	  	  The	  amount	  of	  information	  that	  could	  be	  learned	  from	  a	  project	  such	  as	  this	  would	  be	  staggering.	  	  A	  screen	  of	  this	  scale	  is	  feasible	  over	  several	  years	  with	  a	  small	  team	  of	  researchers	  (H.	  Huang	  and	  K.	  Kathrein,	  personal	  communication).	  	  These	  types	  of	  wide	  scale	  screens,	  whether	  in	  tumors	  or	  in	  embryos,	  are	  the	  optimal	  high-­‐throughput	  ways	  to	  learn	  as	  much	  as	  possible	  about	  a	  collection	  of	  genes.	  	   Based	  on	  this	  dissertation	  and	  other	  studies,	  it	  is	  becoming	  evident	  that	  H3K9	  methylation	  plays	  a	  major	  role	  in	  cancer	  formation.	  	  We	  have	  shown	  that	  excess	  H3K9me3	  suppresses	  ERMS	  initiation,	  whereas	  others	  have	  found	  it	  enhances	  proliferation	  in	  ARMS	  [251].	  	  	  The	  mark	  was	  associated	  with	  growth	  arrest	  in	  murine	  lymphomas	  and	  has	  been	  referred	  to	  as	  a	  marker	  of	  senescence	  [186,	  264,	  265].	  	  SETDB1	  was	  found	  to	  be	  amplified	  in	  human	  melanomas	  and	  to	  accelerate	  zebrafish	  melanomas,	  likely	  mediated	  through	  aberrant	  H3K9	  methylation	  [181].	  	  Whether	  the	  presence	  of	  H3K9	  methylation	  promotes	  or	  suppresses	  cancer	  formation	  seems	  to	  be	  context-­‐dependent.	  	  This	  suggests	  that	  these	  enzymes	  are	  interacting	  with	  a	  wide	  variety	  of	  cell	  lineage	  regulators	  to	  have	  such	  varying	  cell-­‐specific	  effects.	  	  This	  has	  been	  shown	  for	  the	  Polycomb	  Repressive	  Complexes	  (PRCs),	  as	  PRC1	  interacts	  with	  Runx1	  in	  megakaryocytes	  and	  thymocytes	  and	  PRC2	  interacts	  with	  Gata1	  in	  erythroid	  cells,	  recruiting	  these	  complex	  directly	  to	  genes	  of	  interest	  [392,	  397].	  	  Runx1	  also	  interacts	  with	  the	  SWI/SNF	  complex	  to	  activate	  genes	  key	  for	  hematopoietic	  differentiation	  [393].	  	  It	  is	  likely	  to	  assume	  HMTs	  are	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acting	  in	  the	  same	  manner.	  	  Additionally,	  it	  can	  be	  appreciated	  how	  disrupting	  one	  of	  these	  interactions	  could	  promote	  or	  suppress	  tumorigenesis.	  	  If	  the	  chromatin-­‐modifying	  enzyme	  cannot	  interact	  with	  its	  cell-­‐specific	  regulator,	  it	  will	  silence	  or	  activate	  the	  wrong	  genomic	  regions.	  	  If	  there	  is	  too	  much	  of	  the	  enzyme,	  excess	  enzyme	  may	  interact	  with	  other	  complexes	  and	  act	  on	  the	  wrong	  genes.	  	  If	  there	  is	  too	  little,	  it	  may	  not	  silence	  or	  activate	  all	  the	  genes	  it	  should,	  leaving	  some	  to	  be	  unregulated.	  	  Each	  of	  these	  scenarios	  would	  impact	  differentiation	  or	  self-­‐renewal	  of	  a	  cell	  lineage,	  and	  skewing	  these	  processes	  can	  lead	  to	  tumorigenesis.	  	  As	  these	  fields	  move	  forward,	  it	  is	  imperative	  to	  understand	  how	  chromatin	  modification,	  such	  as	  H3K9me3,	  interplay	  with	  the	  cell	  specific	  master	  regulators	  to	  truly	  comprehend	  the	  full	  biology	  at	  play.	  	  
Future	  screening	  approach	  in	  zebrafish	  with	  clinical	  relevance	  Our	  studies	  demonstrated	  that	  the	  impact	  of	  chromatin-­‐modifying	  factors	  on	  zebrafish	  RMS	  could	  be	  detected	  while	  the	  fish	  were	  still	  larvae.	  	  By	  using	  rag2-­‐GFP	  as	  a	  fluorescent	  tracker	  of	  developing	  tumors,	  this	  approach	  could	  be	  adapted	  to	  a	  high-­‐throughput	  manner	  for	  a	  primary	  drug	  screen.	  	  Ideally,	  a	  rag2-­‐hKRASG12D;	  
rag2-­‐GFP	  stable	  line	  would	  be	  created	  for	  use	  in	  the	  screen	  to	  ensure	  microinjections	  are	  not	  the	  limiting	  step.	  	  Then,	  F1	  embryos	  from	  this	  line	  could	  be	  treated	  with	  a	  library	  of	  drugs	  and	  assessed	  for	  fluorescence	  in	  the	  musculature	  at	  5,	  7,	  and	  9	  dpf	  (Figure	  4.1).	  	  This	  rapid	  time	  scale	  is	  wide	  enough	  to	  show	  strong	  acceleration	  and	  suppression,	  as	  it	  is	  rare	  to	  see	  fish	  with	  fluorescence	  spots	  at	  5	  dpf	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Figure	  4.1:	  Schematic	  for	  a	  larval	  RMS	  screen	  in	  zebrafish	  to	  identify	  clinically	  
relevant	  compounds.	  	  Following	  drug	  treatment,	  rag2-­‐KRASG12D;	  rag2-­‐GFP	  fish	  could	  be	  monitored	  for	  tumor	  formation	  by	  fluorescence	  at	  5,	  7,	  and	  9	  dpf.	  	  This	  screen	  would	  unveil	  chemicals	  that	  inhibit	  tumor	  formation,	  which	  represent	  potential	  therapeutics,	  as	  well	  as	  those	  that	  accelerate	  tumor	  formation,	  enhancing	  our	  understanding	  of	  tumorigenesis.
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yet	  often	  over	  one-­‐third	  of	  the	  control	  fish	  are	  positive	  by	  9	  dpf.	  	  To	  screen	  for	  drugs	  with	  clinical	  relevance,	  only	  the	  strongest	  modifiers	  are	  preferred	  to	  move	  towards	  human	  trials.	  	  Drugs	  that	  suppress	  tumor	  formation	  could	  be	  putative	  therapeutics.	  	  Drugs	  that	  accelerate	  tumor	  formation	  would	  reveal	  pathways	  interesting	  to	  tumor	  development;	  these	  drugs	  could	  also	  provide	  insight	  to	  potential	  therapeutics,	  as	  we	  would	  be	  looking	  for	  compounds	  with	  opposite	  effects.	  	  If	  automated	  fluorescent	  scoring	  could	  be	  developed,	  particularly	  since	  it	  is	  a	  straightforward	  binary	  question	  of	  fluorescent	  or	  not,	  then	  this	  screen	  could	  occur	  extremely	  rapidly.	  	  Automated	  fluorescent	  scoring	  has	  been	  developed	  utilizing	  microfluidics	  in	  Caenorhabditis	  
elegans,	  so	  this	  technology	  may	  be	  applicable	  to	  the	  zebrafish	  system	  [398].	  	  Even	  manually,	  researchers	  could	  still	  score	  a	  set	  of	  fish	  three	  days	  per	  week,	  leading	  to	  the	  completion	  of	  a	  few	  hundred	  drugs	  within	  a	  few	  months	  time.	  This	  screen	  would	  truly	  encapsulate	  the	  best	  features	  of	  the	  zebrafish	  as	  a	  model	  organism.	  	  First,	  the	  screen	  takes	  place	  while	  the	  fish	  are	  still	  larvae.	  	  This	  allows	  us	  to	  take	  full	  advantage	  of	  the	  tools	  that	  the	  embryonic	  zebrafish	  has	  to	  offer.	  	  The	  screen	  would	  occur	  while	  the	  larvae	  are	  still	  optically	  clear	  and	  small	  enough	  to	  maintain	  in	  tissue	  culture	  dishes.	  	  Increased	  transparency	  could	  also	  be	  obtained	  by	  using	  the	  casper	  strain	  of	  fish,	  which	  lacks	  pigmented	  cells	  [154].	  	  Second,	  despite	  being	  in	  a	  young	  zebrafish,	  this	  screen	  would	  occur	  in	  a	  setting	  of	  tumorigenesis.	  	  This	  approach	  allows	  for	  chemical	  inactivation	  of	  targeted	  molecules	  and	  pathways	  in	  a	  cancer	  environment,	  filling	  a	  void	  in	  zebrafish	  genetics.	  	  Current	  methods	  fall	  short,	  as	  the	  zebrafish	  lacks	  shRNA	  technology	  and	  the	  translation	  inhibiting	  effects	  of	  antisense	  morpholinos	  would	  not	  persist	  long	  enough	  for	  the	  screen.	  	  In	  contrast,	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treating	  adult	  tumorigenic	  fish	  with	  chemicals	  is	  tedious,	  time-­‐consuming,	  and	  requires	  a	  large	  amount	  of	  housing	  space	  (R.	  White,	  personal	  communication).	  	  Third,	  our	  assay	  enables	  a	  high-­‐throughput	  cancer	  drug	  screen	  to	  occur	  in	  a	  whole	  organism	  rather	  than	  a	  cell	  line.	  	  This	  is	  preferable	  to	  ensure	  that	  any	  effects	  observed	  are	  occurring	  in	  the	  environment	  of	  a	  tumor	  and	  niche,	  rather	  than	  just	  isolated	  tumor	  cells,	  as	  they	  would	  be	  in	  a	  human	  cancer.	  	  Being	  able	  to	  use	  a	  vertebrate	  organism	  such	  as	  the	  zebrafish	  keeps	  novel	  drug	  discovery	  one	  step	  closer	  to	  getting	  to	  human	  patients.	  	  In	  conclusion,	  using	  fluorescence	  as	  a	  marker	  of	  developing	  RMS	  tumors	  could	  be	  converted	  to	  a	  novel,	  high-­‐throughput	  assay	  for	  cancer	  drug	  discovery.	  	  This	  would	  be	  executed	  in	  larval	  zebrafish,	  where	  the	  embryonic	  advantages	  of	  zebrafish	  use	  could	  be	  combined	  with	  the	  tumorigenic	  environment	  to	  ascertain	  the	  most	  relevant	  drugs	  possible.	  	  
Conclusion	  	   In	  summary,	  this	  dissertation	  utilizes	  the	  zebrafish	  as	  a	  model	  organism	  for	  cancer	  and	  hematopoietic	  development.	  	  We	  have	  shown	  SUV39H1,	  a	  histone	  methyltransferase,	  to	  be	  a	  suppressor	  of	  rhabdomyosarcoma	  initiation.	  	  Its	  mechanism	  cannot	  solely	  be	  explained	  by	  a	  defect	  in	  the	  muscle	  program	  and	  likely	  involves	  a	  cell	  cycle	  or	  growth	  arrest	  program	  through	  suppression	  of	  cyclin	  B1.	  	  We	  have	  also	  described	  a	  novel	  screening	  approach	  that	  assessed	  a	  number	  of	  chromatin-­‐modifying	  factors	  for	  their	  roles	  in	  hematopoietic	  development.	  	  This	  strategy	  will	  be	  applicable	  in	  situations	  involving	  hard	  to	  reach	  tissues,	  toxic	  factors,	  and	  lethal	  mutants.	  	  The	  studies	  performed	  here	  will	  be	  the	  basis	  for	  future	  work	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Abstract	  	   Hematopoietic	  stem	  cells	  (HSCs)	  are	  responsible	  for	  creating	  each	  cellular	  component	  of	  the	  vertebrate	  blood	  system.	  	  However,	  HSCs	  must	  also	  self	  renew	  to	  maintain	  their	  own	  population	  so	  that	  the	  blood	  system	  always	  has	  the	  capacity	  to	  be	  reconstituted.	  	  This	  balance	  of	  HSCs	  producing	  more	  HSCs	  as	  well	  as	  differentiated	  blood	  cells	  is	  regulated	  by	  several	  extrinsic	  pathways.	  	  The	  Cdx/Hox	  pathway	  has	  been	  shown	  to	  have	  a	  role	  in	  regulating	  embryonic	  stem	  cells,	  with	  the	  zebrafish	  caudal	  genes	  cdx4	  and	  cdx1a	  acting	  upstream	  of	  the	  Hox	  clusters	  to	  aid	  in	  the	  formation	  of	  blood.	  	  The	  Notch	  pathway	  has	  been	  shown	  in	  mice	  and	  zebrafish	  to	  be	  a	  positive	  regulator	  of	  HSC	  self	  renewal;	  experiments	  in	  fish	  revealed	  that	  this	  pathway	  signals	  through	  the	  HSC	  transcription	  factor	  runx1	  to	  do	  so.	  	  Lastly,	  the	  action	  of	  prostaglandin	  E2	  was	  found	  to	  positively	  regulate	  HSCs,	  and	  treatment	  with	  this	  compound	  leads	  to	  increased	  recovery	  kinetics	  of	  the	  hematopoietic	  system	  upon	  acute	  injury	  or	  transplantation.	  	  This	  knowledge	  is	  currently	  being	  applied	  in	  the	  clinic	  as	  a	  means	  to	  increase	  the	  success	  rates	  of	  umbilical	  cord	  blood	  transplantations	  in	  adult	  patients.	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1.	  Introduction	  to	  Hematopoiesis	  and	  Zebrafish	  	   All	  vertebrates	  require	  blood	  flowing	  through	  their	  circulatory	  systems	  that	  carries	  oxygen	  and	  other	  nutrients	  to	  cells	  of	  all	  tissues	  of	  the	  body	  and	  that	  provides	  defense	  against	  foreign	  pathogens.	  	  Hematopoiesis,	  or	  the	  differentiation	  of	  the	  mature	  blood	  lineages	  from	  immature	  progenitors,	  occurs	  throughout	  the	  lifetime	  of	  an	  organism	  to	  regularly	  replenish	  the	  different	  cellular	  components	  of	  the	  blood.	  	  It	  is	  ultimately	  supported	  by	  the	  hematopoietic	  stem	  cell	  (HSC).	  	  The	  HSC	  sits	  atop	  the	  entire	  hematopoietic	  hierarchy	  as	  it	  has	  the	  ability	  to	  differentiate	  into	  each	  member	  of	  every	  blood	  lineage;	  it	  also	  has	  the	  capacity	  to	  self	  renew,	  maintaining	  a	  population	  of	  undifferentiated,	  immature	  HSCs.	  	   Vertebrate	  hematopoiesis	  occurs	  in	  the	  following	  two	  successive	  waves:	  primitive,	  to	  support	  the	  developing	  embryo,	  and	  definitive,	  to	  provide	  the	  organism	  with	  long	  term	  HSCs	  to	  last	  its	  entire	  lifetime.	  	  The	  primitive	  and	  definitive	  waves	  produce	  different	  cell	  types	  from	  different	  locations,	  with	  the	  primitive	  typically	  limited	  to	  nucleated	  erythrocytes	  containing	  embryonic	  globins	  and	  macrophages	  for	  non-­‐specific	  defense.	  	  The	  definitive	  wave	  produces	  long	  term	  HSCs	  (LT-­‐HSCs),	  which	  give	  rise	  to	  a	  multipotent	  progenitor;	  this	  produces	  a	  common	  lymphoid	  progenitor,	  which	  will	  become	  T	  lymphocytes,	  B	  lymphocytes,	  dendritic	  cells,	  and	  natural	  killer	  cells,	  and	  a	  common	  myeloid	  progenitor,	  which	  will	  become	  monocytes,	  neutrophils,	  eosinophils,	  basophils,	  thrombocytes,	  and	  erythrocytes.1,2	  	   Danio	  rerio,	  commonly	  known	  as	  the	  zebrafish,	  is	  a	  member	  of	  the	  teleost	  family,	  bony	  fish	  with	  rayed	  fins.	  	  Technically	  easy	  to	  work	  with,	  the	  zebrafish	  is	  an	  excellent	  vertebrate	  model	  organism	  for	  studying	  hematopoiesis.	  	  Zebrafish	  eggs	  are	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fertilized	  externally,	  development	  occurs	  entirely	  ex	  vivo,	  and	  embryos	  are	  optically	  clear.	  	  Additionally,	  zebrafish	  perform	  well	  as	  a	  genetic	  model	  organism;	  they	  are	  competent	  for	  large-­‐scale	  genetic	  screens	  since	  they	  require	  less	  space	  than	  mammalian	  systems,	  females	  can	  produce	  one	  to	  two	  hundred	  eggs	  every	  week,	  and	  their	  generation	  time	  is	  short.	  	  The	  zebrafish	  genome	  is	  fully	  sequenced,	  and	  a	  series	  of	  large-­‐scale	  mutagenesis	  screens	  have	  been	  completed,	  leading	  to	  the	  production	  of	  numerous	  genetic	  mutants	  that	  are	  available	  for	  study.3,4	  	   Zebrafish	  development	  occurs	  rapidly	  over	  the	  course	  of	  a	  few	  days.	  	  Immediately	  after	  fertilization,	  the	  zygote	  remains	  in	  the	  one	  cell	  stage	  for	  forty-­‐five	  minutes,	  facilitating	  genetic	  manipulations	  of	  the	  embryo	  as	  nucleic	  acid	  injections	  can	  be	  performed	  at	  this	  stage.	  	  Gastrulation	  commences	  around	  5	  hours	  post	  fertilization	  (hpf),	  as	  morphogenetic	  movements	  form	  the	  three	  primary	  germ	  layers.	  	  Somites	  and	  organs	  begin	  to	  form	  at	  10	  hpf.	  	  Shortly	  after	  24	  hpf,	  circulation	  and	  pigmentation	  commence;	  by	  48	  hpf	  the	  zebrafish	  begin	  hatching	  out	  of	  their	  clear	  chorions	  and	  by	  72	  hpf	  are	  swimming	  freely.5	  	  
2.	  Stages	  of	  Hematopoiesis	  
2.1.	  Primitive	  Hematopoiesis	  	   In	  vertebrates,	  the	  first	  wave	  of	  hematopoiesis,	  the	  primitive	  wave,	  produces	  erythrocytes	  and	  myeloid	  cells	  for	  the	  developing	  embryo.	  	  In	  the	  zebrafish,	  the	  primitive	  erythropoiesis	  wave	  occurs	  within	  the	  intermediate	  cell	  mass	  (ICM);	  this	  hematopoietic	  site	  is	  functionally	  equivalent	  to	  the	  extraembryonic	  yolk	  sac	  blood	  islands	  in	  mammals	  and	  birds.	  	  The	  ICM	  is	  located	  in	  the	  trunk	  ventral	  to	  the	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notochord.	  	  Following	  gastrulation,	  the	  developing	  primitive	  HSCs	  are	  marked	  by	  expression	  of	  the	  genes	  stem	  cell	  leukemia	  (scl)	  and	  LIM	  domain	  only	  2	  (lmo2),	  first	  seen	  by	  the	  2	  somite	  stage	  (10	  hpf).	  	  They	  exist	  in	  two	  bilateral	  stripes	  in	  the	  embryo	  until	  merging	  into	  the	  ICM	  at	  the	  18	  somite	  stage	  (18	  hpf).	  	  Around	  the	  6	  somite	  stage	  (12	  hpf),	  expression	  of	  gata1,	  an	  erythrocyte	  marker,	  commences	  in	  a	  subset	  of	  scl-­‐positive	  cells	  in	  the	  ICM	  as	  the	  first	  primitive	  red	  blood	  cells	  are	  produced	  (Figure	  A.1A).	  	  About	  three	  hundred	  primitive	  erythrocytes	  will	  be	  produced	  by	  this	  hematopoietic	  wave.	  	  These	  cells	  are	  first	  seen	  in	  circulation	  by	  about	  24	  hpf	  and	  last	  until	  about	  4	  days	  post	  fertilization	  (dpf).	  	  The	  rest	  of	  the	  scl-­‐positive	  cells,	  those	  that	  do	  not	  express	  gata1,	  will	  differentiate	  into	  vasculature,	  marked	  by	  expression	  of	  the	  vascular	  endothelial	  growth	  factor	  receptor	  2	  (vegfr2/flk1).1,6,7	  	   Primitive	  myelopoiesis	  occurs	  concomitantly	  with	  primitive	  erythropoiesis.	  	  However,	  whereas	  primitive	  erythropoiesis	  takes	  place	  in	  the	  ICM,	  primitive	  myelopoiesis	  occurs	  instead	  in	  the	  rostral	  blood	  islands	  (RBI)	  in	  the	  anterior	  mesoderm.	  	  The	  RBI	  are	  also	  marked	  by	  expression	  of	  scl	  and	  lmo2.	  	  Similar	  to	  how	  a	  proportion	  of	  cells	  in	  the	  ICM	  will	  express	  gata1,	  a	  subset	  of	  these	  cells	  in	  the	  RBI	  will	  additionally	  express	  pu.1,	  a	  myeloid-­‐specific	  transcription	  factor.	  	  These	  cells	  will	  develop	  into	  primitive	  macrophages	  and	  granulocytes,	  which	  are	  functional	  and	  circulating	  in	  the	  bloodstream	  by	  26	  hpf.1	  	   The	  appropriate	  proportion	  of	  erythroid	  to	  myeloid	  cells	  is	  maintained	  during	  the	  primitive	  wave	  by	  an	  equilibrium	  between	  expression	  of	  gata1	  and	  pu.1	  in	  the	  ICM.	  	  ICM	  cells	  have	  a	  bipotentiality,	  being	  able	  to	  form	  either	  cell	  lineage,	  so	  this	  regulation	  plays	  an	  important	  role	  in	  the	  embryo.	  	  Loss	  of	  gata1	  results	  in	  an	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expansion	  of	  myeloid	  precursors	  at	  the	  expense	  of	  erythroid	  cells,	  with	  pu.1	  expression	  persisting	  longer	  than	  usual;	  conversely,	  loss	  of	  pu.1	  leads	  to	  ectopic	  
gata1	  expression	  and	  an	  expansion	  of	  erythroid	  cells.8,9	  	  This	  reciprocal	  regulation	  suggests	  that	  each	  marker	  promotes	  development	  of	  one	  lineage	  while	  actively	  suppressing	  the	  other.	  	  
2.2.	  Definitive	  Hematopoiesis	  	   The	  definitive	  wave	  of	  hematopoiesis	  provides	  an	  animal	  with	  LT-­‐HSCs	  which,	  due	  to	  their	  ability	  to	  undergo	  self	  renewal,	  will	  support	  the	  generation	  of	  all	  blood	  lineages	  for	  the	  life	  of	  the	  organism.	  	  These	  differentiated	  lineages	  include	  not	  only	  erythroid	  and	  myeloid	  cells	  like	  the	  primitive	  wave,	  but	  also	  lymphocytes,	  thrombocytes,	  and	  a	  larger	  variety	  of	  myeloid	  cells.	  	  In	  mammals,	  the	  first	  anatomic	  site	  of	  definitive	  hematopoiesis	  is	  the	  aorta-­‐gonad-­‐mesonephros	  region	  (AGM;	  Figure	  A.2).	  	  The	  AGM	  equivalent	  in	  zebrafish	  is	  the	  ventral	  wall	  of	  the	  dorsal	  aorta.	  	  It	  is	  here	  at	  31	  hpf	  that	  expression	  of	  the	  first	  definitive	  HSC	  markers,	  the	  transcription	  factors	  c-­myb	  and	  runx1,	  arises.	  	  In	  situ	  hybridizations	  at	  36	  hpf	  for	  these	  two	  genes	  reveal	  clusters	  of	  HSCs	  on	  the	  floor	  of	  the	  dorsal	  aorta	  (Figure	  A.1B).	  	  They	  then	  likely	  bud	  off	  from	  the	  epithelium	  to	  enter	  circulation	  and	  migrate	  to	  their	  next	  location.1,6,7	  	  Additionally,	  in	  mammals,	  a	  parallel	  population	  of	  definitive	  HSCs	  can	  be	  found	  in	  the	  placenta.10	  	   In	  mammalian	  systems,	  HSCs	  are	  next	  found	  in	  the	  fetal	  liver;	  the	  equivalent	  intermediate	  larval	  site	  of	  hematopoietic	  expansion	  in	  the	  zebrafish	  is	  the	  caudal	  hematopoietic	  tissue	  (CHT;	  Figures	  A.1C,	  A.2).	  	  Lineage	  tracing	  of	  HSCs	  forming	  in	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the	  vascular	  plexus	  below	  the	  floor	  of	  the	  dorsal	  aorta	  shows	  that	  the	  cells	  formed	  by	  2	  dpf	  will	  seed	  the	  CHT,	  later	  becoming	  myeloid	  cells	  and	  lymphoid	  precursors.	  	  The	  CHT	  develops	  in	  association	  with	  the	  caudal	  vein,	  consisting	  of	  endothelial	  stroma	  that	  harbors	  the	  hematopoietic	  cells.11	  Finally,	  in	  mammals,	  HSCs	  seed	  the	  bone	  marrow,	  their	  permanent	  location.	  	  In	  zebrafish,	  the	  permanent	  niche	  for	  HSCs	  is	  the	  kidney	  marrow,	  in	  the	  reticular	  stromal	  cells	  of	  the	  kidney	  between	  the	  renal	  tubules	  and	  blood	  vessels	  (Figures	  A.1D,	  A.2).	  	  While	  most	  blood	  cell	  progenitors	  are	  also	  found	  in	  the	  kidney	  marrow,	  T	  lymphocyte	  progenitors,	  after	  being	  born	  in	  the	  kidney,	  can	  additionally	  be	  found	  in	  the	  thymus.	  	  HSCs	  formed	  at	  2	  dpf	  go	  through	  the	  CHT	  on	  their	  way	  to	  the	  kidney	  marrow	  and	  thymus.	  	  Those	  HSCs	  formed	  at	  3	  dpf	  will	  seed	  the	  kidney	  with	  fewer	  cells	  heading	  for	  the	  CHT	  and	  thymus;	  these	  are	  presumed	  to	  be	  the	  definitive	  HSCs.11,12	  	  By	  5	  dpf,	  nearly	  all	  HSCs	  can	  be	  found	  in	  the	  kidney	  marrow	  and	  will	  inhabit	  there	  for	  the	  remainder	  of	  the	  zebrafish’s	  life.	  	  All	  mature	  blood	  cell	  lineages	  originate	  from	  the	  kidney,	  with	  only	  T	  lymphocytes	  progenitors	  then	  migrating	  to	  the	  bilateral	  thymi	  to	  be	  educated.	  	  Kidney	  marrow	  cells	  can	  be	  analyzed	  by	  flow	  cytometry;	  separation	  by	  forward	  scatter	  and	  side	  scatter,	  which	  are	  measures	  of	  cell	  size	  and	  granularity,	  respectively,	  reveals	  four	  distinct	  populations	  that	  correspond	  to	  lymphoid,	  myeloid,	  erythroid,	  and	  precursor	  cells	  (plots	  on	  Figure	  A.3).13	  	   The	  definitive	  wave	  of	  erythropoiesis	  to	  replace	  the	  primitive	  red	  blood	  cells	  commences	  around	  5	  dpf.	  	  Erythrocyte	  differentiation	  is	  highly	  conserved	  between	  zebrafish	  and	  mammals,	  with	  the	  exception	  that	  mature	  erythrocytes	  in	  zebrafish	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retain	  their	  nuclei	  and	  have	  an	  elliptical	  shape,	  as	  opposed	  to	  mammalian	  erythroid	  cells	  that	  have	  an	  enucleated	  discoid-­‐shape.	  	  Myelopoiesis	  results	  in	  two	  granulocyte	  lineages,	  one	  resembling	  mammalian	  neutrophils	  and	  the	  other	  resembling	  a	  combination	  of	  mammalian	  eosinophils	  and	  basophils.	  	  They	  are	  found	  in	  the	  kidney	  by	  7	  dpf.	  	  The	  zebrafish	  immune	  system	  is	  supported	  by	  B	  cells	  that	  develop	  from	  the	  kidney	  by	  19	  dpf	  and	  by	  T	  cells	  that	  originate	  in	  the	  kidney	  and	  mature	  in	  the	  bilateral	  thymi	  beginning	  around	  3	  to	  4	  dpf.	  	  Thrombopoiesis	  in	  zebrafish	  yields	  small	  round	  nucleated	  thrombocytes	  that	  are	  equivalent	  to	  mammalian	  platelets,	  which	  appear	  beginning	  at	  36	  hpf.1	  	  
3.	  Hematopoietic	  Assays	  	   Hematopoiesis	  can	  be	  studied	  in	  vitro	  through	  a	  series	  of	  colony-­‐forming	  unit-­‐culture	  (CFU-­‐C)	  assays.	  	  Hematopoietic	  progenitors	  are	  grown	  in	  culture,	  consisting	  of	  a	  mixture	  of	  media,	  growth	  factors,	  and	  methylcellulose.	  	  When	  the	  progenitors	  proliferate	  and	  differentiate,	  a	  colony	  forms,	  which	  can	  be	  quantified	  and	  characterized.14,15	  	  Variations	  in	  the	  media	  conditions	  promote	  the	  growth	  of	  specific	  kinds	  of	  colonies	  with	  varying	  potentials.	  	   In	  the	  murine	  system,	  the	  classic	  in	  vivo	  assay	  to	  determine	  the	  presence	  of	  HSCs	  is	  the	  colony-­‐forming	  unit-­‐spleen	  (CFU-­‐S)	  assay.	  	  After	  lethal	  irradiation,	  progenitor	  cells	  from	  the	  bone	  marrow	  will	  form	  nodules	  of	  hematopoietic	  cells	  on	  the	  spleen.	  	  Those	  that	  appear	  relatively	  quickly,	  by	  eight	  days	  post-­‐irradiation,	  likely	  arise	  from	  short-­‐term	  HSCs	  or	  precursor	  cells;	  nodules	  forming	  later,	  by	  twelve	  or	  fourteen	  days,	  are	  from	  the	  long-­‐term	  HSCs.16	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HSCs	  can	  be	  sorted	  out	  in	  mammalian	  systems	  based	  on	  the	  antigens	  on	  their	  cell	  surface;	  recognition	  of	  these	  antigens	  by	  monoclonal	  antibodies	  facilitates	  the	  sorting	  process.	  	  In	  the	  human,	  the	  HSCs	  are	  marked	  by	  the	  presence	  of	  CD34	  and	  the	  absence	  of	  Lineage	  marker.	  	  In	  the	  mouse,	  the	  long-­‐term	  HSCs	  are	  enriched	  in	  the	  Lineage-­‐negative,	  Sca-­‐positive,	  c-­‐kit-­‐positive	  population.17	  HSC	  presence	  can	  also	  be	  noted	  by	  performing	  an	  acute	  injury-­‐recovery	  experiment,	  where	  the	  hematopoietic	  system	  is	  injured	  and	  assessed	  for	  recovery.	  	  In	  mice,	  the	  injury	  is	  traditionally	  5-­‐fluorouracil	  (5-­‐FU)	  injection;	  then	  the	  recovery	  kinetics	  of	  the	  whole	  bone	  marrow	  are	  monitored.	  	  A	  similar	  assay	  has	  been	  developed	  for	  the	  zebrafish.	  	  The	  fish	  are	  sublethally	  irradiated,	  then	  analyzed	  over	  a	  time	  course	  by	  forward	  scatter-­‐side	  scatter	  FACS	  analysis.	  	  In	  this	  way,	  the	  recovery	  of	  the	  different	  blood	  populations,	  erythroid,	  myeloid,	  lymphoid,	  and	  precursor,	  can	  be	  monitored	  over	  time	  (Figure	  A.3).13,18	  	   Transplantation	  is	  another	  classic	  assay	  to	  definitively	  determine	  the	  presence	  of	  HSCs	  in	  a	  cell	  population.	  	  This	  can	  be	  executed	  in	  both	  mouse	  and	  zebrafish.17,13	  	  Transplanting	  donor	  marrow	  cells	  into	  an	  irradiated	  recipient	  allows	  for	  the	  assessment	  of	  long-­‐term	  donor	  engraftment,	  which	  can	  only	  be	  fulfilled	  by	  long-­‐term	  HSCs.	  	  If	  5%	  of	  the	  recipient’s	  blood	  is	  found	  to	  originate	  from	  the	  donor,	  either	  by	  cell	  surface	  antigens	  in	  the	  mouse	  or	  fluorescent	  markers	  in	  the	  zebrafish,	  the	  marrow	  cells	  are	  considered	  to	  have	  engrafted.	  	  The	  actual	  percentage	  of	  donor	  cells	  found	  in	  the	  recipient’s	  blood	  is	  known	  as	  the	  percent	  chimerism.	  	  Competitive	  transplants	  are	  performed	  to	  test	  the	  desired	  cell	  population	  against	  a	  secondary	  population,	  serving	  as	  the	  challenger.	  	  The	  two	  cell	  populations	  are	  mixed,	  and	  co-­‐
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transplanted	  into	  the	  same	  animal;	  if	  one	  engrafts	  better	  than	  the	  other,	  this	  will	  be	  noted	  in	  the	  recipient.	  	  Serial	  transplants	  are	  performed	  to	  assess	  self	  renewal.	  	  A	  population	  containing	  HSCs	  is	  transplanted	  into	  a	  recipient;	  at	  a	  later	  time	  point,	  marrow	  cells	  from	  this	  first	  recipient	  are	  then	  transplanted	  into	  another	  animal,	  a	  secondary	  recipient.	  	  A	  population	  containing	  a	  greater	  number	  of	  HSCs	  or	  HSCs	  enhanced	  for	  self	  renewal	  will	  sustain	  more	  rounds	  of	  serial	  transplants;	  those	  with	  fewer	  HSCs	  or	  HSCs	  impaired	  in	  self	  renewal	  will	  undergo	  hematopoietic	  exhaustion,	  essentially	  running	  out	  of	  HSCs	  to	  repopulate	  the	  recipient’s	  blood.	  	   Alongside	  these	  traditional	  assays,	  recent	  work	  has	  combined	  pathway	  analysis,	  mutants,	  and	  transgenic	  animals	  to	  study	  hematopoietic	  stem	  cells.	  	  Understanding	  of	  the	  extrinsic	  pathways	  regulating	  HSCs	  has	  benefited	  greatly	  from	  this	  work.	  	  In	  the	  paragraphs	  that	  follow,	  three	  of	  these	  pathways	  will	  be	  discussed:	  Cdx/Hox,	  Notch,	  and	  Prostaglandins.	  	  
4.	  Regulatory	  Pathways	  for	  HSC	  Development	  
4.1.	  Cdx/Hox	  Pathway	  	   Many	  aspects	  of	  embryonic	  patterning	  and	  development,	  including	  hematopoiesis,	  are	  determined	  by	  the	  homeobox	  transcription	  factors,	  which	  are	  encoded	  by	  the	  Hox	  genes.	  	  In	  vertebrates,	  there	  exist	  thirty-­‐eight	  Hox	  genes	  clustered	  into	  four	  areas	  of	  the	  genome;	  these	  clusters	  are	  each	  oriented	  in	  the	  same	  transcriptional	  direction	  and	  are	  known	  as	  Hoxa,	  Hoxb,	  Hoxc,	  and	  Hoxd.19	  	  Within	  these	  clusters,	  there	  is	  a	  direct	  correlation	  between	  the	  order	  of	  genes	  along	  the	  chromosome	  and	  the	  gene’s	  function	  according	  to	  the	  anterior-­‐posterior	  (AP)	  axis	  of	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the	  organism.	  	  This	  colinearity	  refers	  both	  to	  the	  location	  a	  gene	  is	  expressed	  along	  the	  AP	  axis	  as	  well	  as	  the	  time	  it	  is	  expressed	  in	  development.	  	  For	  example,	  the	  genes	  positioned	  at	  the	  3’	  end	  of	  a	  Hox	  cluster	  tend	  to	  be	  expressed	  first	  and	  the	  most	  anterior;	  the	  more	  5’	  genes	  in	  the	  cluster	  are	  expressed	  at	  later	  time	  points	  and	  spatially	  more	  posterior	  in	  the	  embryo.	  	  Any	  gene	  mutations	  or	  other	  perturbations	  in	  the	  Hox	  clusters	  typically	  lead	  to	  changes	  in	  cell	  fate	  and	  embryonic	  patterning.	  	  Loss	  of	  function	  in	  the	  most	  3’	  region	  of	  a	  cluster	  will	  cause	  the	  embryo	  to	  become	  posteriorized,	  losing	  some	  anterior	  structures;	  conversely,	  gain	  of	  function	  in	  this	  genomic	  region	  would	  result	  in	  anteriorization	  of	  the	  embryo	  and	  loss	  of	  certain	  posterior	  structures.19	  	   Vertebrates	  also	  have	  other	  homeobox	  genes	  that	  are	  not	  members	  of	  the	  main	  four	  Hox	  clusters.	  	  Among	  these	  genes	  include	  the	  caudal	  paralogues,	  Cdx1,	  
Cdx2,	  and	  Cdx4.	  	  A	  proposed	  role	  for	  such	  genes,	  being	  that	  they	  are	  in	  a	  different	  genomic	  location	  from	  the	  Hox	  clusters,	  is	  that	  they	  affect	  AP	  patterning	  by	  directly	  regulating	  the	  Hox	  genes.	  	  Promoters	  of	  many	  of	  the	  clustered	  Hox	  genes	  contain	  binding	  sites	  with	  consensus	  sequences	  for	  Cdx1,	  Cdx2,	  and	  Cdx4.20	  	  Several	  studies	  of	  murine	  mutants	  for	  Cdx1	  and	  Cdx2	  have	  shown	  that	  these	  mutations	  led	  to	  shifts	  in	  the	  expression	  patterns	  and	  boundaries	  of	  several	  Hox	  genes,	  resulting	  in	  aberrant	  vertebral	  column	  and	  tail	  development.21,22	  	   Being	  that	  the	  Cdx/Hox	  genes	  play	  key	  roles	  in	  development,	  it	  was	  not	  surprising	  that	  some	  of	  these	  genes	  would	  participate	  in	  hematopoietic	  development.	  	  A	  zebrafish	  mutant	  referred	  to	  as	  kugelig	  has	  a	  mutation	  in	  the	  cdx4	  gene.	  	  It	  has	  abnormal	  AP	  patterning,	  and	  several	  genes	  of	  the	  Hoxa	  and	  Hoxb	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clusters	  display	  altered	  expression	  patterns.	  	  The	  cdx4-­‐/-­‐	  mutant	  presents	  with	  severe	  anemia	  by	  1dpf	  that	  partially	  recovers	  by	  5	  dpf;	  pleiotrophic	  defects	  lead	  to	  the	  mutant’s	  early	  death	  by	  7	  to	  10	  dpf.	  	  Kugelig	  also	  has	  reduced	  expression	  of	  hemoglobin,	  scl,	  and	  gata1	  with	  a	  complete	  lack	  of	  runx1.	  	  Overexpressing	  hoxb7a	  or	  
hoxa9a	  in	  the	  cdx4-­‐/-­‐	  mutant	  rescues	  levels	  of	  gata1	  expression.	  	  However,	  overexpressing	  scl	  in	  the	  cdx4-­‐/-­‐	  mutant	  was	  unable	  to	  rescue	  these	  erythroid	  precursors,	  suggesting	  that	  scl’s	  role	  in	  determining	  hematopoietic	  cell	  fate	  is	  cdx4-­‐dependent	  and	  further	  downstream.	  	  Overexpression	  analysis	  of	  cdx4	  was	  also	  performed,	  which	  showed	  a	  posteriorization	  of	  the	  zebrafish	  embryo	  and	  ectopic	  expression	  of	  scl	  and	  gata1.23	  	  These	  observations	  showed	  that	  cdx4	  is	  upstream	  of	  
Hox	  gene	  expression.	  	   A	  follow-­‐up	  study	  was	  performed	  involving	  one	  of	  the	  other	  caudal	  genes,	  
cdx1a,	  since	  it	  was	  noted	  that	  the	  cdx4-­‐/-­‐	  mutant	  was	  not	  completely	  bloodless,	  likely	  due	  to	  redundancy.	  	  Knocking	  down	  cdx1a	  by	  injection	  of	  an	  antisense	  morpholino	  oligonucleotide	  led	  to	  an	  increase	  in	  expression	  of	  the	  gene,	  implying	  that	  it	  normally	  negatively	  regulates	  itself.	  	  Injection	  of	  this	  same	  cdx1a	  morpholino	  into	  the	  cdx4-­‐/-­‐	  mutant	  zebrafish	  embryos	  yielded	  loss	  of	  posterior	  structures	  and	  development	  of	  fewer	  somites;	  it	  appears	  that	  the	  two	  genes	  normally	  act	  simultaneously	  to	  form	  the	  posterior	  tissues	  of	  the	  animal.	  	  Cdx1a-­‐morpholino;cdx4+/-­‐	  embryos	  had	  fewer	  scl-­‐positive	  cells	  in	  the	  ICM	  as	  well	  as	  a	  reduction	  in	  gata1-­‐positive	  cells;	  these	  phenotypes	  were	  more	  severe	  in	  cdx1a-­‐morpholino;cdx4-­‐/-­‐	  embryos,	  suggesting	  a	  dose-­‐dependent	  effect	  of	  cdx4.	  	  The	  
cdx1a-­‐morpholino;cdx4-­‐/-­‐	  embryos	  also	  suffered	  from	  a	  complete	  failure	  to	  specify	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the	  ICM	  blood	  precursors;	  these	  also	  lacked	  in	  forming	  definitive	  HSCs,	  as	  noted	  by	  a	  reduction	  in	  runx1a	  expression.	  	  However,	  these	  effects	  could	  be	  rescued	  by	  co-­‐injection	  of	  hoxa9a	  mRNA.24	  	  The	  cdx	  pathway	  plays	  a	  major	  role	  in	  primitive	  hematopoiesis	  in	  the	  ICM,	  as	  this	  region	  was	  particularly	  sensitive	  to	  the	  gene	  dosage	  of	  cdx4;	  the	  cdx-­hox	  pathway	  is	  also	  required	  to	  form	  definitive	  HSCs	  in	  the	  AGM.	  	  These	  studies	  confirmed	  the	  idea	  that	  the	  caudal	  genes	  act	  upstream	  of	  and	  regulate	  the	  Hox	  clusters,	  playing	  an	  important	  role	  in	  blood	  formation.	  	   Other	  studies	  of	  Cdx4	  have	  confirmed	  the	  pathway’s	  role	  among	  HSCs.	  	  In	  the	  mouse,	  Cdx4	  is	  expressed	  in	  adult	  stem	  and	  progenitor	  population	  yet	  is	  significantly	  reduced	  in	  differentiated	  blood	  cells.25	  	  Induction	  of	  Cdx4	  in	  embryoid	  bodies	  promoted	  formation	  of	  CD41-­‐positive	  and	  c-­‐kit-­‐positive	  presumptive	  HSCs	  in	  a	  colony-­‐forming	  assay.	  	  Additionally,	  an	  increase	  in	  blood	  markers	  was	  observed	  upon	  Cdx4	  induction,	  including	  lmo2,	  scl,	  gata1,	  embryonic	  and	  adult	  globins,	  c-­myb,	  and	  runx1	  expression.	  Similar	  to	  cdx	  regulation	  in	  zebrafish,	  Hox	  genes	  were	  found	  to	  be	  the	  downstream	  mediators	  of	  cdx4	  in	  vitro.26,27	  	  These	  observations	  show	  that	  the	  Cdx	  genes	  play	  a	  role	  in	  regulating	  blood	  stem	  and	  progenitor	  stems	  through	  the	  
Hox	  genes.	  	  	  	  
4.2.	  Notch	  Signaling	  	   The	  Notch	  pathway	  is	  an	  evolutionarily	  conserved	  signaling	  pathway	  that	  is	  known	  for	  playing	  important	  roles	  in	  development,	  and	  it	  has	  been	  shown	  to	  indeed	  participate	  in	  the	  formation	  of	  HSCs.	  	  The	  Notch	  proteins	  themselves	  are	  type	  1	  single	  pass	  transmembrane	  glycoprotein	  receptors	  that	  activate	  downstream	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transcriptional	  targets	  upon	  binding	  to	  their	  transmembrane	  ligands,	  Jagged	  and	  Delta.	  	  Receptor-­‐ligand	  interactions	  occur	  when	  a	  cell	  expressing	  the	  ligand	  is	  juxtaposed	  to	  a	  cell	  expressing	  the	  Notch	  receptor.	  	  This	  interaction	  results	  in	  an	  external	  cleavage	  of	  Notch,	  caused	  by	  an	  ADAM	  metalloprotease,	  that	  splits	  the	  receptor	  into	  the	  Notch	  extracellular	  domain	  and	  an	  activated	  membrane-­‐bound	  form	  of	  Notch.	  	  A	  second	  cleavage	  then	  occurs	  within	  the	  activated	  transmembrane	  domain	  by	  presenilin-­‐dependent	  gamma-­‐secretase;	  this	  releases	  the	  Notch	  intracellular	  domain	  (NICD),	  which	  translocates	  to	  the	  nucleus	  and	  participates	  as	  a	  member	  of	  various	  transcriptional	  activation	  complexes.28	  	   Examination	  of	  live	  Notch	  expression	  in	  HSCs	  was	  facilitated	  by	  the	  creation	  of	  a	  transgenic	  Notch	  reporter	  mouse.	  	  The	  transgene	  contained	  an	  upstream	  Notch	  response	  element	  as	  well	  as	  four	  binding	  sites	  for	  CBF-­‐1,	  Notch	  target	  gene,	  driving	  enhanced	  green	  fluorescent	  protein	  (GFP).	  	  In	  the	  transgenic	  mice,	  HSCs,	  designated	  by	  the	  marker	  c-­‐kit,	  were	  also	  GFP-­‐positive,	  showing	  in	  vivo	  that	  Notch	  signaling	  is	  active	  in	  HSCs.	  	  Analysis	  of	  more	  mature	  blood	  cells	  revealed	  significantly	  less	  GFP	  expression,	  suggesting	  that	  Notch	  activation	  decreases	  with	  differentiation.	  	  This	  was	  confirmed	  in	  vitro	  by	  comparing	  the	  amount	  of	  CFU-­‐S12	  colonies	  formed	  by	  HSC-­‐enriched	  GFP-­‐positive	  and	  GFP-­‐negative	  cells;	  those	  expressing	  GFP,	  and	  thus	  having	  active	  Notch	  signaling,	  tended	  to	  form	  more	  CFU-­‐S12	  colonies	  and	  thus	  had	  more	  HSC	  function.29	  	   Results	  of	  overexpression	  studies	  of	  Notch	  are	  consistent	  with	  these	  conclusions.	  	  Mice	  containing	  an	  expanded	  population	  of	  osteoblasts	  in	  the	  murine	  bone	  marrow,	  which	  serve	  as	  a	  stem	  cell	  niche,	  possessed	  increased	  numbers	  of	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Notch-­‐expressing	  HSCs.	  	  The	  osteoblast	  niche	  presents	  the	  appropriate	  Notch	  ligands	  to	  HSCs,	  leading	  to	  an	  increase	  in	  NICD	  within	  HSCs	  and	  a	  concomitant	  increase	  in	  HSC	  number,	  presumably	  reflecting	  an	  increase	  in	  HSC	  self	  renewal.30	  	  If	  primary	  murine	  bone	  marrow	  cells	  enriched	  for	  stem	  cells	  are	  retrovirally	  transduced	  with	  the	  NICD,	  differentiation	  is	  inhibited,	  the	  cells	  appear	  primitive,	  and	  more	  colonies	  form	  in	  the	  CFU-­‐C	  in	  vitro	  assay,	  implying	  there	  are	  more	  HSCs	  present	  than	  in	  controls.	  	  Upon	  competitive	  transplantation	  of	  the	  NICD-­‐transduced	  bone	  marrow	  cells	  into	  irradiated	  mice,	  there	  are	  more	  primitive	  cells	  and	  fewer	  mature	  cells	  present,	  as	  the	  Notch	  gain	  of	  function	  appears	  to	  impede	  exit	  from	  the	  undifferentiated	  state	  of	  the	  HSCs.	  	  Secondary	  recipients	  in	  serial	  transplants	  do	  not	  experience	  the	  hematopoietic	  exhaustion	  that	  control	  cells	  undergo,	  possibly	  due	  to	  enhanced	  self	  renewal	  creating	  a	  larger	  HSC	  pool.31	  	  Forced	  expression	  of	  NICD	  in	  irradiated	  zebrafish	  adults	  enhanced	  recovery	  of	  multi-­‐lineage	  precursor	  cells,	  and	  thus	  all	  the	  blood	  lineages;	  HSCs	  were	  likely	  increased	  as	  well,	  as	  shown	  by	  increased	  runx1	  and	  lmo2	  expression.32	  	  Similarly,	  retroviral	  transduction	  of	  Hairy-­‐Enhancer	  of	  Split	  (HES-­‐1),	  a	  Notch	  target	  gene	  encoding	  a	  basic	  helix-­‐loop-­‐helix	  transcription	  factor,	  cDNA	  into	  fetal	  liver	  and	  bone	  marrow	  HSCs	  maintained	  the	  cells	  as	  immature,	  undergoing	  self	  renewal.	  	  Upon	  transplantation,	  the	  HES-­‐1	  transduced	  HSCs	  also	  yielded	  a	  higher	  proportion	  of	  immature	  cells	  in	  the	  recipient	  mouse	  as	  well	  as	  a	  higher	  donor	  chimerism.33	  	   Loss	  of	  function	  studies	  have	  also	  helped	  elucidate	  the	  role	  of	  Notch	  in	  definitive	  HSC	  induction.	  	  A	  zebrafish	  known	  as	  mindbomb,	  harboring	  a	  mutation	  in	  an	  E3	  ligase	  required	  for	  Delta	  ligand	  trafficking,	  lacks	  expression	  of	  runx1	  and	  c-­
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myb	  in	  the	  AGM;	  this	  suggests	  that	  Notch	  signaling	  is	  required	  for	  the	  definitive	  wave	  of	  hematopoiesis.32	  	  To	  assess	  the	  effect	  of	  Notch1	  on	  AGM	  HSC	  formation,	  AGM	  cells	  from	  day	  E9.5	  embryonic	  Notch1-­‐/-­‐	  mice	  were	  removed	  and	  cultured	  in	  
vitro,	  then	  assayed	  for	  functional	  implications.	  	  The	  cells	  were	  found	  to	  have	  impaired	  ability	  to	  produce	  functional	  HSCs	  in	  a	  colony	  forming	  assay	  or	  to	  reconstitute	  an	  irradiated	  mouse.	  	  These	  effects	  could	  not	  be	  rescued	  by	  the	  addition	  of	  signaling	  factors	  belonging	  to	  other	  pathways	  in	  the	  environment,	  suggesting	  that	  HSCs	  have	  a	  cell	  autonomous	  requirement	  for	  Notch.34	  	   The	  zebrafish	  has	  proved	  particularly	  useful	  in	  the	  elucidation	  of	  a	  genetic	  pathway	  involved	  in	  definitive	  HSC	  formation.	  	  Crossing	  two	  fish,	  one	  carrying	  the	  yeast	  transactivator	  Gal4	  driven	  by	  the	  zebrafish	  heat-­‐shock	  promoter	  (hsp70:gal4)	  and	  the	  other	  with	  the	  Gal4-­‐responsive	  upstream	  activating	  sequence	  (uas)	  driving	  the	  zebrafish	  NICD	  (uas:NICD),	  led	  to	  a	  fish	  harboring	  heat	  shock	  inducible	  NICD.	  	  A	  pulse	  of	  heat	  shock	  at	  14	  hpf	  led	  to	  NICD	  induction,	  which	  caused	  ectopic	  runx1	  and	  
c-­myb	  expression	  at	  36	  hpf.	  	  This	  included	  an	  expansion	  of	  these	  definitive	  HSC	  markers	  into	  the	  aortic	  roof	  and	  vein.	  	  Similar	  results	  were	  found	  by	  overexpressing	  
runx1	  by	  injection	  of	  runx1	  mRNA	  into	  single	  cell	  stage	  embryos.	  	  Conversely,	  knocking	  down	  runx1	  by	  morpholino	  injection	  led	  to	  a	  lack	  of	  definitive	  HSC	  formation;	  both	  this	  and	  the	  mindbomb	  mutant	  could	  not	  be	  rescued	  by	  NICD	  induction	  by	  heat	  shock	  or	  overexpression	  of	  runx1	  mRNA.	  	  This	  implied	  that	  runx1	  and	  Notch	  acted	  together	  in	  a	  pathway	  to	  induce	  HSC	  formation.	  	  This	  pathway	  was	  teased	  out	  by	  knocking	  down	  either	  mindbomb	  or	  runx1	  in	  the	  heat	  shock	  inducible	  NICD	  fish.	  	  Forced	  NICD	  expression	  showed	  Notch	  gain	  of	  function	  effects	  when	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mindbomb	  was	  knocked	  down,	  thus	  showing	  that	  Notch	  is	  downstream	  of	  
mindbomb;	  however,	  with	  runx1	  knocked	  down	  and	  NICD	  induced,	  the	  fish	  still	  had	  a	  lack	  of	  HSCs,	  thus	  displaying	  that	  runx1	  is	  downstream	  of	  Notch.	  	  These	  zebrafish	  experiments	  enabled	  the	  finding	  that	  Notch	  is	  necessary	  to	  establish	  HSC	  fate,	  sufficient	  to	  expand	  HSCs	  in	  vivo,	  and	  signals	  through	  the	  transcriptional	  factor	  
runx1	  to	  perform	  these	  effects.32	  	  
4.3.	  Prostaglandin	  Signaling	  	   Prostaglandins	  (PG)	  are	  a	  type	  of	  eicosanoid	  that	  have	  a	  variety	  of	  physiological	  effects	  at	  low	  concentrations.	  	  They	  are	  derived	  from	  twenty-­‐carbon	  unsaturated	  fatty	  acids,	  the	  most	  common	  being	  arachidonic	  acid.	  	  Arachidonic	  acid	  is	  stored	  in	  the	  cell	  membrane	  and	  is	  turned	  into	  PGH2	  by	  cyclooxygenases	  (COX).	  	  COX1	  is	  expressed	  in	  most	  tissues	  constitutively	  whereas	  COX2	  expression	  is	  regulated	  within	  specific	  tissues;	  aspirin	  inhibits	  both	  COX	  enzymes.	  	  The	  PGH2	  intermediate	  then	  gives	  rise	  to	  a	  variety	  of	  PGs	  through	  PG	  synthases;	  the	  most	  common	  PG	  is	  PGE2.	  	  The	  PGs	  bind	  to	  G-­‐protein	  coupled	  receptors	  to	  mediate	  their	  actions.35	  	   A	  few	  studies	  have	  shown	  the	  role	  of	  PGE2	  in	  promoting	  blood	  cell	  proliferation.	  	  Adding	  PGE2	  to	  a	  murine	  bone	  marrow	  suspension	  stimulated	  cell	  proliferation	  at	  concentrations	  comparable	  to	  those	  found	  in	  human	  serum.	  	  A	  colony	  forming	  assay	  was	  performed	  and	  revealed	  a	  higher	  proportion	  of	  colonies	  were	  in	  S	  phase	  than	  the	  controls.	  	  These	  results	  implied	  that	  PGE2	  prompts	  quiescent	  HSCs	  to	  move	  into	  the	  cell	  cycle.36	  	  A	  similar	  effect	  was	  shown	  in	  the	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zebrafish	  thymi.	  	  Embryos	  treated	  with	  PGE2	  contained	  increased	  expression	  of	  the	  lymphocyte-­‐specific	  recombination	  activation	  gene	  (rag1)	  in	  the	  thymi	  whereas	  those	  treated	  with	  COX	  inhibitors	  or	  antagonist	  of	  the	  PGE2	  receptor	  lacked	  rag1	  expression.	  	  Additionally,	  PGE2	  treatment	  could	  rescue	  the	  COX2	  inhibitor	  phenotype.	  	  These	  effects	  of	  PGE2	  were	  shown	  to	  be	  due	  to	  increased	  cell	  proliferation	  as	  shown	  by	  the	  presence	  of	  the	  proliferating	  cell	  nuclear	  marker	  (PCNA)	  that	  was	  missing	  in	  controls.37	  	   Recently,	  a	  major	  study	  on	  PGE2	  and	  HSC	  development	  was	  completed	  in	  the	  zebrafish.	  	  It	  was	  shown	  that	  treatment	  of	  zebrafish	  embryos	  with	  PGE2	  increased	  AGM	  expression	  of	  runx1	  and	  c-­myb,	  while	  exposure	  to	  COX1	  and	  COX2	  inhibitors	  gave	  a	  decrease	  in	  HSC	  number.	  	  Knockdown	  of	  COX1/2	  by	  morpholino	  injection	  similarly	  decreased	  runx1	  and	  c-­myb	  expression;	  this	  effect	  was	  rescued	  by	  addition	  of	  dimethylPGE2	  (dmPGE2),	  a	  long-­‐acting	  form	  of	  PGE2,	  showing	  the	  loss	  of	  AGM	  HSCs	  was	  a	  result	  of	  the	  loss	  of	  PG	  signaling.	  	  COX1	  is	  expressed	  in	  the	  endothelial	  cells	  of	  the	  AGM	  region,	  yet	  both	  COX1	  and	  COX2	  are	  expressed	  in	  CD41-­‐positive	  cells,	  likely	  the	  HSCs	  themselves.	  	  This	  implies	  that	  PGE2	  could	  be	  regulating	  both	  the	  HSC	  and	  the	  niche.	  	  In	  adult	  zebrafish,	  exposure	  to	  dmPGE2	  enhanced	  the	  recovery	  kinetics	  of	  the	  kidney	  marrow	  following	  irradiation,	  leading	  to	  faster	  repopulation	  of	  the	  precursor	  cells.38	  	   Follow-­‐up	  studies	  in	  mammalian	  systems	  confirmed	  that	  the	  regulation	  of	  HSCs	  by	  PGE2	  was	  evolutionarily	  conserved.	  	  Addition	  of	  dmPGE2	  to	  murine	  embryonic	  stem	  cells	  increased	  the	  amount	  of	  hematopoietic	  colonies	  formed	  in	  a	  dose-­‐dependent	  manner.	  	  Similar	  to	  zebrafish	  AGM	  analysis,	  treatment	  with	  an	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inhibitor	  of	  COX1/2	  prevented	  colony	  growth,	  and	  this	  was	  rescued	  by	  dmPGE2	  treatment.	  	  Murine	  bone	  marrow	  was	  exposed	  ex	  vivo	  to	  dmPGE2	  and	  then	  transplanted	  into	  an	  irradiated	  recipient.	  	  This	  led	  to	  an	  increase	  in	  the	  number	  of	  CFU-­‐S8	  and	  CFU-­‐S12	  colonies	  formed,	  indicating	  an	  increase	  in	  HSC	  and	  precursor	  populations,	  respectively;	  complementary	  results	  were	  obtained	  upon	  treatment	  with	  COX	  inhibitors.	  	  Similar	  results	  were	  obtained	  when	  these	  experiments	  were	  performed	  on	  isolated	  HSCs.	  	  dmPGE2-­‐treated	  bone	  marrow	  showed	  an	  increase	  in	  the	  frequency	  of	  repopulating	  cells	  in	  a	  limiting	  dilution	  competitive	  transplant	  assay.	  	  Since	  no	  difference	  in	  homing	  to	  the	  bone	  marrow	  was	  observed,	  these	  results	  indicate	  an	  increase	  in	  HSC	  number.38	  	  COX2-­‐/-­‐	  mice	  have	  normal	  hematopoiesis	  and	  HSC	  formation	  due	  to	  maternal	  and	  sibling	  contribution	  of	  the	  enzyme.	  	  However,	  upon	  5FU	  injury	  treatment,	  these	  mice	  recover	  slowly,	  have	  significantly	  lower	  numbers	  of	  cells	  in	  all	  blood	  lineages	  by	  day	  12	  post-­‐injury	  and	  fail	  to	  repopulate	  the	  bone	  marrow	  with	  hematopoietic	  cells.39	  	  These	  findings	  conclude	  that	  PGE2,	  produced	  by	  COX2	  in	  particular,	  plays	  a	  key	  role	  in	  the	  creation	  of	  HSCs.	  	  
5.	  Clinical	  Applications	  	   Umbilical	  cord	  blood	  transplantation	  is	  a	  common	  therapy	  used	  when	  an	  immunological	  match	  donor	  cannot	  be	  found	  for	  a	  patient.	  	  However,	  cord	  blood	  contains	  few	  HSCs	  and	  typically	  takes	  longer	  to	  engraft	  than	  bone	  marrow	  transplantations.	  	  It	  has	  been	  successful	  for	  the	  pediatric	  population,	  but	  expansion	  of	  HSCs	  is	  necessary	  to	  be	  more	  useful	  for	  adult	  patients.40	  	  Understanding	  the	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extrinsic	  pathways	  that	  impact	  HSC	  development	  can	  lead	  to	  the	  development	  of	  an	  
ex	  vivo	  treatments	  that	  increase	  HSC	  frequency	  in	  cord	  blood	  samples	  in	  the	  clinic.	  Researchers	  have	  made	  several	  attempts	  to	  take	  knowledge	  of	  the	  above	  pathways	  to	  expand	  HSC	  populations	  in	  cord	  blood.	  	  Similar	  to	  overexpression	  of	  the	  
Hox	  genes	  in	  zebrafish	  and	  mouse	  studies,	  by	  treating	  cord	  blood	  ex	  vivo	  with	  a	  peptide	  containing	  Hox	  sequences,	  the	  amount	  of	  HSCs	  and	  multipotent	  progenitors	  doubled;	  additionally,	  the	  cord	  blood	  reconstituted	  the	  blood	  system	  when	  transplanted	  into	  irradiated	  mice	  more	  efficiently	  and	  with	  faster	  kinetics.41	  	  Since	  Notch	  signaling	  seems	  to	  be	  required	  for	  HSC	  formation,	  adding	  Notch	  ligands	  at	  appropriate	  concentrations	  to	  cord	  blood	  has	  been	  shown	  to	  increase	  the	  number	  of	  immature	  precursor	  cells.42	  	  Whereas	  lower	  concentrations	  of	  the	  ligands	  result	  in	  better	  repopulation	  of	  irradiated	  mice	  in	  comparison	  to	  no	  ex	  vivo	  treatment,	  higher	  concentrations	  appear	  to	  cause	  too	  much	  apoptosis	  and	  hence	  a	  decreased	  population.43	  	  Similar	  trials	  are	  underway	  for	  prostaglandin	  E2,	  since	  overexpression	  has	  also	  been	  shown	  to	  increase	  HSC	  numbers	  and	  functionality	  in	  zebrafish	  and	  mice.44	  	  This	  is	  just	  one	  example	  of	  how	  work	  in	  model	  organisms,	  especially	  the	  zebrafish,	  can	  be	  translated	  into	  therapies	  for	  human	  disease.	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Figures	  	  
Figure	  A.1:	  In	  situ	  hybridizations	  of	  blood	  markers	  during	  the	  various	  stages	  of	  zebrafish	  hematopoiesis.	  (A)	  Gata1,	  an	  erythrocyte	  marker,	  at	  the	  5	  somite	  stage	  (12	  hpf).	  	  The	  2	  bilateral	  stripes	  form	  the	  ICM	  and	  will	  merge	  together	  by	  18	  somites	  (18	  hpf)	  (X.	  Bai)	  (B)	  C-­myb	  and	  runx1,	  markers	  of	  definitive	  stem	  cells,	  at	  36	  hpf	  in	  the	  ventral	  wall	  of	  the	  dorsal	  aorta	  (T.	  North)	  (C)	  Scl,	  an	  HSC	  and	  progenitor	  marker,	  is	  seen	  expressed	  in	  the	  CHT	  at	  4	  dpf	  (T.	  Bowman)	  (D)	  Scl	  at	  6.5	  dpf;	  additional	  expression	  near	  the	  head	  is	  the	  kidney	  marrow	  (T.	  Bowman)	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Figure	  A.2:	  Approximate	  temporal	  and	  anatomical	  locations	  of	  hematopoietic	  activity,	  based	  on	  current	  knowledge	  (adapted	  from	  reference	  7)	  (A)	  Mouse	  (B)	  Zebrafish	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Figure	  A.2	  (Continued)	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
217	  	  	  	  
Figure	  A.3:	  Schematic	  of	  the	  acute	  injury	  recovery	  assay.	  	  By	  treating	  zebrafish	  with	  a	  sublethal	  dose	  of	  irradiation,	  the	  blood	  system	  undergoes	  injury	  and	  recovers	  over	  time.	  	  By	  day	  7	  post-­‐irradiation,	  the	  HSCs	  will	  begin	  to	  produce	  cells	  that	  will	  differentiate	  into	  the	  blood	  system.	  	  Common	  lymphoid	  and	  myeloid	  progenitors	  recover	  by	  day	  10	  with	  more	  mature	  erythroid,	  lymphoid,	  and	  myeloid	  cells	  recovering	  by	  day	  14.	  	  These	  kinetics	  are	  observed	  via	  the	  forward	  scatter-­‐side	  scatter	  FACS	  plots.	  	  Within	  a	  few	  weeks,	  levels	  of	  all	  populations	  are	  back	  to	  and	  can	  even	  surpass	  pre-­‐irradiation	  levels	  (T.	  Bowman).	  
	  	  
